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Abstract 
In recent years evidence has emerged that the endocannabinoid system (ECS) 
may have a significant role in metabolism and energy homeostasis. Several 
studies have identified upregulation of the peripheral ECS in obesity and type 2 
diabetes, but the mechanisms behind this and the consequences of upregulation 
are unclear. The aim of this thesis was to further elucidate the role of the ECS in 
mature adipocytes, and its activity in obesity and related metabolic dysfunction.  
Three adipose tissue depots were dissected from lean, obese and obese 
diabetic Zucker rats (n=6-8). In human studies, written informed consent was 
obtained from healthy volunteers within the University of Nottingham and obese 
surgical patients at the Royal Derby Hospital. Anthropometric measurements and 
venous blood samples were obtained. In these studies, subcutaneous abdominal 
adipose tissue was taken from all subjects (n=28 healthy study; n=27 surgical 
study), and visceral adipose tissue was obtained from some of the surgical 
patients (n=14). In all studies, collagenase was used to isolate mature adipocytes 
from the adipose tissue, and FAAH and MGL activities in the adipocytes were 
assayed using tritium labelled substrates. Human subcutaneous preadipocytes 
(Promocell, Germany) were cultured and differentiated. Adipocytes were cultured 
ZLWKKLJKFRQFHQWUDWLRQVRIJOXFRVHP0DQGRULQVXOLQȝ0IRUKRXUVLQ
combination with anandamide or 2-AG for 2 or 24 hours. Adiponectin, leptin and 
resistin in the cell culture media were then measured using sandwich ELISAs. In 
another study, anandamide and 2-AG uptake were measured in differentiated 
DGLSRF\WHVDIWHURUKRXUV¶VWLPXODWLRQZLWKJOXFRVHDQGRULQVXOLQ)$$+DQG
MGL activities in the cultured adipocytes were also measured in this study. 
In rats, FAAH and MGL activities correlated with body mass. In healthy 
humans, FAAH activity in subcutaneous adipocytes correlated with BMI and waist 
circumference, but not with other anthropometric measurements, serum 
glycaemic markers or adipokines. In obese patients, the enzyme activities had no 
relationships with any of the anthropometric or metabolic markers investigated. 
Furthermore, there were no differences in activity between patients with metabolic 
syndrome or diabetes and those without. In both rats and humans, there were no 
significant differences in FAAH and MGL activities between subcutaneous and 
visceral adipocytes. In the cell culture studies, anandamide and 2-AG did not alter 
adipokine secretion under normal, high glucose or high insulin conditions. Chronic 
insulin exposure increased anandamide uptake, but none of the other acute or 
chronic treatments with glucose and/or insulin affected anandamide or 2 -AG 
uptake. Glucose and insulin were found to reduce MGL activity. 
 These studies suggest that the rate of anandamide hydrolysis in mature 
adipocytes is increased in obesity. This relationship was not apparent in a 
morbidly obese sample. MGL activity in humans does not have relationships with 
adiposity or metabolic markers, and this may reflect its role as a major component 
of lipid metabolism, particularly lipolysis. Anandamide and 2-AG are unlikely to be 
direct mediators of adipokine secretion, at least in cell culture. Insulin may affect 
endocannabinoid signalling in adipocytes by increasing anandamide uptake and 
suppressing MGL activity. Overall, these results support the notion that the ECS 
in adipocytes is dysregulated in obesity, but this is not driven by specific factors 
associated with obesity. 
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 1. Introduction  
The endocannabinoid system (ECS) is a complex and ubiquitously 
expressed signalling system that comprises the endocannabinoids, their 
receptors and the enzymes required for endocannabinoid synthesis and 
degradation. The ECS has been identified in most human organs and 
tissues, and the system has roles in a wide range of normal and 
pathological processes, such as pain, energy homeostasis, fertility, 
immune responses and behaviour, with both central and peripheral 
involvement (for review see De Petrocellis and Di Marzo, 2009). Initially 
interest in the ECS was focussed on its presence and role in the central 
nervous system (CNS), but more recently its role and regulation in adipose 
tissue and metabolism has been a matter of intense research. Despite this 
work and many significant advances in knowledge, in many cases, the 
molecular mechanisms and physiological significance of the ECS have yet 
to be fully elucidated.  
 
1.1.1 The Endocannabinoids  
The endocannabinoids identified to date are mostly lipid derivatives of 
arachidonic acid. The two most extensively characterised endocannabinoids 
are N-arachidonoylethanolamide (anandamide), which was the first to be 
described (Devane et al., 1992), and its glycerol ester analogue 2-
arachidonoylglycerol (2-AG) which was reported a few years later 
(Mechoulam et al., 1995; Sugiura et al., 1995). The degradation of these 
two endocannabinoids is one of the major foci of this thesis. There are 
many other compounds which are sometimes referred to as 
endocannabinoids, due to their activity at one or more of the cannabinoid 
receptors (for extensive review on cannabinoid pharmacology see Pertwee  
et al., 2010). Three such molecules are virodhamine (Porter et al., 2002), 
2-arachidonoyl glyceryl ether (noladin ether) (Hanus et al., 2001) and N-
arachidonoyl dopamine (NADA) (Bisogno et al., 2000). Virodhamine has a 
very similar structure to anandamide, but opposite orientation around the 
arachidonic acid-ethanolamine bond (Porter et al., 2002). Likewise, noladin 
ether and 2-AG are structurally similar (see Figure 1.1). 
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Figure 1.1 Chemical structures of the endocannabinoids. 
 
In addition to these, there are other N-acylethanolamines (NAEs), 
similar in structure to anandamide, which are not usually considered to be 
endocannabinoids, but which are ligands for some of the same non-
cannabinoid receptor targets as endocannabinoids. Two of these, 
oleoylethanolamine (OEA) and palmitoylethanolamide (PEA) have been 
extensively investigated as they are present at higher concentrations than 
the endocannabinoids in many mammalian tissues and are metabolised by 
the same enzymes (Alexander and Kendall, 2007; Lambert and Muccioli, 
2007). 
In addition to the endocannabinoids, there are many other 
cannabinoid receptor ligands, from plant and synthetic sources. Two of the 
most common phytocannabinoids (from Cannabis sativa) are Ʃ9-
tetrahydrocannabinol (THC) and cannabidiol (CBD). THC was one of the 
first cannabinoids to be identified (Gaoni and Mechoulam, 1964) and there 
are at least 60 further phytocannabinoids with wide ranging pharmacology 
(for reviews see Pertwee and Ross, 2002; Elsohly and Slade, 2005). 
 
1.1.2 Endocannabinoid synthesis pathways  
Anandamide and 2-AG are thought to be synthesised predominantly via 
cleavage of membrane phosphoglyceride precursors (as reviewed by 
Bisogno, 2008). As the endocannabinoid precursors are a normal 
component of cell membranes, it is the presence or absence of 
endocannabinoid synthesising enzymes and receptors that dictate whether 
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the ECS will be activated and where it will act (for review see Di Marzo et 
al., 2007). Endocannabinoids are often referred to as signalling molecules 
ZKLFK DUH V\QWKHVLVHG ³RQ GHPDQG´ DQG LQ QHXURQV DW OHDVW
endocannabinoids are synthesised and released very rapidly upon 
stimulation (for review see Alger and Kim, 2011). There is however 
mounting evidence that under certain conditions endocannabinoids may be 
stored before their release (for reviews see Maccarrone et al., 2010; Alger 
and Kim, 2011). Several anabolic pathways for anandamide and 2-AG have 
been described to date, and alternative enzymes are currently under 
investigation, suggesting that endocannabinoid regulation has the potential 
to be very complex. 
 
1.1.2.1 Anandamide synthesis  
The major pathway for anandamide synthesis involves an N-
acyltransferase to convert 1,2-di-arachidonylphosphatidylcholine to N-
arachidonylphosphatidylethanolamine (NAPE) (Astarita et al., 2008). 
Hydrolysis of this molecule by a Ca2+-sensitive NAPE-selective 
phospholipase D (NAPE-PLD) then yields anandamide (Okamoto et al., 
2004; Wang et al., 2008a). 
The presence of anandamide in NAPE-PLD knockout mice (Leung et 
al., 2006) indicates that alternative pathways exist to convert 
phosphatidylethanolamine to anandamide. One of the proposed pathways 
relies on a phospholipase C  and protein tyrosine phosphatase N22 (Liu et 
al., 2006), while another uses a phospholipase A2 and a lyso-phospholipase 
D (Sun et al., 2004) (see Figure 1.2a). The physiological relevance of these 
alternative pathways under normal conditions in humans has yet to be 
explored (reviewed by Muccioli, 2010). 
 
1.1.2.2 2-AG synthesis  
In common with anandamide, the biosynthesis of 2-AG has been shown to 
be possible via more than one pathway. The pathway thought to be 
physiologically important in most cells and under normal conditions is the 
conversion of phosphatidylinositol, via a phospholipase C , to diacylglycerol, 
which is subsequently hydrolysed by a non-specific diacylglycerol lipase 
(DAGL) to 2±AG (Kondo et al., 1998; Bisogno et al., 2003). The 
intermediate in this pathway, diacylglycerol, can also be generated from 
phosphatidic acid under the action of a phosphatidic acid hydrolase 
(Bisogno et al., 1999). Alternatively, 2-AG may be synthesised from a 
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lysophospholipid under the action of a lyso-phospholipase C (Ueda et al., 
1993; Sugiura et al., 1995) (see Figure 1.2b). It is also likely that, in 
adipocytes at least, a proportion of 2-AG synthesis occurs as a result of 
triglyceride lipolysis through adipose triglyceride lipase (ATGL) and 
hormone sensitive lipase (HSL) (Zechner et al., 2009). 
 
 
Figure 1.2 Endocannabinoid synthesis pathways 
Endocannabinoid synthesis pathways for anandamide (a) and 2-AG (b) 
(adapted from Muccioli, 2010). PC , phosphatidylcholine; DAG, 
diacylglycerol; pNAE, phospho-NAE; lyso-NAPE, lysophosphatidyl-NAPE; 
lyso-PLC, lysophosphatidylinositol-selective phospholipase C; NAE, N-
acylethanolamine; NAPE, N-acylphosphatidylethanolamine; NAPE-PLD, N-
acylphosphatidylethanolamine-selective phospholipase D; NAT, N-
acyltransferase; PA, phosphatidic acid; PE, phosphatidylethanolamine; PI, 
phosphatidylinositol; PLA1, phospholipase A1; PLC, phospholipase C; 
PTPN22, phosphatase protein tyrosine phosphatase 22; sPLA2, secreted 
phospholipase A2. 
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1.1.3 Endocannabinoid degradation pathways  
Endocannabinoid signalling is terminated in two stages. Cellular uptake of 
the endocannabinoids occurs first, via mechanisms that are still under 
debate (reviewed by Yates and Barker, 2009b), and this is discussed in 
detail in Chapter 7. Then intracellular enzymes catalyse endocannabinoid 
degradation. The major pathways for anandamide and 2-AG catabolism are 
well characterised, but as with the synthesis pathways, alternative 
catabolic pathways are likely to exist. 
Anandamide is predominantly degraded under the action of fatty 
acid amide hydrolase (FAAH) (Deutsch and Chin, 1993; Cravatt et al., 
1996). Indeed, the rate of anandamide hydrolysis in tissues from FAAH 
knockout mice is 50-100 fold reduced, and anandamide concentrations in 
the brain (Cravatt et al., 2001; Lichtman et al., 2002) and liver (Tourino et 
al., 2010) are elevated. 
2-AG is inactivated by monoacylglycerol lipase (MGL) and also by 
FAAH to some extent (Dinh et al., 2002b), although anandamide is 
hydrolysed at a faster rate and more efficiently than 2-AG by FAAH (Di 
Marzo et al., 1998). However, the rate of anandamide hydrolysis by FAAH 
is reduced when the concentration of 2-AG is high, as is the case in many 
cells (Di Marzo et al., 1998). In animal studies it has been shown that, 
despite the ability of FAAH to metabolise 2-AG, MGL appears to have the 
pivotal role. In homogenised mouse brain, MGL accounts for approximately 
85% of 2-AG hydrolysis, with FAAH contributing just 1% (Blankman et al., 
2007). In mice, intraperitoneal administration of JZL184 (a specific MGL 
inhibitor) causes an increase in brain 2-AG concentrations (Long et al., 
2009). Similarly, in rats, depletion of MGL causes a significant decrease in 
the rate of 2-AG hydrolysis (Dinh et al., 2004).  
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Figure 1.3 Degradation pathways for anandamide  
PGH2-EA, prostaglandin H2 ethanolamide; EET, epoxyeicosatrienoic acid 
(adapted from Muccioli, 2010).  
 
As an alternative to hydrolysis, anandamide may be oxidised by 
cyclooxygenase-2 (COX-2) to PGE2-ethanolamide (Ross et al., 2002), 
which is a prostaglandin based molecule. The 12- and 15-lipoxygenases 
(12- and 15-LOX) can also use anandamide as a substrate to yield 12- and 
15-hydroxy-anandamide (Ueda et al., 1995b). Alternatively, the family of 
cytochrome p450 enzymes can catalyse the conversion of anandamide to 
various polar lipids (for review see Burstein et al., 2000) (see Figure 1.3). 
Similarly, 2-AG has been shown to be a substrate for these enzymes, with 
COX-2 yielding prostaglandin H2 glycerol ester (Kozak et al., 2000), 12-
LOX giving 12(S)-hydroperoxyeicosa-5,8,10,14-tetraenoic acid (Moody et 
al., 2001) and 15-LOX giving 15(S)-hydroperoxyeicosatetraenoic acid 
glyceryl ester (Kozak et al., 2002) (Figure 1.4). It should be noted that 
many of these studies have been conducted using animal tissues and FAAH 
or MGL inhibitors, so the physiological prevalence and relevance of these 
alternative endocannabinoid inactivation pathways has yet to be 
demonstrated in humans (for review see Fowler, 2007). 
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Figure 1.4 Degradation pathways for 2-AG  
15-HETE-G,15-hydroxyeicosatetraenoic acid glyceryl ester (from Muccioli, 2010).       
          
  
Given that FAAH and MGL are thought to contribute the majority of 
endocannabinoid inactivation in vivo, the activities of these two enzymes 
have been investigated in depth in the work presented in this thesis.  
 
1.1.3.1 Fatty acid amide hydrolase   
7KHWHUP³IDWW\DFLGDPLGHK\GURODVH´ZDVILUVWSXEOLVKHGLQ6, when it 
was conclusively shown that the enzymes previously referred to as 
oleamide hydrolase and anandamide amidohydrolase are in fact the same 
molecule (Maurelli et al., 1995; Cravatt et al., 1996). It was also shown 
that FAAH catalyses the hydrolysis of anandamide faster than that of 
oleamide (Cravatt et al., 1996). FAAH has many substrates, but exhibits 
specificity for the long-chain amides of ethanolamine (Schmid et al., 
1985). 
There are two isoforms of FAAH (1 and 2) which share only 
approximately 20% DNA sequence homology, although the catalytic site is 
relatively well conserved (Wei et al., 2006). The two isoforms are 
differentially expressed across species and tissues, with FAAH-1 expressed 
across many species, including human and rat, and FAAH-2 existing in 
humans but not rodents (Wei et al., 2006). In human kidney, liver, lung 
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and prostate both isoforms are expressed. However, only FAAH-1 levels 
are high in human brain, small intestine and testis, whereas in the heart 
FAAH-2 is the predominant form expressed (Wei et al., 2006). In 
subcutaneous adipose tissue, FAAH-1 and -2 are generally expressed to 
similar levels, with a slightly greater expression of FAAH-1 in lean humans 
(Bennetzen et al., 2011). Additionally, the two forms have different 
substrate specificity, with FAAH-1 having greater hydrolytic activity on 
anandamide than FAAH-2 (Wei et al., 2006). URB597 is a potent, selective 
and irreversible inhibitor of both enzyme isoforms, although it is more 
potent at FAAH-2 (Piomelli et al., 2006; Wei et al., 2006).  
FAAH is a membrane-bound enzyme (McKinney and Cravatt, 2005) 
and, interestingly, FAAH-1 is thought to be expressed on the cytosolic side 
of the cell membrane, whereas FAAH-2 may reside on the extracellular 
surface (Wei et al., 2006). FAAH is thought to form homodimers, although 
this has yet to be confirmed physiologically (Bracey et al., 2002). The 
location and structure of FAAH, attached to the cell membrane and with 
several channels, may allow the hydrolysis of anandamide from the 
extracellular space without it ever reaching the cytosol (McKinney and 
Cravatt, 2005). For reviews on this topic, see (McKinney and Cravatt, 2005; 
McPartland et al., 2007).  
Under experimental conditions, it has been shown that FAAH may 
catalyse the condensation of arachidonic acid and ethanolamine, but it is 
unlikely that this occurs physiologically, given the high energy requirement 
of this reaction (Schmid et al., 1985; Ueda et al., 1995a; Kurahashi et al., 
1997). 
 
1.1.3.2 Monoacylglycerol lipase  
MGL was first described in lipid metabolism, many years before the ECS 
was discovered (Vaughan et al., 1964). Its role in the hydrolysis of 1(3)- 
and 2-monoacylglycerols is essential for the release of free fatty acids from 
adipocytes, when required, to maintain energy homeostasis. MGL is able to 
catalyse the hydrolysis of a range of monoacylglycerols with various chain 
lengths (C8 to C18) (Labar et al., 2010b). The primary role of MGL in many 
organs is likely to be in the regulation of the ECS rather than in generalised 
fatty acid release, particularly in the CNS (Dinh et al., 2002a). The MGL 
isoform found in human adipose tissue, and many other organs, is a 33kDa 
protein, which shares 83% primary structure homology between rodents 
and humans (Karlsson et al., 1997; Dinh et al., 2002a; Ho et al., 2002). X-
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ray crystallography revealed MGL to exist as a homodimer, as for FAAH 
(Labar et al., 2010a). 
In adipocytes, MGL catalyses the final step in the lipolysis pathway, 
in which triacylglycerols are catabolised to glycerol and free fatty acids. It 
is widely thought that MGL does not represent the rate-limiting step of 
lipolysis, as it is present in excess in adipocytes. Perhaps as a result of 
this, the regulation of MGL has not been comprehensively investigated, but 
other lipases involved in lipolysis have been shown to be extensively 
regulated at the post-transcriptional level (Lafontan and Langin, 2009; 
Zechner et al., 2009).   
Unlike FAAH, MGL is localised in the cytosol. It has been shown that 
in adipose tissue homogenates, the majority of MGL activity is found in the 
supernatant fraction, in large lipid-protein aggregates, after centrifugation 
(Tornqvist and Belfrage, 1976).  
 
1.1.4 Cannabinoid receptors 
The two cloned cannabinoid receptors, CB1 and CB2, are G protein-coupled 
receptors (GPCRs) with seven transmembrane domains (Pertwee et al., 
2010). Most of the G proteins linked to the cannabinoid receptors are the 
inhibitory proteins G i or Go, and these act predominantly to inhibit adenylyl 
cyclase (Mackie, 2008). The cannabinoid type 1 (CB1) receptor was the 
first to be cloned (Matsuda et al., 1990) and is principally located in the 
CNS, where it is highly abundant and appears to participate in negative 
retrograde signalling (Mackie, 2008). CB1 receptors have also been 
identified in many peripheral tissues in humans and laboratory animals, 
including adipose, cardiac and skeletal muscle (Kurz et al., 2008). In 
contrast, relatively few CB2 receptors are found in the CNS, and the 
majority of CB2 receptors are expressed by cells with immunological 
functions, such as leucocytes and microglia (Munro et al., 1993; Cabral et 
al., 2008). 
The CB1 receptor can be activated by both anandamide and 2-AG, 
and the endocannabinoids have similar affinities for this receptor, although 
2-AG is more potent and anandamide is often considered to be a partial 
agonist. Similarly, both endocannabinoids are agonists of the CB2 receptor, 
although again 2-AG is more potent. Both anandamide and 2-AG have 
greater affinities for the CB1 receptor than the CB2. Noladin ether is a 
selective CB1 receptor agonist, virodhamine is a partial CB2 agonist and a 
CB1 receptor antagonist, and NADA is a selective CB1 receptor agonist.  
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THC is a partial agonist for the cannabinoid receptors but has high affinity 
for them (Pertwee and Ross, 2002; Pertwee et al., 2010). By contrast, 
cannabidiol has low affinity for CB1/2 receptors, and is thought to be an 
antagonist of various endogenous and synthetic cannabinoid receptor 
ligands, leading to similar effects as cannabinoid receptor antagonists 
(Mechoulam et al., 2007). 
Endocannabinoids are known to bind to a variety of other receptors 
and channels. One such superfamily is the transient receptor potential 
(TRP) channels. These transmembrane cation channels are most 
extensively expressed in nociceptive neurons (Tominaga and Caterina, 
2004), but are also found in many other tissues such as skeletal muscle, 
adipose (Cavuoto et al., 2007b) and the CNS (Mezey et al., 2000). In 
general, the TRP channels respond to various noxious stimuli, including 
heat, physical damage and chemical messengers (Tominaga and Caterina, 
2004). With regard to cannabinoid pharmacology, the vanilloid channels 
(TRPV) are best characterised to date. TRPV1 is primarily a heat receptor 
expressed in sensory neurons (Latorre et al., 2007), and its activation has 
been found to cause vasodilation (Zygmunt et al., 1999), but there is also 
evidence that TRPV1 has an important role in metabolism, as TRPV1 
knockout mice are resistant to the obesity-protective effects of capsaicin 
when fed a high-fat diet (Zhang et al., 2007). TRPV1 is activated by 
anandamide, OEA, PEA and cannabidiol, but not efficiently by 2-AG or THC 
(reviews by Pertwee, 2006; De Petrocellis and Di Marzo, 2010). Other TRP 
channels with known cannabinoid ligand interactions include TRPV2, 
TRPV4, TRPM8 and TRPA1 (reviewed by De Petrocellis and Di Marzo, 
2010). 
Additionally, endocannabinoids are ligands for the nuclear 
peroxisome proliferator-activated receptors (PPARs) (O'Sullivan et al., 
2005; Lenman and Fowler, 2007)  and there is evidence that these 
interactions may be as significant in some cells as CB1/2 receptor activation 
(O'Sullivan, 2007; Pagano et al., 2008). Three PPAR isoforms (ĮǄDQGȕ 
įKDYHEHHQLGHQWLILHGWRGDWHDQGWKHVHIRUPKHWHURGLPHUVZLWKUHWLQRLG
X receptors (RXRs) before binding to target gene promoters in order to 
regulate transcription. The PPARs have key roles in regulating cellular 
differentiation, lipid metabolism and inflammation, and accordingly they 
are expressed in the majority of human cells and have many known 
ligands, particularly fatty acids and their metabolites (for PPAR review see 
Glass and Ogawa, 2006). PPARĮ is highly expressed in metabolically active 
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tissues, such as liver, adipose, skeletal muscle and heart, and is also 
relatively abundant in monocytes, lymphocytes and macrophages, 
reflecting its roles in metabolism and immunity. Generally PPAR Į activation 
is metabolically protective and causes reductions in steatosis and 
inflammatory processes associated with overfeeding in liver and adipose 
tissue (for review see Stienstra et al., 2007). PPARĮ agonists (fibrates) are 
XVHGFOLQLFDOO\ LQWKHWUHDWPHQWRIG\VOLSLGDHPLD33$5įKDVQRWEHHQZHOO
characterised, but it is relatively highly expressed in brain and adipose 
tissue. Studies using murine models have indicated that it has an 
important role in metabolic regulation, and possibly in immunosuppression. 
,QWHUHVWLQJO\ ERWK 33$5į NQRFNRXW PLFH DQG WKRVH WUHDWHG ZLWK 33$5į
agonists have reduced adipose tissue mass (Stienstra et al., 2007). PPARǄ
is most abundantly expressed in adipose tissue compared to other tissues 
(Auboeuf et al., 1997) and has an essential role in adipogenesis, lipid 
VWRUDJH DQG JOXFRVH PHWDEROLVP $FFRUGLQJO\ 33$5Ǆ DJRQLVWV
(thiazolidinediones) have been used therapeutically to increase insulin 
VHQVLWLYLW\ LQW\SHGLDEHWHV$VZLWKWKHRWKHULVRIRUPV33$5ǄDFWLYDWLRQ
is associated with dampening inflammatory processes (Stienstra et al., 
2007) 7KHUH DUH DW OHDVW  33$5Ǆ LVRIRUPV ZKLFK DUH GLIIHUHQWLDOO\
H[SUHVVHG 33$5Ǆ ZKLFK LV XELTXLWRXV DQG 33$5Ǆ ZKLFK LV UHODWLYHO\
specific to adipose tissue (Auboeuf et al., 1997). Anandamide, 
virodhamine, OEA and PEA have all been shown, to varying degrees, to be 
PPARĮ agonists (Fu et al., 2003; Lo Verme et al., 2005; Sun et al., 2006). 
7R GDWH 2($ LV WKH RQO\ FDQQDELQRLG UHODWHG DJRQLVW UHSRUWHG IRU 33$5į
(Fu et al., 2003). Cannabinoid related aJRQLVWVLGHQWLILHGWRGDWHIRU33$5Ǆ
include anandamide, 2-AG, THC, cannabidiol and NADA (Bouaboula et al., 
2005; O'Sullivan et al., 2005; Rockwell et al., 2006; O'Sullivan et al., 
2009a; O'Sullivan et al., 2009b). 
Further to these well recognised endocannabinoid targets, several 
others have been postulated, including calcium and potassium channels 
(for review see Pertwee et al., 2010), and serotonergic (Kimura et al., 
1998; Xiong et al., 2008) and muscarinic receptors (Christopoulos and 
Wilson, 2001). In some environments anandamide, 2-AG, THC, PEA and 
OEA are agonists of the orphan receptor GPR55 (Ryberg et al., 2007), but 
other studies have questioned the response of GPR55 to anandamide and 
2-AG (Lauckner et al., 2008; Henstridge et al., 2009). The inclusion of 
GPR55 in the ECS will remain under debate until its cannabinoid 
pharmacology has been conclusively characterised. GPR119 is another 
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orphan receptor which has been considered with regard to the ECS, as 
anandamide, PEA and OEA were reported to be agonists (Overton et al., 
2006; Chu et al., 2010). However, interactions were only found at higher 
than physiological concentrations, and as no other cannabinoid l igands 
have been identified it is thought that GPR119 is not involved in the ECS 
(Pertwee et al., 2010). Another potential endocannabinoid target is the 
novel endothelial cannabinoid receptor. This receptor was first postulated 
in rat mesenteric blood vessels (Jarai et al., 1999) and has yet to be fully 
characterised. Work to date has shown that it may be a G i/o protein 
coupled receptor which is activated by anandamide and abnormal 
cannabidiol (Mukhopadhyay et al., 2002; Begg et al., 2003). 
 As a further complication when considering the signalling of the 
ECS, recent research indicates that the CB1 receptor may form 
heterodimers with receptors such as adenosine A2A (Carriba et al., 2007), 
dopamine D2 (Kearn et al., 2005) and orexin 1 (Ellis et al., 2006). 
Similarly, there is some evidence that cannabinoid receptors and TRPV 
channels may co-ORFDOLVH DQG HQKDQFH RU LQKLELW HDFK RWKHU¶V VLJQDOOLQJ
(Hermann et al., 2003; reviewed by Di Marzo and Cristino, 2008). Whether 
all of these interactions occur physiologically remains to be answered, but 
they may explain some of the apparently contradictory results that are 
sometimes found within cannabinoid pharmacology.  
 
1.2 Adipose tissue  
The primary function of white adipose tissue is to store lipids when food 
LQWDNHH[FHHGVWKHERG\¶VHQHUJ\UHTXLUHPHQWDQGWRVXEVHTXHQWO\UHOHDVH
this energy as required. The triacylglycerols stored in mature adipocytes 
themselves constitute up to 85% of the total mass of adipose tissue, but 
adipocytes account for less than half of the total number of cells in white 
adipose tissue; the remaining cellular number comprises cells such as 
preadipocytes, fibroblasts, endothelial cells and macrophages (Trayhurn et 
al., 2006). Sites of adipose tissue deposition in humans fall into two 
categories: visceral and subcutaneous. Visceral adipose tissue is largely 
restricted to the omentum in healthy people, whereas subcutaneous 
adipose tissue is found throughout the body directly under the skin. These 
two major adipose tissue depots are widely thought to be metabolically 
distinct (for extensive review see Wajchenberg, 2000) and this concept is 
discussed with reference to various findings throughout the remainder of 
this chapter.  
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1.2.1 Lipid metabolism 
Lipids are transported in blood plasma in several forms, including free 
cholesterol, lipoproteins, triacylglycerols and free fatty acids bound to 
albumin. These molecules are then transported in and out of mature 
adipocytes as required in the form of free fatty acids and 
monoacylglycerols. During lipogenesis, lipoprotein lipase is recruited to the 
endothelium of capillaries and triacylglycerols are catabolised. Fatty acids 
accumulated in adipocytes from the blood are then re-esterified through 
the glycerol 3-phosphate pathway to triacylglycerols (see Figure 1.5). 
These triacylglycerols are stored in a large lipid droplet surrounded by a 
phospholipid monolayer, which has various proteins embedded in it (for 
review see Zweytick et al., 2000).  
 
 
 
Figure 1.5 Lipid uptake by adipocytes 
Simplif ied schematic of fatty acid uptake from the circulation and some 
stages of lipid metabolism in the adipocyte. LPL, lipoprotein lipase; FATP, 
fatty acid transport protein; GPAT, glycerol-3-phosphate acyltransferase; 
AGPAT, acylglycerophosphate acyltransferase; PAP, phosphatidic acid 
phosphohydrolase; DGAT, diacylglycerol acyltransferase. 
 
Conversely, during times of fasting or excess energy expenditure, 
lipolysis is activated in adipocytes and fatty acids are released from 
storage back into circulation. The major lipolysis pathway has been revised 
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in relatively recent years by the discovery of ATGL (Jenkins et al., 2004; 
Villena et al., 2004; Zimmermann et al., 2004). It is now thought that the 
majority of triglycerides are catabolised to diacylglycerols by ATGL, and are 
then converted to monoacyglcyerols and further free fatty acids under the 
action of HSL. MGL then catalyses the final stage, to produce glycerol and 
a free fatty acid (see Figure 1.6). 
 
ADIPOCYTE
ATGL
HSL
MGL
Triglyceride
FFA
Glycerol
 
 
Figure 1.6 Lipolysis 
Major lipolysis pathway, involving MGL. FFA, free fatty acid; MGL, 
monoacylglycerol lipase; HSL, hormone sensitive lipase; ATGL, adipose 
triglyceride lipase. 
 
1.2.2 The endocrine function of adipose tissue: adipokines  
In recent years our understanding of the functions of adipose tissue has 
developed greatly. Adipose tissue is no longer considered to be merely an 
inert energy storage facility, but a specialised endocrine organ (Sethi and 
Vidal-Puig, 2007). Given the total mass of white adipose tissue in healthy 
humans this is a significant consideration. In healthy men adipose tissue 
contributes 10-20% to total body mass, whilst in females this figure is 20-
30% (Williams and Frühbeck 2009). The signalling proteins, lipids and 
other factors released by adipose tissue are collectively termed adipokines, 
although technically adipokines are secreted or modified only by adipocytes 
(Wang et al., 2008b). The structures and functions of the adipokines are 
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diverse, and their targets include many organs, such as the skeletal 
muscle, brain and kidneys (Ronti et al., 2006; Trayhurn et al., 2006). Their 
effects on these organs are largely metabolic, such as the regulation of 
fatty acid oxidation and control of appetite, although many adipokines, 
directly or indirectly, also affect processes such as inflammation, immunity 
and angiogenesis (Ronti et al., 2006; Trayhurn et al., 2006). In addition, 
some adipokines behave in a paracrine or autocrine fashion and feedback 
directly on adipose and its associated tissues (Wang et al., 2008b). Some 
of the most extensively investigated adipokines involved in energy 
homeostasis are described in the following paragraphs. 
 
1.2.2.1 Adiponectin  
One of the major adipokines, with regard to energy homeostasis and 
inflammatory processes, is the peptide hormone adiponectin. Adiponectin 
is a 30 kDa protein which forms trimers, hexamers and larger oligomers 
(Pajvani et al., 2003). It is produced by mature adipocytes and secreted 
into the blood in relatively large concentrations compared to many other 
adipokines (Ronti et al., 2006). Adiponectin secretion and its concentration 
in blood plasma in humans are inversely correlated with the total volume 
of adipose tissue in the individual (Arita et al., 1999). In mice fed a high-
fat content diet, the rate of adiponectin clearance from blood plasma was 
found to be reduced, indicating that in obesity the production of 
adiponectin is likely to be suppressed (Halberg et al., 2009). Females have 
a higher concentration of circulating adiponectin than males (Arita et al., 
1999; Nishizawa et al., 2002) and murine experiments have indicated that 
this may be due to an increased rate of production, as liver clearance rates 
are similar (Halberg et al., 2009). Other experiments in mice and cell 
culture indicate that this difference may be mediated by testosterone 
(Nishizawa et al., 2002). In contrast with many metabolic mediators, some 
studies have not found any diurnal variation in plasma adiponectin 
concentrations in lean or obese humans (Hotta et al., 2000; Yildiz et al., 
2004). However, a detailed study using more frequent blood sampling has 
found that adiponectin concentrations fall overnight (Gavrila et al., 2003). 
The importance of adiponectin in maintaining insulin sensitivity is 
demonstrated by the finding that, in healthy humans, serum adiponectin 
concentration is negatively correlated with the risk of developing type 2 
diabetes, and this predictor was found to be independent of BMI (Spranger 
et al., 2003). Furthermore, in obese humans, adiponectin secretion from 
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omental adipocytes is inversely correlated with fasting plasma glucose 
concentration (Bakker et al., 2006). Adiponectin receptors have been 
identified in organs targeted by insulin, such as adipose tissue, the liver 
and skeletal muscle (Wang et al., 2008b). To date, two adiponectin 
receptors have been identified: AdipoR1, which is ubiquitously expressed, 
and AdipoR2, which is primarily found in the liver (Williams and Frühbeck, 
2009). In mice, AdipoR1 has been shown to activate AMP-activated protein 
kinase (AMPK), whereas AdipoR2 was found to be linked to PPARĮ 
signalling (Yamauchi et al., 2007). The net effects of activation of these 
two receptors therefore include increased glucose uptake and fatty acid 
oxidation in the liver and skeletal muscle, and suppression of hepatic 
gluconeogenesis, inflammatory processes and ectopic triglyceride storage 
(Robinson et al., 2011).  
 
1.2.2.2 Leptin  
Another key adipokine is leptin, a 16 kDa polypeptide hormone which 
suppresses appetite and regulates lipid metabolism, primarily via its 
receptors in the hypothalamus (Hochberg and Hochberg, 2010). In 
adipocytes, its actions include the activation of fatty acid oxidation and 
lipolysis, and the downregulation of lipogenesis (Scherer and Buettner, 
2011).  
Leptin secretion is increased in obesity and its blood plasma 
concentration correlates with BMI. It has been suggested that the primary 
role of leptin is actually to stimulate feeding during times of starvation, as 
plasma leptin concentrations fall during periods of both chronic 
(Baranowska et al., 2008) and acute (overnight) anorexia (Gavrila et al., 
2003). There is mounting evidence that leptin regulates energy 
homeostasis primarily via its signalling in the brain, particularly in the 
hypothalamus (Scherer and Buettner, 2011). Systemic disruption of leptin 
signalling in rodents causes obesity, and several rodent models of obesity 
(for example ob/ob mice and fa/fa Zucker rats) have mutations in the 
leptin receptor (Zhang et al., 1994; Ogawa et al., 1995). By contrast, in 
mice, deletion of peripheral leptin receptors, but not those in the brain, 
does not appear to affect energy homeostasis or adipose tissue deposition 
(Guo et al., 2007).  
In humans, congenital leptin deficiency is rare, but causes obesity 
and severe dyslipidaemia. This finding that both insufficient and excess 
concentrations of leptin in the circulation are associated with similar 
Chapter 1: Introduction 
 
   31 
 
pathologies has led to the suggestion of leptin resistance. This concept has 
yet to be conclusively proven, but it is a theory which explains many of the 
relationships between obesity and leptin (Heymsfield et al., 1999; Ronti et 
al., 2006; Oswal and Yeo, 2010). In the pathological state of chronic 
overfeeding, plasma concentrations of leptin rise and resistance occurs. 
This reduces anorexigenic signalling and inhibition of lipolysis, leading to a 
positive feedback loop resulting in increased adipose tissue mass and 
further resistance (Oswal and Yeo, 2010). In keeping with this hypothesis, 
a recent review found that even moderate weight-loss in obese humans, 
via calorie restriction, markedly reduced serum leptin concentration before 
the secretion of other adipokines was detectably affected (Klempel and 
Varady, 2011). This may be partly explained by the finding that in mice 
hypertriglyceridaemia, which is common in obesity, inhibited leptin 
transport in the brain, further reducing leptin signalling (Banks et al., 
2004).  
 The importance of leptin sensitivity in maintaining normal 
physiology has also been demonstrated in cell culture, as leptin improves 
insulin sensitivity and glucose handling in leptin sensitive cells (Ronti et al., 
2006). This relationship between leptin and glycaemic regulation is further 
shown by the finding that leptin secretion by omental adipocytes isolated 
from obese humans correlates with fasting plasma glucose concentration 
(Bakker et al., 2006), although it should be noted that adipocyte size is 
thought to be the most important regulator of leptin secretion . 
 
1.2.2.3 Resistin  
Resistin is a 12.5 kDa peptide which was first described in 2001 (Steppan 
et al., 2001). This protein is a pro-inflammatory mediator which has been 
shown to increase inflammatory cytokine production and release from 
several cells, including adipocytes, leucocytes and endothelial cells (for 
review see Stofkova, 2010). Initially, resistin was thought to be secreted 
by adipocytes, but it has been shown that the presence of resistin in 
adipose tissue is largely due to preadipocytes (Janke et al., 2002), 
leucocytes (Kaser et al., 2003), and other non-adipose tissue cells (Fain et 
al., 2003) rather than mature adipocytes.  
Cell culture work conducted in murine adipocytes and 3T3-L1 cells 
has shown that resistin expression was induced during preadipocyte 
differentiation, but also that it inhibited differentiation (Kim et al., 2001). 
These findings are not supported by a study using human adipocytes 
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isolated from subcutaneous and omental adipose tissue, which found that 
resistin release from adipose tissue was not accounted for by mature 
adipocytes (Fain et al., 2003). Further work in 3T3-L1 cells, indicating a 
role for resistin in glycaemic regulation and insulin resistance, has shown 
resistin mRNA to be upregulated by glucose (Shojima et al., 2002) and 
decreased by insulin (Haugen et al., 2001; Shojima et al., 2002; Liu et al., 
2008). Conversely, the effect of resistin on 3T3-L1 cells was to decrease 
insulin-stimulated glucose uptake (Steppan et al., 2001). 
Some authors have suggested that resistin may mediate insulin 
resistance. Serum resistin concentration may be elevated in obese insulin 
resistant humans compared to obese insulin sensitive humans (Baranova 
et al., 2006), but this finding followed a study showing that serum resistin 
concentrations are only related to insulin sensitivity in lean humans 
(Heilbronn et al., 2004). Other studies found no difference in serum 
resistin concentrations (Kielstein et al., 2003; Chen et al., 2006) or 
adipose tissue resistin mRNA levels (Janke et al., 2002) between healthy, 
insulin resistant and diabetic patients. Furthermore, the relationship 
between resistin and obesity remains unclear. In some studies, blood 
plasma concentrations of resistin were found to be increased in obese mice 
(Steppan et al., 2001) and humans (Degawa-Yamauchi et al., 2003; 
Piestrzeniewicz et al., 2008), with corresponding increases in both resistin 
mRNA (Savage et al., 2001) and protein (Degawa-Yamauchi et al., 2003) 
in the adipose tissue of obese humans. Weight loss in obese females was 
found to correlate with a reduction in fasting serum resistin concentration, 
although this was accounted for by waist circumference rather than BMI 
(Valsamakis et al., 2004), possibly indicating that visceral adiposity may 
be more important in predicting resistin concentrations than generalised 
obesity. This was also supported by a study showing that omental adipose 
tissue in culture secreted 2.5-fold more resistin than subcutaneous adipose 
tissue (Fain et al., 2003). By contrast, some investigations have not found 
any relationship between human obesity and serum resistin concentrations 
(Heilbronn et al., 2004; Anderlova et al., 2007).  
Much of the work on resistin to date has been performed in animals 
and in 3T3-L1 cells and is highly contradictory (reviewed by Schwartz and 
Lazar, 2011). Further studies will need to be conducted in humans and 
isolated human adipocytes before the role and mechanisms of resistin in 
human physiology, obesity and diabetes are fully understood.  
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1.3 Obesity  
1.3.1 Obesity 
In obesity, adipose tissue becomes hyperplasic and hypertrophic, and, as 
already described to some extent, this is associated with abnormalities in 
its function and signalling. The incidence and prevalence of obesity have 
risen sharply over recent decades. In 2005 an estimated 400 million adults 
worldwide were obese, with a further 1.6 billion adults classified as 
overweight (BMI 25-30). By 2015 these figures are expected to rise to 700 
million and 2.3 billion respectively (WHO, 2006b). The mortality associated 
with obesity is significant. According to one report obesity is associated 
with an average 7 year decreased life expectancy for women, and 6 years 
in men (Peeters et al., 2003). As survival rates fall with increasing BMI, 
this has been further assessed as a median survival reduction of 2 to 4 
years in the 30-35 BMI range, increasing to 8 to 10 years when BMI is 
greater than 40 (Whitlock et al., 2009).  
Obesity is known to be a causative risk factor in the development of 
many pathological conditions besides metabolic disease, such as 
cardiovascular diseases, musculoskeletal disorders and some cancers (Biro 
and Wien, 2010). The expression of many adipokines and other molecules 
becomes dysregulated in obesity and these changes have roles in the 
development of many of the diseases associated with obesity. In 
particular, high concentrations of free fatty acids in the circulation are 
thought to affect the liver, skeletal muscle, pancreas and heart resulting in 
LQFUHDVHG JOXFRVH SURGXFWLRQ LQVXOLQ UHVLVWDQFH DQG ǃ-cell damage 
(Williams and Frühbeck, 2009).   
 
1.3.2 Type 2 diabetes  
Type 2 diabetes is a common disease that was estimated to affect 
approximately 171 million adults globally in 2000, with this figure expected 
to at least double by the year 2030 (Wild et al., 2004). Type 2 diabetes is 
characterised by insulin resistance ZLWK SDQFUHDWLF ǃ-cell failure and 
elevated plasma glucose concentration (WHO, 2006a), although there are 
various different local criteria and cut-off points for the diagnosis of 
diabetes. Obesity is the most significant risk factor in the development of 
type 2 diabetes. More specifically, excess visceral fat confers a greater risk 
than the same volume of subcutaneous or lower body fat in the 
development of type 2 diabetes and other metabolic disorders (Bray et al., 
2008; Taksali et al., 2008). In addition, it is visceral adipose mass rather 
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than total adipose mass that determines the rate of glucose infusion 
required during a euglycaemic-hyperinsulinaemic clamp (Blüher et al., 
2006).  
The term metabolic syndrome, although debatable and not 
internationally defined, is often used in research to describe patients who 
are at an increased risk of developing type 2 diabetes and cardiovascular 
diseases (Després and Lemieux, 2006). Different combinations of simple 
tests and measurements are used to define metabolic syndrome. These 
include fasting glucose, glucose tolerance, fasting plasma lipids and 
cholesterol, body mass index (BMI), waist circumference, waist-to-hip ratio 
and blood pressure (Grundy et al., 2004; Després and Lemieux, 2006; 
Alberti et al., 2009). It has been argued that waist circumference should 
be used in preference to BMI, as this better estimates excess visceral 
adiposity and therefore cardiovascular and metabolic risk (Després and 
Lemieux, 2006). It is necessary to include metabolic function markers in 
addition to adiposity measurements in defining metabolic syndrome, as 
there is a well recognised, but not well characterised, subset of the obese 
population who do not develop overt metabolic or cardiovascular 
diseases(Pataky et al., 2010). 
Although the correlation between obesity and certain metabolic 
disorders has been recognised for some time, many of the cellular 
mechanisms that are responsible for this relationship are still a matter of 
research. 
 
1.3.3 Dyslipidaemia in obesity  
One of the common co-morbidities associated with obesity, and particularly 
insulin resistance, is dyslipidaemia. Very simply, dyslipidaemia results from 
alterations in the synthesis and degradation of lipoproteins. In obesity, 
very low density lipoprotein cholesterol (VLDL-cholesterol) production and 
high density lipoprotein cholesterol (HDL-cholesterol) degradation both 
tend to be increased. Additionally, the concentration of triglycer ides in the 
blood is often increased. Dyslipidaemia is thought to arise as a 
consequence of insulin resistance and increased fat accumulation in the 
liver and visceral adipose tissue (for recent review see Watts and Chan, 
2010).    
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1.4 The ECS in adipocytes and adipose tissue  
It is well established that the ECS is present and functional in human 
adipose tissue, although to date its precise role and regulation have not 
been determined. 
 
1.4.1 Endocannabinoids  
The basal concentrations of anandamide and 2-AG in human subcutaneous 
adipocytes in cell culture are approximately equal (Gonthier et al., 2007) 
and isolated adipocytes from human visceral adipose also contain both 
endocannabinoids (Matias et al., 2006). It has been shown in a murine 
preadipocyte cell line that induction of adipogenesis led to a significant 
increase in intracellular concentrations of anandamide and 2-AG, and that 
2-AG concentrations remained high in mature adipocytes compared to 
preadipocyte levels (Matias et al., 2006; D'eon et al., 2008). In addition, 
anandamide has been shown to induce differentiation of 3T3-L1 
preadipocytes, possibly by direct activaWLRQ RI 33$5Ǆ (Bouaboula et al., 
2005). Human subcutaneous adipocytes also produce OEA and PEA. The 
concentration of OEA is similar to those of anandamide and 2-AG, whereas 
PEA is present in considerably larger amounts (Gonthier et al., 2007), and 
this may be of importance when considering metabolic signalling. 
 
1.4.2 Receptors  
Functional CB1 and CB2 receptors are expressed by preadipocytes and, at 
higher concentrations, by mature adipocytes from visceral and 
subcutaneous adipose depots in humans (Roche et al., 2006). Further to 
this, the CB1 and CB2 receptor agonist CP55,940 has been used in studies 
with 3T3-L1 cells to show that the binding efficiency of the receptors 
almost doubles 9 days after differentiation is initiated (Gasperi et al., 
2007). The relative levels of cannabinoid receptor expression in human 
adipocytes are a matter of dispute. One study showed CB2 receptor mRNA 
levels in mature adipocytes to be approximately 4-fold higher than those of 
the CB1 receptor (Roche et al., 2006), whereas another reported CB2 
receptor mRNA levels to fall to almost nothing in human adipocytes after 
differentiation (Pagano et al., 2007). In human adipocytes, CB1 receptor 
mRNA and protein have been reported to be increased in mature 
adipocytes compared to preadipocytes (Engeli et al., 2005). In 3T3-L1 
cells, CB1 receptor protein expression increases with differentiation, 
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whereas CB2 receptor level decreases (Gasperi et al., 2007; Karaliota et 
al., 2009).  
The effects of cannabinoids on adipocytes are summarised in Table 
1.1. CB1 receptor activation with WIN-55,212 in human adipocytes 
increases glucose uptake via the glucose transporter GLUT-4, even in the 
absence of insulin. Although WIN-55,212 is a CB1/CB2 receptor agonist, the 
use of the selective CB1 receptor antagonist rimonabant showed these 
effects to be CB1 mediated (Pagano et al., 2007). Similarly, in 3T3-L1 
adipocytes, anandamide stimulation, albeit only at a high concentration of 
10µM, for 24 hours caused an increase in insulin-stimulated glucose uptake 
but did not alter the basal glucose uptake rate (Gasperi et al., 2007). 
Interestingly, in this study, rimonabant only partially blocked the effect of 
anandamide. Furthermore, anandamide did not affect glucose uptake at 
the 4 hour time-point (Gasperi et al., 2007), possibly implicating the 
involvement of receptors with longer response times, such as the PPARs.  
In primary culture of murine adipocytes, WIN-55,212 was found to 
increase lipoprotein lipase activity, and rimonabant blocked this effect, 
showing it to be CB1 receptor mediated (Cota et al., 2003). In vivo this 
would lead to an increase in fatty acids available for lipogenesis. 
Furthermore, in 3T3-L1 cells stimulation of cannabinoid receptors using 
HU-210, a THC analogue, in differentiating adipocytes increased the rate at 
which lipid droplets formed. The use of a CB1 receptor antagonist showed 
this effect to be CB1 receptor mediated (Matias et al., 2006). In another 
study using 3T3-L1 cells, THC stimulation was also found to increase 
lipogenesis and inhibit lipolysis, and these effects were at least partially 
blocked using cannabinoid receptor antagonists (Teixeira et al., 2010). 
There is also evidence that other cannabinoid targets may have roles in the 
regulation of lipid metabolism, as TRPV1 activation (using capsaicin) was 
found to inhibit lipogenesis in cultured 3T3-L1 cells (Zhang et al., 2007). 
Anandamide has been shown to dose-dependently increase the rate of 
differentiation of 3T3-L1 cells, as measured by triglyceride accumulation 
DQG33$5ǄH[SUHVVLRQDQGDFWLYLW\DOWKRXJKWKHVHHIIHFWVPD\EHSDUWLDOO\
mediated by anandamide metabolites (Bouaboula et al., 2005; Karaliota et 
al., 2009). Interestingly, in one of these studies, the use of rimonabant 
showed anandamide mediated lipid droplet accumulation to be 
independent of the CB1 receptor (Bouaboula et al., 2005). This indicates 
that P3$5Ǆ DFWLYDWLRQ PD\ EH UHVSRQVLEOH IRU WKH REVHUYHG LQFUHDVHV LQ
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GLIIHUHQWLDWLRQ DV 33$5Ǆ VWLPXODWLRQ LV NQRZQ WR PHGLDWH OLSLG
accumulation (Stienstra et al., 2007). 
 
Effect References 
ĹJOXFRVHXSWake (basal and insulin 
stimulated) 
Gasperi et al., 2007; Pagano et 
al., 2007 
Ĺ/ipoprotein lipase activity Cota et al., 2003 
ĹOLSLGGURSOHWIRUPDWLRQ / lipogenesis Matias et al., 2006; Teixeira et 
al., 2010 
ĹGLIIHUHQWLDWLRQ Bouaboula et al., 2005; Karaliota et al., 2009 
ĻOLSRO\VLV Teixeira et al., 2010 
 
Table 1.1 Cannabinoids and adipocytes 
Effects of endocannabinoids, phytocannabinoids and synthetic 
cannabinoids in adipocytes.  
  
7DNHQWRJHWKHUWKHVHILQGLQJV LQGLFDWHWKDWDORQJZLWK33$5Ǆ&%1 
receptor activation in adipocytes in vivo might increase the rate of 
preadipocyte differentiation and triglyceride synthesis (Vettor and Pagano, 
2009), providing evidence for a role of the ECS in energy storage and 
homeostasis.  
 
1.4.3 Enzymes   
The enzymes of the ECS are known to be present in adipocytes. The 
principal enzymes responsible for anandamide and 2-AG synthesis, NAPE-
PLD and DAGL respectively, are also both present and active in human 
adipocytes (Spoto et al., 2006) and 3T3-L1 cells (Gasperi et al., 2007). 
DAGL has a specific activity approximately 8 times greater than that of 
NAPE-PLD (Spoto et al., 2006), probably reflecting its role in adipocyte 
lipid metabolism rather than in ECS signalling. 
The expression of FAAH is higher in mature human adipocytes than 
preadipocytes (Engeli et al., 2005; Spoto et al., 2006). This has been 
further investigated in 3T3-L1 cells, in which FAAH protein and its activity 
are increased in differentiated cells compared to fibroblasts (Gasperi et al., 
2007). Furthermore, stimulating differentiating 3T3-L1 cells with 
anandamide causes an increase in FAAH mRNA and protein (Karaliota et 
al., 2009), although whether this is due to the differentiation effects of 
anandamide or is a mechanism to decrease the intracellular anandamide 
concentration is unclear. 
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 MGL is also present in human adipocytes and its activity is 
considerably higher than that of FAAH (Spoto et al., 2006), which is as 
would be expected given the role of MGL in lipid metabolism. The 
mechanisms of MGL regulation in adipocytes remain unknown (Labar et al., 
2010b) and the activity of MGL in rat adipocytes was found to be stable, 
regardless of whether the rats were fed or fasted (Tornqvist et al., 1978). 
  
1.5 The ECS in the CNS and adipose tissue in obesity and diabetes  
1.5.1 CNS  
The ECS was first described in neurons, as a retrograde signalling system, 
and indeed, the CB1 receptor is one of the most abundant receptors in the 
human brain. It has been recognised for many years that CB1 receptor 
agonists, such as THC, stimulate appetite and feeding in humans and this 
is thought to be largely mediated by the hypothalamus and mesolimbic 
pathways (for review see Bermudez-Silva et al., 2010).  
 In the hypothalamus, activation of the ECS suppresses satiety 
signalling pathways and increases orexigenic signalling (Bermudez-Silva et 
al., 2010), and there is evidence that endocannabinoid concentrations in 
the hypothalamus of rats fluctuate with metabolic status. 2-AG in 
particular has been found to be elevated in fasting rats and suppressed 
post-prandially (Kirkham et al., 2002). Additionally, anandamide 
administration directly into the hypothalamus of non-fasted rats increased 
food intake and this was demonstrated to be CB1 receptor mediated 
(Jamshidi and Taylor, 2001). Leptin is known to be crucial in hypothalamic 
metabolic signalling and its relationship with ECS signalling has been 
studied in some depth. It has been suggested that endocannabinoids are 
under the negative regulation of leptin in the hypothalamus, as obese 
rodents and those with leptin mutations have increased anandamide and 
2-AG concentrations which can be reduced with leptin administration (Di 
Marzo et al., 2001; Di Marzo, 2008). 
 The ECS is also involved in the reward and behavioural aspects of 
feeding, via its signalling in the mesolimbic pathways. It has been 
recognised for many years that cannabinoids increase feeding motivation 
in humans (for review see Kirkham, 2003) and more recently CB1 receptor 
antagonism in rats, in the mesolimbic reward areas of the brain, has been 
shown to suppress palatable food mediated dopamine release (Melis et al., 
2007). Similarly, FAAH inhibition in the brain of rats causes a CB1 receptor 
Chapter 1: Introduction 
 
   39 
 
dependent increase in the intake of palatable foods (Dipatrizio and 
Simansky, 2008). 
 
1.5.2 Rimonabant and the CB1 receptor in metabolism and obesity 
The study of the effects of the potent and relatively specific CB1 receptor 
antagonist, SR141716A (rimonabant), has greatly contributed to a better 
understanding of the ECS in metabolic regulation. Rimonabant has a higher 
affinity for the CB1 receptor than CB2, and is a higher affinity antagonist at 
the CB1 receptor than at any other targets described to date. It should be 
noted however that rimonabant has been reported to bind to a number of 
other receptors and channels, including opioid, dopamine, TRPs and PPARs 
(Pertwee et al., 2010). Additionally, rimonabant is sometimes referred to 
as an inverse agonist, possibly due to inhibition of basal G -protein activity, 
and there is evidence that these effects may be non-CB1 receptor mediated 
(Breivogel et al., 2001; Savinainen et al., 2003; C inar and Szucs, 2009). 
In humans, the effects of rimonabant include appetite suppression and 
increased energy expenditure, and the drug was therefore licensed in 
Europe to aid weight loss in obese patients (Van Gaal et al., 2005). 
Rimonabant has now been withdrawn due to an increased risk of suicide, 
depressed mood disorders and anxiety, despite the exclusion of  patients 
with a history of depression from the clinical trials (Christensen et al., 
2007), but some of the data collected from the clinical trials and animal 
studies are discussed below. 
In the published trials of rimonabant its effects on body mass were 
modest, with mean weight losses of 2.5-8.6 kg reported in patients with a 
BMI of at least 27 kg.m-2 (Van Gaal et al., 2005; Pi-Sunyer et al., 2006; 
Scheen et al., 2006; Rosenstock et al., 2008; Van Gaal et al., 2008b; 
Despres et al., 2009; Hollander et al., 2010). These weight losses should 
be considered against the fact that many of the studies involved calorie 
restriction and/or exercise regimes, and patients on placebo lost 1.4 to 3.6 
kg. Specifically, in one trial only 27.4% of patients lost at least 10% of 
their body weight after 12 months on a 20mg daily dose of rimonabant 
(Van Gaal et al., 2005). A two year trial showed that weight loss reached 
its maximal level at one year, and this was maintained for a second year if 
rimonabant therapy was continued (Van Gaal et al., 2008b). A follow-up 
study has shown that the majority of patients return to their pre-treatment 
BMI within one year of rimonabant cessation (Pi-Sunyer et al., 2006). Food 
behaviour analyses revealed that patients taking rimonabant had 
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decreased appetite and desire for highly palatable foods, and adhered to a 
calorie restricted diet more easily (Scheen et al., 2006). Another CB1 
receptor antagonist, taranabant, predictably produced very similar results 
to rimonabant in phase III trials, but its development was discontinued in 
2010 for the same reasons (Aronne et al., 2010; Kipnes et al., 2010; 
Wadden et al., 2010). 
Given that waist circumference is used as a clinical marker of 
visceral obesity, it has been reported in many of the rimonabant studies. 
In keeping with the BMI data, rimonabant caused a reduction in mean 
waist circumference of between 5.2 and 9.1 cm (Despres et al., 2005; Van 
Gaal et al., 2005; Pi-Sunyer et al., 2006; Scheen et al., 2006; Van Gaal et 
al., 2008a; Van Gaal et al., 2008b). Interestingly, rimonabant was found to 
reduce waist circumference more significantly than would be predicted by 
weight loss alone. Fasting blood concentrations of various metabolic 
markers such as glucose, HDL-cholesterol and triglycerides were measured 
throughout the trials and, as with waist circumference, the studies 
reported larger improvements in these markers than could be accounted 
for solely by a body mass reduction of 5-10%. For example, the mean 
circulating triglyceride concentration in one study was reduced by 6.8% in 
patients treated with rimonabant, compared to a rise in the placebo group, 
and it was calculated that only 45% of this decrease could be attributed to 
loss of adipose tissue (Van Gaal et al., 2005). These findings imply the 
involvement of peripheral organs and tissues in addition to the CNS (Van 
Gaal et al., 2005). This has also been demonstrated in several animal 
studies and is described in more detail towards the end of this section, 
although tKH SUHFLVH PHFKDQLVPV RI ULPRQDEDQW¶V HIIHFWV remain under 
question. 
As a result of these findings, a trial was established to assess the 
JO\FDHPLFUHJXODWLQJHIIHFWVRIULPRQDEDQWLQRYHUZHLJKW%0,NJP2) 
patients with type 2 diabetes not adequately controlled by metformin or 
sulphonylurea (Scheen et al., 2006). This study found that haemoglobin 
A1c (HbA1c), a marker of medium-long term glycaemia, was reduced by 
rimonabant therapy over 1 year, with a value <6.5 in 43% of patients 
compared to 21% in the placebo group. Similar improvements were 
reported in fasting glucose concentration and calculated insulin resistance 
(HOMA-IR), although not in fasting blood insulin concentration. As with 
other metabolic changes observed in patients given rimonabant, these 
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improvements could not be entirely accounted for by adipose tissue loss 
(Scheen et al., 2006). 
A further result of the preliminary rimonabant trials was that a large 
multicentre trial (n=18,695) was established to determine the benefit, if 
any, of long-term rimonabant therapy (20 mg.day-1) in the prevention of 
stroke, myocardial infarction and death due to cardiovascular events. All 
participants were obese and had either known cardiovascular disease (such 
as myocardial infarction or stroke) or increased risk of developing 
cardiovascular disease (including type 2 diabetes and renal artery disease). 
The trial was stopped prematurely when rimonabant was withdrawn, but 
data analysed at this point showed no significant difference between 
rimonabant and placebo (Topol et al., 2010). 
Rimonabant has been used in many animal studies to try to 
determine its precise modes of action. In one such study obese (ob/ob) 
mice were given rimonabant (10 mg.kg-1) daily for 7 days. The treated 
mice initially reduced their food intake and lost body fat, as has been found 
in humans, but a novel finding was that their oxygen consumption was 
significantly increased. Oxygen consumption is a marker of energy 
expenditure and thermogenesis and this may explain why humans and 
animals in other studies of CB1 receptor antagonists maintain their initial 
weight loss even when hypophagia ceases (Liu et al., 2005). Similarly, in 
another study, rats fed the same amount as paired rats on rimonabant 
dropped to the same body weight, but the rats on rimonabant had a 
significantly lower body fat percentage after 17 days of treatment (Cota et 
al., 2009). The significance of the CB1 receptor in feeding can also be seen 
in CB1 knockout mice, who consume less food than wild-type controls. 
Feeding the normal mice the same amounts as consumed by CB1
-/- mice 
brought about significant weight loss in young mice, but not in adult mice 
(Cota et al., 2003). These results are further evidence that the metabolic 
effects of rimonabant are not restricted to appetite suppression and diet-
related weight loss. 
In cell culture it has been found that rimonabant inhibits 
proliferation of murine preadipocytes and increases markers of adipocyte 
maturation without increasing the lipid content of the cells (Gary-Bobo et 
al., 2006). The team who conducted this research hypothesise that this 
may help to reduce adipocyte mass and, by returning the adipocytes 
towards a more normal morphology, restore the homeostatic function of 
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adipose tissue. In agreement with this, rimonabant has been found to 
halve the cell size of adipocytes in obese mice (Jbilo et al., 2005).  
Several studies have investigated the adiposity and metabolic 
effects of peripherally restricted CB1 receptor antagonists such as LH-21 
(Pavon et al., 2006; Pavon et al., 2008), AM6545 (Tam et al., 2010) and 
Compound-1 (Son et al., 2010). In rodents it has been reported that these 
drugs also cause moderate weight loss and, in some cases, improvements 
in metabolic profiles, albeit not as efficaciously as rimonabant. However, 
the findings of the earlier studies have been questioned by other research 
indicating that LH-21 may be capable of crossing the blood-brain barrier in 
appreciable quantities and is not CB1 receptor specific (Chen et al., 2008). 
In another study designed to measure the effects of peripheral and central 
CB1 receptor antagonism, rimonabant was administered either 
intraperitoneally or intracerebroventricularly in rats. Central CB1 receptor 
blockade reduced food intake and body weight, but did not affect metabolic 
markers, whereas peripheral administration did not affect feeding or body 
weight but did result in beneficial metabolic changes, particularly in obese 
animals (Nogueiras et al., 2008). Further pharmacological characterisation 
of the novel compounds will be required before firm conclusions on the 
effects of peripheral CB1 receptor blockade can be drawn. 
 
1.5.3 Cannabinoid receptor expression in obesity  
The effects of obesity on CB1 receptor expression in adipose tissue have 
been investigated, but the results to date are highly contradictory. In 
subcutaneous adipose tissue, several papers show CB1 receptor mRNA to 
be reduced in obese subjects compared to lean (Engeli et al., 2005; Blüher 
et al., 2006; Sarzani et al., 2009; Bennetzen et al., 2010). Specifically, 
one study reported CB1 receptor mRNA to be reduced by 34% in 
subcutaneous abdominal adipose samples from obese postmenopausal 
women compared to lean controls (Engeli et al., 2005). This has also been 
shown for CB1 receptor protein levels in subcutaneous adipose tissue, 
although again using an exclusively female sample (Bennetzen et al., 
2010). Conversely, other research has shown CB1 receptor mRNA to be 
increased in the subcutaneous adipose tissue of obese patients compared 
to lean (Pagano et al., 2007). In contrast to both of these findings, 
Murdolo and colleagues (2007) found no significant differences in CB1 or 
CB2 receptor mRNA in subcutaneous abdominal adipose tissue between 
lean and obese groups, and CB1 receptor mRNA in subcutaneous from 
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obese and lean humans did not correlate with BMI or metabolic status 
(Lofgren et al., 2007).   
In visceral adipose tissue, there are similar discrepancies as found 
in the subcutaneous depot. Some research has shown CB1 receptor mRNA 
to be increased in the visceral adipose tissue of obese patients compared 
to lean (Pagano et al., 2007; Bennetzen et al., 2010), and mRNA levels to 
be positively correlated with BMI (Sarzani et al., 2009). Whereas another 
study showed that CB1 receptor mRNA in visceral adipose samples from 
lean and obese humans is not correlated with BMI or metabolic status 
(Lofgren et al., 2007). Further to this, CB1 receptor protein levels were not 
found to differ between lean and obese humans, and this was reported in 
the same study which reported mRNA levels to be increased in obesity 
(Bennetzen et al., 2010). This difference between results and conclusions 
drawn from mRNA and protein assays highlights the importance of 
measuring the final protein levels or activity of the receptors instead of , or 
in addition to, mRNA. Alongside these human studies, a recent unpublished 
study has shown that adipocyte specific CB1 receptor knockout mice are 
resistant to diet-induced obesity, which indicates that adipose tissue ECS 
signalling can affect whole body metabolism (Mancini et al., 2010). 
Studies using paired samples of subcutaneous and visceral adipose 
tissue have highlighted differences in the expression of CB1 receptor 
between these adipose tissue depots. In lean subjects, CB1 receptor 
expression and protein levels are higher in subcutaneous adipose tissue 
compared to visceral (Sarzani et al., 2009; Bennetzen et al., 2010). 
However, in obese patients, CB1 receptor mRNA was found to be elevated 
in the visceral depot when compared to paired subcutaneous samples 
(Pagano et al., 2007; Sarzani et al., 2009) or not different (Bennetzen et 
al., 2010). Increases in CB1 expression in visceral adipose tissue have 
additionally been demonstrated in subsets of viscerally and subcutaneously 
obese patients (Blüher et al., 2006).  
 In some studies, the potential relationship between CB1 receptor 
expression in adipose tissue and glycaemic dysregulation has been 
investigated. A CB1 receptor mutation has been found to be protective 
against the development of metabolic syndrome in obese, hypertensive, 
menopausal women. Carriers of the mutation had lower CB1 expression 
levels in perirenal adipose tissue, although the sample size was small and 
the mechanism of the finding is still under question (Bordicchia et al., 
2009). Conversely, sustained hyperinsulinaemia was not found to alter 
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cannabinoid receptor expression in human adipose tissue (Murdolo et al., 
2007). In addition to this, CB1 receptor deletion in adipocytes in mice has 
been shown to improve glucose handling during high fat feeding (Mancini 
et al., 2010).  
The role of the cannabinoid receptors in lipid metabolism and 
systemic energy homeostasis has also been investigated. CB1 receptor 
mRNA in adipose tissue was shown to be correlated with fasting blood 
plasma fatty acid concentrations and CB2 receptor mRNA with adipose 
tissue adiponectin mRNA (Murdolo et al., 2007). By contrast, another study 
reported no relationship between CB1 receptor mRNA levels in human 
adipose tissue and BMI, metabolic markers such as fasting blood plasma 
insulin, glucose and lipids, or adipocyte function (Lofgren et al., 2007). In 
addition to the cannabinoid receptors, TRPV1 mRNA has been found to be 
downregulated in visceral adipose tissue in obese males (Zhang et al., 
2007).  
It should be noted that a recent study found that, although not 
statistically significant, CB1 receptor mRNA expression in the stroma-
vascular fraction of subcutaneous abdominal adipose tissue was double 
that found in isolated adipocytes from the same adipose tissue (Bennetzen 
et al., 2010). This indicates that the activity of the ECS is likely to differ 
between mature adipocytes and adipose tissue, so the results described in 
adipose tissue above may not apply to adipocytes. 
Considered together, these studies indicate that regulation of the of 
the endocannabinoid receptors in human adipocytes in health and obesity 
is still very much a matter of debate. 
 
1.5.4 Endocannabinoid levels in obesity  
Blood plasma concentrations of anandamide and 2-AG are increased in 
otherwise healthy obese human volunteers (Engeli et al., 2005; Blüher et 
al., 2006; Cote et al., 2007). More specifically, circulating 2-AG 
concentrations have been shown to correlate with waist circumference, and 
blood plasma anandamide concentration correlates with BMI (Engeli et al., 
2005). In another study, in which subjects were subclassified as 
subcutaneously or viscerally obese, the most significant rise in circulating 
2-AG occurred in those with visceral obesity. However in this study, no 
significant difference in plasma anandamide was detected between the 
obese and lean subjects (Blüher et al., 2006).  
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Initial studies have shown that the dysregulation of 2-AG levels may 
be at least partially reversible. The reduction of visceral adipose tissue 
volume in viscerally obese men, as measured by body mass, waist 
circumference and computed tomography, through diet improvement and 
increased activity, led to a 62% decrease in circulating 2-AG 
concentrations (Di Marzo et al., 2008). It is likely that weight loss must be 
substantial for these changes to occur, as other studies have shown that a 
5% weight loss in obese humans does not affect blood concentrations of 
anandamide or 2-AG (Engeli et al., 2005), or mRNA expression of FAAH, 
MGL or CB1 receptor in subcutaneous adipose tissue (Engeli et al., 2008).  
When considering these results, it should be noted that the blood 
concentrations of anandamide and 2-AG only reach trace levels, and there 
is no evidence that endocannabinoids are secreted into the blood as 
signalling or endocrine factors. It may be that elevated blood plasma 
endocannabinoid concentrations are a result of overflow from various 
tissues, and therefore a reflection of systemic ECS tone. 
 
1.5.5 FAAH and MGL in obesity  
As seen with CB1 receptor expression, there is currently no consensus as to 
whether FAAH is up- or down-regulated in adipose tissue in obesity. In 
several studies, FAAH mRNA levels have been found to be elevated in the 
subcutaneous adipose tissue of obese compared to lean subjects (Murdolo 
et al., 2007; Pagano et al., 2007), whilst others have detected decreased 
FAAH mRNA levels in obese humans (Engeli et al., 2005; Blüher et al., 
2006; Kempf et al., 2007).  
The importance of FAAH in maintaining normal body weight has 
been shown via a missense mutation in the FAAH gene, which occurs in 
3.6-10.8% of the population (depending on ethnicity) and is associated 
with obesity (Sipe et al., 2005). Some variants in the promoter section of 
the gene have also been linked to an increased risk of obesity (Harismendy 
et al., 2010), but the effects of these mutations on adipose tissue mass 
may owe more to hypothalamic and CNS signalling than adipose tissue 
metabolism. Another large study into polymorphisms in the FAAH gene and 
obesity revealed two single nucleotide polymorphisms (SNPs) which are 
associated with early onset extreme obesity in children, but did not find 
any associations between the FAAH polymorphisms identified and adult 
obesity (Muller et al., 2007). Further to this, another FAAH missense 
mutation has been shown to prevent metabolic improvements, as 
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measured by the homeostasis model assessment (HOMA), normally seen 
after weight loss in obese humans (de Luis et al., 2010b). The relationship 
between FAAH in adipose tissue and glycaemic regulation has been further 
explored in a study in which the euglycaemic-hyperinsulinaemic clamp 
technique was used to maintain hyperinsulinaemia in obese subjects and 
matched lean controls. This treatment induced a significant increase of 
FAAH mRNA in the subcutaneous abdominal adipose tissue of lean 
subjects, but no change in the obese group, leading the authors to suggest 
that chronic hyperinsulinaemia could contribute to FAAH upregulation in 
adipose tissue (Murdolo et al., 2007). However, none of these studies has 
reported FAAH activity, and using mRNA alone it is not possible to 
conclusively show that protein levels or activity are altered.    
Similar findings to the human FAAH mutation associations with 
obesity have also been reported in FAAH knockout mice. In these animals, 
although food intake was not increased, visceral adipose mass (and total 
body mass) was increased compared to wild-type mice, particularly when 
on a high-fat diet (Tourino et al., 2010). Additionally, triglyceride 
accumulation in adipose tissue was higher in the FAAH knockout mice and 
ectopic fat deposition occurred, accompanied by increased plasma insulin, 
glucose and leptin concentrations (Tourino et al., 2010). These effects of 
FAAH are clearly systemic, and it would be informative to study the effects 
of FAAH dysfunction in adipocytes only, in order to further understand the 
role of FAAH and endocannabinoid signalling in adipocytes with regard to 
whole body metabolic homeostasis. 
As yet, it is unknown whether FAAH expression is different between 
visceral and subcutaneous adipose tissue. One study reports that the 
expression of FAAH in humans does not differ between visceral or 
subcutaneous adipose tissue, even in obesity (Pagano et al., 2007).  
However, other research shows FAAH mRNA to be upregulated in visceral 
compared to subcutaneous depots, and this was observed in humans with 
both subcutaneous and visceral obesity (Blüher et al., 2006).  
MGL expression levels have not been widely investigated in human 
adipose tissue to date. This may be in part due to early reports that MGL is 
not hormonally regulated and is not the rate-limiting step in lipolysis, 
however, in a recent study MGL mRNA was found to be elevated in 
subcutaneous compared to visceral adipose tissue, regardless of BMI 
(Pagano et al., 2007). This is an area in which data are lacking, and 
several further studies into the expression and regulation of FAAH and MGL 
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in human adipose tissue from different depots will need to be completed 
before a clearer understanding is achieved. 
 
1.6 The role of the ECS in metabolic homeostasis and obesity in 
other organs 
The ECS is involved in systemic metabolic regulation and components of 
the ECS, particularly the CB1 receptor, have been identified in all of the 
organs involved in energy homeostasis and metabolism (Matias and Di 
Marzo, 2007). Overall, ECS activation seems to be associated with 
increases in feeding and energy storage. Interestingly, this has been 
shown to be important in normal physiology from a very early age, as CB1 
receptor activation is crucial in the early suckling response (Mechoulam et 
al., 2006). In many organs, the precise function of the ECS has yet to be 
fully elucidated, but, given the potential contribution of ECS signalling in 
adipose tissue to overall metabolic homeostasis, a brief overview of some 
of the findings to date are presented here.  
  
1.6.1 Pancreas 
Both CB1 and CB2 receptors are present in the human pancreas. Research 
conducted on islets in primary culture indicate that anandamide and other 
CB1 receptor agonists can act via the CB1 receptor to cause the release of 
insulin and glucagon, regardless of the glucose concentration (Bermudez-
Silva et al., 2008). In contrast, CB2 receptor stimulation in pancreatic cells 
appears to have an inhibitory effect (Bermudez-Silva et al., 2008). It has 
been suggested by the authors of this study that the apparent 
contradiction of a system whereby the same signalling molecule brings 
about an increase in two opposing hormones may be explained by a 
µVDYLQJF\FOH¶ This involves maintaining a hyperglycaemic state under the 
action of glucagon, in order that insulin can mediate the storage of this 
glucose. Along with a supply of fatty acids, these are the conditions 
required for adipose tissue expansion, and this is in keeping with the 
notion that ECS tone is upregulated in obesity. In support of this 
hypothesis, elevated levels of anandamide and 2-AG have been measured 
in the pancreas of obese mice fed a high fat content diet (Matias et al., 
2006; Starowicz et al., 2008). ,QDUDWFHOOPRGHORISDQFUHDWLFLVOHWǃ-cells 
in culture it was found that 2-AG and anandamide concentrations were 
raised by a two hour incubation in high glucose media and this effect was 
counteracted by insulin. In addition, cells kept under chronic 
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hyperglycaemic conditions were not affected by insulin, and in fact insulin 
caused concentrations of anandamide and 2-AG to increase further (Matias 
et al., 2006). ,QNHHSLQJZLWKWKLVVWXG\DQRWKHUJURXSXVLQJDǃ-cell line 
reported elevated insulin secretion under the action of cannabinoid 
receptor agonists in both low and high glucose medium (Chen et al., 
2010).   
ECS enzymes have also been measured in the pancreas of lean and 
diet-induced obese mice. In ǃ-cells, DAGL expression was much higher in 
the obese mice than lean controls, whereas FAAH mRNA levels were lower. 
The effect of these changes would be to increase endocannabinoid levels, 
as has been observed (Starowicz et al., 2008).  
 
1.6.2 Skeletal muscle  
All of the ECS components are present in mammalian skeletal muscle, but 
the CB1 receptor has received the most attention (Cavuoto et al., 2007b; 
Crespillo et al., 2010). The expression of CB1 receptors is higher than that 
of CB2 receptors in human muscle (Cavuoto et al., 2007b) and it has been 
shown in cell cultures of human muscle that CB1 receptor protein levels 
increase during differentiation (Eckardt et al., 2009). 
 In a human study, CB1 mRNA levels in skeletal muscle were not 
found to differ between lean and obese subjects, although the sample size 
was very small (Cavuoto et al., 2007b). This finding is at odds with a 
rodent study which found high fat feeding to increase CB1 receptor 
expression (Pagotto et al., 2006). However, another study using obese 
Zucker rats found CB1 receptor protein levels in skeletal muscle to be 
decreased compared to lean controls (Lindborg et al., 2010). CB2 receptor 
mRNA levels have also been reported to be downregulated in obese rats 
(Crespillo et al., 2010). 
 CB1 receptor activation or blockade in muscle has been shown by 
several teams to affect glucose transport. In rodent studies, CB1 receptor 
agonsim decreased glucose uptake (Lindborg et al., 2010) and antagonists 
increased glucose uptake (Liu et al., 2005; Lindborg et al., 2010). 
However, in cultured human muscle cells, anandamide increased both 
basal and insulin-stimulated glucose uptake (Eckardt et al., 2009). 
Interestingly, anandamide has also been shown to activate pathways 
associated with insulin resistance (Eckardt et al., 2009). Further to this, 
CB1 receptor antagonism increased markers of fatty acid oxidation in 
primary cultures of human muscle (Cavuoto et al., 2007a). It may be that 
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species differences account for the discrepancies between these results, 
and further work in human muscle will need to be conducted to 
demonstrate the effects of the CB1 receptor in normal and pathological 
physiology. 
 
1.6.3 Liver 
The CB1 receptor is present in human liver, whereas CB2 receptor 
expression is not detectable in healthy liver, but is expressed in various 
pathological states, probably due to inflammatory changes (Mallat et al., 
2011). Likewise, CB1 receptor expression is increased in diseases such as 
carcinoma and cirrhosis and in mice fed high calorie diets (for review see 
Tam et al., 2011).  
Predictably, given the difficulties in obtaining human samples, most 
of our knowledge of the ECS in the liver comes from animal studies. In 
mice, hepatic levels of anandamide were found to be increased in animals 
fed a high-fat diet, even before a significant difference in weight between 
the high-fat diet mice and normal-diet mice could be detected. This 
suggests that, at least in the liver, the endocannabinoid system is 
upregulated before obesity occurs. In addition to this, the wild type mice 
fed a high-fat diet had higher levels of hepatic anandamide than CB1 
receptor null mice fed the same diet, indicating that the CB1 receptor is 
involved in anandamide upregulation (Osei-Hyiaman et al., 2005). 
CB1 agonists have been shown to increase de novo lipogenesis in 
the liver of rodents, and correspondingly, CB1 antagonists reduced insulin 
resistance and the rate of lipogenesis (Tam et al., 2011). This has also 
been demonstrated using human hepatocytes in a model of fatty liver, in 
which both CB1 and CB2 agonists increased the amount of lipid deposition 
in hepatocytes (De Gottardi et al., 2010). 
 
1.7 Summary 
Taken together, the data published to date shows that the ECS is present 
and functional in human and other mammalian adipose tissue, and in some 
cases this has also been specifically demonstrated in mature adipocytes. 
However, there are contradictions between many of the studies published 
to date, and questions remain over the precise role and signalling effects of 
the ECS in adipocytes, and how these are affected by obesity and diabetes. 
This is the key issue addressed in this thesis.  
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 There is evidence that in adipose tissue, mRNA levels of 
components of the ECS, such as the CB receptors and enzymes, may be 
up- or down-regulated in human obesity and type 2 diabetes, but many 
discrepancies between studies are apparent. In the cases of the catabolic 
enzymes FAAH and MGL, only mRNA levels in adipose tissue have been 
reported and it is unknown whether the activities of these enzymes are 
altered with adiposity or metabolic dysfunction. As the post-transcriptional 
regulation of these enzymes has yet to be fully characterised, it is 
important to measure their activities to determine whether these are 
affected by obesity or diabetes. 
In all of the human studies examining the ECS and obesity in 
adipose tissue reported to date, discrete samples of lean and obese people 
have been compared. As a consequence, there are very few studies 
available on the ECS in humans in the overweight but pre-obese state.  
 In the majority of studies published to date with a focus on 
comparing the ECS in adipose tissue between lean and obese humans, 
whole adipose tissue samples have been used when reporting gene 
expression levels. The work presented in this thesis is novel in that it is 
based on isolated mature adipocytes from whole adipose tissue biopsies. 
The power of this approach is that it provides a better idea of the 
catabolism of the endocannabinoids in adipocytes only, and whether this is 
dysregulated in obesity or metabolic dysfunction. Interference from other 
cells in adipose tissue, such as macrophages, is excluded. Obesity has 
been described as a state of chronic inflammation, and this pathology in 
adipose tissue could have lead to data showing that the ECS is 
dysregulated in obesity, but it does not provide information on whether 
this is the case in the adipocytes themselves. Consequently, there is 
currently very little information on the ECS in human adipocytes taken 
from biopsies in health, obesity and metabolic disorders. 
 The termination of endocannabinoid signalling involves the uptake 
of the endocannabinoids prior to enzymatic degradation. This has not yet 
been investigated in human adipocytes, and there are therefore no data 
available on whether endocannabinoid uptake in cultured cells is affected 
by insulin or glucose. This is an important consideration in understanding 
the interplay between ECS and metabolic signalling. 
Additionally, the effects of anandamide and 2-AG on adipokine 
secretion in human adipocytes have not been fully reported. In particular, 
data are not available on the combined effects of endocannabinoids and 
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models of metabolic dysfunction on adipokine secretion. These questions 
are addressed in this thesis, as they will help towards an overall 
understanding of the ECS in adipocytes and the influence of metabolic 
factors on this. 
 
1.8 Aims 
The ECS is known to have a role in metabolic regulation, but this has yet to 
be fully characterised, so the overall aim of the study was to investigate 
the ECS, specifically in mature adipocytes, under normal and pathological 
conditions. This aim was met by working on the following specific aims 
using rat models, human samples and human cell culture adipocytes. 
 For the first study three strains of Zucker rat were used: lean, 
obese and obese diabetic. The primary endpoint was to determine whether 
FAAH and MGL activities in rat adipocytes differ between lean and obese or 
obese diabetic rats, as the activity of these enzymes has not yet been 
considered in obesity in isolated mature adipocytes. An additional aim 
using these rats was to compare the subcutaneous, visceral and 
epididymal adipose tissue depots, with regard to FAAH and MGL activities, 
as discrepancies in similar comparison studies have been found when 
reporting FAAH and MGL mRNA levels. The final aim was to determine 
whether insulin or glucose affect adipocyte FAAH or MGL activity, by 
comparing the healthy, obese (hyperinsulinaemic) and obese diabetic rats. 
This work is presented in Chapter 3. 
 The next set of aims was based on human adipocytes, as FAAH and 
MGL activities have yet to be investigated in isolated mature adipocytes, 
and mRNA studies have been inconclusive. The primary aim was to 
determine whether FAAH and MGL activities in adipocytes vary with BMI. 
In line with this aim, the secondary aim was to investigate these enzyme 
activities with regard to waist circumference, as a marker of visceral 
adiposity. Additionally, given the marked differences in metabolic activity 
between subcutaneous and visceral adipose tissue, FAAH and MGL 
activities in adipocytes from these two depots were compared. The final 
aim using isolated human adipocytes was to determine whether there is a 
difference in enzyme activity between healthy humans and those with 
diabetes or markers of metabolic syndrome. The results of these aims are 
presented in Chapters 4 and 5. 
 The final set of aims involved human subcutaneous adipocytes in 
culture, in order to determine directly whether insulin or glucose affect 
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components of the ECS. The first aim was to investigate whether acute or 
chronic exposure to insulin, glucose or both increases adipokine secretion 
in the presence of anandamide or 2-AG. The second aim was to determine 
whether insulin, glucose or both increase anandamide and 2-AG uptake, or 
FAAH and MGL activities in mature adipocytes. 
 
 2. Materials and Methods  
2.1 Zucker rats 
2.1.1 Rat models of obesity  
The protocol used in the rat study was approved by the University of 
Nottingham Ethical Review Committee, and the procedures used were 
approved by the UK Home Office Project and Personal License Authority. 
The three strains of male Zucker rat used were normal (lean), Fatty 
(obese) and Diabetic Fatty (ZDF, diabetic). The obese rats were first 
identified in a colony of Zucker rats which spontaneously developed a fa 
mutation in the leptin receptor (Charles River, UK). This mutation leads to 
overfeeding, a reduction in thermogenesis (Leonard et al., 2005) and the 
excessive accumulation of triglycerides in adipocytes (Unger, 1997). The 
rats therefore become obese and develop insulin resistance, 
hyperinsulinaemia and hypertriglyceridaemia (Charles River, UK). The 
diabetic rats were also indentified after a mutation, and subsequent 
selected inbreeding resulted in a line of diabetic rats (Charles River, UK). 
These rats are slightly less obese than the obese rats, but they become 
insulin resistant and hyperglycaemic by the age of 7 weeks (Leonard et al., 
2005; Metais et al., 2008). The rats then develop type 2 diabetes as the 
pancreatic beta cells fail to respond sufficiently to the hyperglycaemic state 
(Leonard et al., 2005; Marsh et al., 2007; Metais et al., 2008). The lean 
rats are the same strain but do not have these mutations, and were 
therefore used as healthy controls. All rats were purchased from Charles 
River, UK. 
 
2.1.2 Animal housing and food  
The Zucker rats were purchased at 6 weeks and killed at 10-12 weeks. The 
rats were housed in a temperature controlled room with a 12 hour 
light/dark cycle. Standard rat chow and water were available ad libitum.  
 
2.1.3 Adipose tissue collection  
Rats were killed by blunt trauma to the head followed by cervical 
dislocation (Schedule 1). Adipose tissue was immediately dissected from 
the subcutaneous abdominal, visceral and epididymal adipose depots (see 
Figure 2.1) and immediately stored at -80oC. 
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Figure 2.1 Adipose tissue dissection 
Dissection of subcutaneous (A) and visceral (B) adipose tissue from Zucker 
rats. 
 
2.1.4 Blood glucose measurement 
In the obese and diabetic rats blood glucose concentration was measured 
in samples obtained by cardiac puncture immediately after the rats were 
killed. A drop of blood was added to the testing strip of the Optium Xceed 
blood glucometer (Abbott Laboratories Ltd., UK). 
 
2.2 Adipocyte isolation and preparation 
In order to investigate the ECS in mature adipocytes, rather than whole 
adipose tissue, the adipose tissue was processed prior to homogenisation.  
A 
B 
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2.2.1 Purification of mature adipocytes 
The method used to isolate mature adipocytes from adipose tissue was 
adapted from a method published in 1964 (Rodbell, 1964). Each adipose 
sample was thawed on ice, roughly minced using a scalpel and added to an 
approximately equal volume of type II collagenase (Sigma-Aldrich, UK, 
1mg.ml-1) in PBS. The mix was incubated at 37oC for 45 minutes on a 
shaking platform to digest the connective tissue, and allow the various 
cells of adipose tissue to be released. Approximately 20 ml of PBS (room 
temperature) was then added to the digested tissue and centrifuged (2 
minutes, 500 x g). The mature adipocytes and any free lipids were found 
on top of the aqueous phase, whereas all other cellular components 
remained in the aqueous phase or sedimented to the bottom of the tube. 
The top layer was carefully removed with a Pasteur pipette and transferred 
to a clean tube. 10ml of PBS was added, to wash the adipocytes free of 
any remaining debris, and the cells were centrifuged (2 minutes, 500 x g). 
The floating adipocytes were then collected for homogenisation. 
 
2.2.2 Homogenisation of mature adipocytes  
The majority of FAAH is membrane-bound (McKinney and Cravatt, 2005), 
whereas MGL tends to be cytosolic (Tornqvist and Belfrage, 1976). 
Therefore, the adipocytes were processed to separate the membrane and 
cytosolic fractions. The mature adipocytes from each sample were 
homogenised in approximately 1 ml of Tris-EDTA (TE) buffer using a glass 
Dounce homogeniser (Uniform, UK). During this process, the homogeniser 
containing the sample was periodically (1-2 minutes) placed on ice in order 
to reduce the temperature and therefore the rate of protein degradation. 
After homogenisation, the mix was centrifuged (10 min, 18,000 x g, 5oC) 
and the supernatant removed. The supernatant was spun again (30 min, 
20,000 x g, 5oC) and the supernatant from this step, comprising the 
cytosolic fraction, was then frozen at -80oC for later analysis of FAAH and 
MGL. The membrane pellet was re-homogenised in 1ml of PBS using a 
glass homogeniser and centrifuged (30 min, 20,000 x g, 5oC). The 
supernatant from this step was discarded and the pellet resuspended in 1 
ml of PBS and stored at -80oC for later analysis. 
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2.3 Healthy human volunteers 
2.3.1 Ethics and screening  
Ethical approval was granted by the University of Nottingham Medical 
School Ethics Committee and informed written consent was obtained from 
all subjects. Healthy volunteers were recruited from staff and students 
within the School of Graduate Entry Medicine. The participants were 
screened using a health questionnaire, and the exclusion criteria included 
smoking, hypertension and known metabolic disease. All subjects reported 
a stable weight in the three month period preceding the biopsy. From an 
initial 34 participants, 6 were excluded due to insufficient biopsy size or 
fasting blood glucose >5.6 mmol.L-1, indicating impaired glucose tolerance 
(American Diabetes Association, 1997). 
Volunteers were asked to make two visits. In visit one, 
anthropometric measurements and blood pressure were taken. In the 
second visit, no later than one week after visit one, adipose tissue and 
blood samples were taken.  
 
2.3.2 Anthropometric measurements   
Systolic and diastolic blood pressures were measured using an automated 
digital blood pressure monitor (UA-767, A&D) with the patient rested and 
in the supine position. Measurements were taken three times and the 
lowest recorded reading was used for data analysis.  
The guidelines followed for taking anthropometric measurements 
were taken from Norton and Olds (1996). For the skinfold thicknesses, 
each measurement was taken twice and the mean value was recorded. If 
the values differed by more than 3 mm then a third reading was obtained 
and the outlying value was disregarded. Waist circumference was 
measured at the midpoint between the iliac crest and costal margin. Hip 
circumference was taken at the widest point around the hips. Neck 
circumference was measured at the level of the cricothyroid cartilage. Arm 
circumference was measured at the midpoint between the shoulder and 
elbow. 
Skinfold thickness was measured at 7 anatomical sites using 
Harpenden callipers, and a tape measure was used to locate the arm sites. 
The 7 sites were: tricep (posterior, level with circumference), bicep 
(anterior, level with circumference), subscapular (parallel with inferior 
angle of scapular), suprailiac (immediately superior to iliac crest), 
abdominal (2 cm to the side of umbilicus), chest (as high as possible 
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between anterior axillary line and nipple) and midaxillary (on midaxillary 
line, level of xiphoid process of sternum) (Norton and Olds, 1996).  
 
 
Figure 2.2 Anthropometric measurement sites 
 
 
 Some authors have questioned the reliability and reproducibility of 
skinfold thickness as an accurate estimate of total body adiposity, but in a 
study designed to test this, the difference in total body fat percentage 
calculated from accurate and inaccurate skinfold sites was found to be 1-
3% (Durnin et al., 1997).  
 Various equations have been published over the past 4 decades for 
the calculation of body fat percentage from skinfold thickness 
measurements, although these are all broadly similar. The equation used 
for the work presented here is based on skinfold thickness at the bicep, 
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tricep, subscapular and suprailiac sites. Table 2.1 shows how body density 
(D) values were calculated (Durnin and Womersley, 1974) before using the 
Siri equation (% Body Fat = [495 / Body Density] ± 450) to convert these 
to body fat percentages (Siri, 1961). 
 
Age 
(years) Male Female 
<17 D = 1.1533 - (0.0643 X L) D = 1.1369 - (0.0598 X L) 
17-19 D = 1.1620 - (0.0630 X L) D = 1.1549 - (0.0678 X L) 
20-29 D = 1.1631 - (0.0632 X L) D = 1.1599 - (0.0717 X L) 
30-39 D = 1.1422 - (0.0544 X L) D = 1.1423 - (0.0632 X L) 
40 -49 D = 1.1620 - (0.0700 X L) D = 1.1333 - (0.0612 X L) 
> 50 D = 1.1715 - (0.0779 X L) D = 1.1339 - (0.0645 X L) 
 
Table 2.1 Body density formulae 
Equations for the calculation of body density (D) from the log of the total 
of four skinfold thicknesses (L). 
 
2.3.3 Adipose tissue collection  
Volunteers were asked to fast for at least 12 hours prior to their second 
visit, in which an abdominal subcutaneous adipose sample was taken by 
trained medical practitioners (Dr Garry Tan or Miss Hye-Chung Kwak). For 
the adipose tissue biopsy, the area was sterilised using iodine, and local 
anaesthetic (1% lidocaine) was injected subcutaneously into the biopsy 
area using a 5 ml syringe fitted with a 21 gauge needle. After 5-10 
minutes, a 14 gauge needle fitted to a 50 ml syringe was inserted under 
the skin and a vacuum was created in the syringe by drawing back the 
plunger. The adipose tissue biopsies, 1-5 ml in volume, were then 
aspirated. The biopsy procedure was tolerated well by all volunteers. All 
volunteers were asked to report back any problems in the hours and days 
after the biopsy procedure. One volunteer reported extensive bruising 
(haematoma) which resolved without treatment.  
The adipose tissue biopsy was immediately added to an 
approximately equal volume of type II collagenase, incubated at 37oC and 
the mature adipocytes isolated as described in Section 2.2.1. Once the 
mature adipocytes had been isolated and washed, they were stored at -
80oC and later homogenised as described in Section 2.2.2.  
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2.3.4 Blood collection 
During the second visit, a fasting venous blood sample (20ml) was taken 
from each volunteer. The blood samples were transferred to Serum 
Separator Tubes (SST) with a clotting activator and gel for serum 
separation (BD Vacutainer System, USA) and allowed to clot (30 minutes). 
The tubes were then centrifuged (1000 x g, 10 minutes). The serum was 
immediately removed and stored in aliquots at -80oC. The remainder of 
each blood sample was discarded.  
 
2.4 Surgical patients  
2.4.1 Ethics for surgical study  
This study was reviewed and approved by Derbyshire Regional Ethics 
Committee and Royal Derby Hospital Trust. This cohort included patients 
undergoing elective laparoscopic bariatric or cholecystectomy surgery at 
Royal Derby Hospital during the period March 2009 to June 2010. Informed 
written consent was obtained from the patients in accordance with Good 
Clinical Practice guidelines by trained staff. 
 
2.4.2 Anthropometric measurements  
Anthropometric measurements were taken using the same protocol as the 
healthy volunteers (see Section 2.3.2) by Miss Hye-Chung Kwak. These 
measurements were taken within the three months preceding surgery and  
fasting blood serum profiles were obtained from hospital records within the 
same period. 
 
2.4.3 Adipose tissue collection 
Omental adipose tissue samples (1-5 g) were dissected during surgery 
using an Endoloop Ligature (Ethicon Endo-Surgery, USA) and scissors, 
which allowed haemostasis to be achieved using diathermy after the 
removal of the biopsy rather than during its removal. Towards the end of 
surgery, the site of the left laparoscopic port is extended to approximately 
5 cm to allow the gastric band reservoir to be fitted subcutaneously. 
During this procedure, 1-5 g of subcutaneous adipose tissue was dissected 
with scissors and haemostasis achieved using diathermy as necessary. The 
adipose tissue samples were stored within one hour at -80oC. The samples 
were thawed, digested and homogenised at a later date as described in 
Section 2.2. 
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2.5 Enzyme activity assays  
Enzyme activity was measured in this project to give an indication of the 
rate of anandamide and 2-AG degradation within mature adipocytes at the 
time-point when the biopsy was taken. 
 
2.5.1 Fatty acid amide hydrolase (FAAH) activity assay 
The rat adipocytes fractions (cytosolic and cell particulate) were used in 
the optimisation and validation stages of the FAAH assay. The results from 
these assays validated the hypothesis that the majority of FAAH activity 
would be localised in the cell particulate fraction (McKinney and Cravatt, 
2005). This was further demonstrated in a small number of human 
samples. Thus, in future studies only the cell particulate fraction was used. 
The use of URB597, a specific FAAH inhibitor, demonstrated that the 
majority of anandamide hydrolysis measured using this assay was indeed 
due to FAAH activity. 
The assay is designed to detect tritium labelled ethanolamine. FAAH 
hydrolyses anandamide to arachidonic acid and ethanolamine (see Figure 
2.3). Both anandamide and arachidonic acid are adsorbed by activated 
charcoal, and are therefore sedimented. By contrast, ethanolamine 
remains in the aqueous phase of the assay and can therefore be easily 
separated (Wilson et al., 2003; Boldrup et al., 2004). 
 
 
Figure 2.3 FAAH assay 
The hydrolysis of tritium labelled anandamide by FAAH (adapted from 
Wilson et al., 2003). 
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The method used was adapted from that developed by Boldrup et 
al. (2004). Each homogenate was diluted (1:5) in TE buffer with essentially 
fatty acid free albumin (1mg.ml-1). 95 ǋO DOLTXRWV RI GLOXWHG KRPRJHQDWH  
were added to 1 µl of either URB597 (final concentration 1 µM) or vehicle 
and incubated at 37oC for 10 minutes in a shaking water bath. 5 ǋORI[3H]-
anandamide (2 ǋ0 ZDV DGGHG WR HDFK WXEH DQG WKH VDPSOHV ZHUH
incubated at 37oC for a further 30 minutes. Activated charcoal (100 ǋO
10% w/v in 0.5 M HC l, room temperature) was added to each tube to stop 
the reaction and the samples were vortexed and left to stand at room 
temperature for at least 30 minutes. The samples were centrifuged (30 
seconds, 1500 x g) and 100 ǋORIHDFKVXSHUQDWDQWZDVtaken for analysis.  
The supernatant aliquot from each tube was added to scintillation 
fluid (3 ml, Ultima Gold XL, Perkin Elmer, USA) and mixed before tritium 
determination (Tri-Carb 2100 TR Liquid Scintillation Analyser, Packard). 
Each sample was run in duplicate with vehicle and once with URB597. 
Tubes without homogenate were run in parallel and used to establish blank 
values. 5 ǋO aliquots of the [3H]-anandamide were counted as standards.  
 The calculation for activity takes into account the amount of tritium 
in each sample aliquot (sample), the background contamination (blank), 
the factor for taking a final aliquot, the maximum amount of tritium that 
could have been in the supernatant (standard), the number of moles of 
anandamide in each assay (anandamide), the reaction time and the 
amount of protein in each sample (see Section 2.5.3 for protein assay): 
Activity = ([([(Sample ± Blank) X 2] / Standard) X moles anandamide] / 
30 minutes) / mg protein in aliquot 
 
2.5.2 Monoacylglycerol lipase (MGL) activity assay 
As with FAAH, the initial validation and optimisation of the MGL assay was 
performed with the rat samples. The majority of MGL activity was found in 
the cytosolic fraction of the adipocyte homogenates, so this fraction was 
used for the MGL assays reported. 2-oleoylglycerol (2-OG) was used in the 
MGL assay instead of 2-AG, as the two molecules are hydrolysed by MGL at 
similar rates (Dinh et al., 2002a) and 2-oleoyl-[3H]-glycerol is considerably 
less expensive than [3H]-2-AG. 
Each sample was diluted (1:5) in TE buffer with essentially fatty 
acid free albumin (1 mg.ml-1) and 95 ǋO DOLTXRWV ZHUH LQFXEDWHG IRU 
minutes at 37oC with the non-specific MGL inhibitor 
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methylarachidonylfluorophosphonate (MAFP, 1 ǋ0 RU YHKLFOH. 2-OG (final 
concentration 100 ǋ0 ZDV ODEHOOHG ZLWK -oleoyl-[3H]-glycerol and 5 ǋO
was added to each tube, including blanks containing buffer only. The 
samples were briefly vortexed and incubated for 15 minutes at 37oC. The 
reaction was stopped by the addition of 100 ǋO DFWLYDWHG FKDUFRDO 
w/v in 0.5 M HC l) and the samples left at room temperature for at least 30 
minutes. The samples were then briefly centrifuged and 100 ǋO RI HDFK
supernatant was added to 3 ml of scintillation fluid for tritium 
determination as described in the FAAH activity assay.  
The specific activities for MGL were calculated in the same way as 
for FAAH: 
Activity = ([([(Sample ± Blank) X 2] / Standard) X moles of 2-OG] / 15 
minutes) / mg protein in aliquot 
 
2.5.3 Enzyme activity optimisation 
Various stages of the enzyme assays were altered to optimise the 
assays, and some of these are represented in Figure 2.4. 8% charcoal 
mixture was initially used, and this was increased to 12% to achieve 
greater separation of substrate and product. The initial MGL assay protocol 
included a chloroform:methanol step to separate hydrolysed 2-OG, but this 
gave unacceptably high blanks and so the activated charcoal method was 
used for the results presented in this thesis. Concentrations of samples 
ranging from undiluted to 1:50 dilution were tried, with 1:5 dilution 
reproducibly giving DPM values within the acceptable range. Additional 
optimisation stages (not shown) included alterations in the length of 
incubation time, the total volume of the assay and the method used to 
create the blanks. The aim of these optimisation steps was to reproducibly 
achieve 5-10% of the standard DPM values in the samples, and to have 
blank values as low as possible, and in any case no greater than 30% of 
the sample values.  
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Figure 2.4 Optimisation of FAAH and MGL assays 
Some of the optimisation steps in the development of the FAAH and MGL 
assays. The method of separation of hydrolysed anandamide or 2-OG was 
optimised using homogenised Zucker rat adipocytes pooled from three 
adipose tissue depots (A). The dilution of the pooled, homogenised rat 
adipocyte membranes was optimised. Results are shown for FAA H (B) and 
were similar for MGL in the cytosolic adipocyte fraction. n=3-6. DPM, 
degradations per minute 
 
2.5.4 Protein assay 
The protein concentration of each homogenate fraction was assayed using 
a commercially available Bradford reagent. 250 µl of Bradford reagent 
(Sigma-Aldrich, UK) was added to 5 µl of each sample or BSA standard in a 
96-well plate, which was then read at 595 nm in a spectrophotometer 
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(Victor 1420 Multilabel Counter, Wallac). All samples and standards were 
run in duplicate and samples with high protein concentrations were diluted 
as necessary. 
A standard curve for each plate was produced using the mean of 
the standard duplicates, minus the blank value. Linear regression was used 
to plot the standard curve and the sample protein concentrations were 
calculated from this. 
 
2.6 Cannabinoid receptor assays 
2.6.1 GTPǄS binding assay 
7KH*73Ǆ6ELQGLQJDVVD\KDVEHHQXVHG E\PDQ\WHDPVWRUHSRUWRQ WKH
activity of cannabinoid receptors (Sim et al., 1995; Hosohata et al., 1997; 
Petitet et al., 1997). The protein concentration of the membrane fraction of 
pooled rat adipocytes was determined using the Bradford method. This 
sample was diluted in buffer (50 mM Tris, 100 mM sodium chloride, 10 mM 
magnesium chloriGH KH[DK\GUDWH  ǋ0 *'3  P0 WKHRSK\OOLQH DQG
0.2 mg/ml BSA), to give final protein concentrations of 50, 100 and 200 
ǋJPO DV UHSURGXFLEOH UHVXOWV ZLWKLQ WKLV FRQFHQWUDWLRQ UDQJH KDG EHHQ
obtained in several types of tissue by others in the laboratory. The 
membrane fraction of homogenised rat brain was used as a positive control 
DWDSURWHLQFRQFHQWUDWLRQRIǋJPO7KHPHPEUDQHVZHUH LQFXEDWHGLQ
this buffer at 30oC for 20 minutes, before DGGLQJ *73Ǆ6-[35S] (final 
FRQFHQWUDWLRQS0DQG*73Ǆ6ILQDOFRQFHQWUDWLRQǋ0:,1-55,212 
(CB1 and CB2 UHFHSWRU DJRQLVW ILQDO FRQFHQWUDWLRQV  S0 WR  ǋ0 RU
buffer only. The samples were then incubated for a further 90 minutes at 
30oC, before the assay mixtures were transferred onto filter paper 
(Brandell Harvester) and washed four times with cold distilled water. The 
filter discs were then collected and the radioactivity measured using 
scintillation fluid (3 ml, Ultima Gold XL, Perkin Elmer, USA) and a 
scintillation counter (Tri-Carb 2100 TR Liquid Scintillation Analyser, 
Packard). 
 
2.6.2 CB1 receptor ELISA 
7KH*73Ǆ6DVVD\GLGQRWJLYHUHVXOWVXVLQJWKHPDWXUHDGLSRF\WHVDPSOHV
so a sandwich ELISA was used to try to measure CB1 receptor protein 
concentration. Polyclonal antibodies for two epitopes of the CB1 receptor 
were purchased (Abcam, UK). Despite several attempts to create a 
standard curve for this assay, the same level of non-specific, low-level 
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binding was detected at several concentrations of primary (1, 2 and 5 
ǋJPO-1) and secondary antibody (1:25 and 1:50), and with various 
concentrations of the C B1 receptor peptide (0 ± ǋJPO-1). It was therefore 
concluded that a CB1 receptor ELISA could not be developed at the time of 
this study. 
 
2.7 Biochemical assays 
2.7.1 Glucose assay 
Serum glucose concentrations were determined using the YSI 2300 STAT 
PLUS glucose and lactate analyser (YSI Life Sciences, USA) within 6 
months of sample collection. Quality control (QC) standards were analysed 
after every 10 samples processed, and, in order to ensure the accuracy of 
the sample results, samples were not processed unless QC values were 
within the limits set by the manufacturer.  
 
2.7.2 Insulin assay  
The insulin concentrations of the serum samples were measured using a 
commercial direct sandwich ELISA kit (Mercodia, Sweden) using two 
monoclonal antibodies. The kit was received as a 96-well plate, pre-coated 
with the primary antibody. All of the reagents were included in the kit and 
reconstituted as directed. The standards were received ready-to-use and 
the human blood serum samples did not require dilution prior to assay.  
 ǋORIHDFKVWDQGDUGRUVDPSOHZDVSLSHWWHGLQWRHDFKZHOODQG
HDFK VWDQGDUG DQG VDPSOH ZDV DVVD\HG LQ GXSOLFDWH  ǋO RI WKH
secondary antibody was then immediately added to each well and the plate 
was incubated on a plate shaker for 60 minutes at room temperature (18-
25oC). The plate was then washed 6 times with wash buffer and blotted on 
D SDSHU WRZHO  ǋO RI tetramethylbenzidine (TMB) was added to each 
ZHOODQGWKHSODWHZDVOHIWIRUPLQXWHVDWURRPWHPSHUDWXUHǋO6WRS
solution (0.5 M sulphuric acid) was then added to each well and the plate 
was tapped to ensure thorough mixing. The plate was read on a 
spectrophotometer (Victor 1420 Multilabel Counter, Wallac) at a 
wavelength of 450 nm. 
The insulin concentrations of the samples were calculated by first 
subtracting the blank value from all other values. The mean for each set of 
duplicates was then calculated and the absorption values for the standards 
were plotted against the insulin concentrations. GraphPad Prism software 
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was used to perform cubic spline regression analysis on the standard curve 
and subsequently interpolate the insulin concentrations of the samples.  
 
2.7.3 Adiponectin, leptin and resistin  
The concentrations of adiponectin, leptin and resistin were determined 
using sandwich (/,6$V 5	' 8. DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions. The concentrations of adiponectin, leptin and resistin were 
measured in the serum samples of the healthy volunteer study. The 
concentrations of all three cytokines were also measured in cell culture 
media. 
The method for the sandwich ELISA was the same for the 
measurement of all of these adipokines. All incubations and reagents were 
at room temperature. The capture antibody was diluted, to the working 
FRQFHQWUDWLRQUHFRPPHQGHG LQ3%6DQGǋO per well was added to 96-
well ELISA plates (Greiner, UK). The plates were sealed and left overnight 
at room temperature. The plates were then washed (0.05% Tween in PBS) 
WKUHHWLPHVXVLQJ ǋORIZDVKEXIIHUSHUZHOO7KHSODWHVZHUHEORWWHG
against paper towels after the final wash. Non-specific binding was 
SUHYHQWHG E\ DGGLQJ  ǋO RI5HDJHQW 'LOXHQW  %6$ LQ 3%6 WR HDFK
well for 60 minutes. The plates were then washed three times and the 
EODQNV VWDQGDUGV DQG VDPSOHV  ǋO SHU ZHOO DGGHG WR WKe plates in 
duplicate, and incubated for 2 hours. One set of standards was used on 
each plate and the standards and samples were diluted in Reagent Diluent 
as necessary. The plates were then washed three times and the detection 
DQWLERG\  ǋO SHU ZHOO Zas added for 2 hours. After washing again, 
Streptavidin-+53 ZDV DGGHG  ǋO SHU ZHOO IRU  PLQXWHV SURWHFWHG
from light. The plates were washed and TMB  ǋOSHUZHOOZDVDGGHG
for 20 minutes, and protected from light. The conversion of TMB was 
halted with the addition of sulphuric acid (Stop solution, Sigma-Aldrich, 
8.  ǋO SHU ZHOO 7KH SODWHV ZHUH WKHQ UHDG DW  QP 9LFWRU 
Multilabel Counter, Wallac). 
The concentrations of the samples were calculated as follows. The 
mean was taken for all duplicates, and the blank optical density reading 
was subtracted from all other values. The standard curve was generated 
with a four parameter logistic curve fit, using Prism GraphPad software. 
The cytokine concentrations of the samples were then interpolated from 
the equation of this curve and multiplied by the dilution factor as 
necessary. 
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2.8 Cell culture experiments 
2.8.1 Adipocyte culture 
Human white subcutaneous preadipocytes obtained from females 
undergoing cosmetic liposuction were purchased from Promocell 
(Germany), and cultured according to the manufacturer recommendations  
using aseptic techniques. The Promocell media (Preadipocyte Growth 
Medium, Preadipocyte Differentiation Medium and Adipocyte Nutrition 
Medium) were supplemented with penicillin (100 units.ml-1, Invitrogen, 
UK) and streptomycin  ǋJPO-1, Invitrogen, UK), and the cells were 
cultured in incubators providing a humidified atmosphere at 37oC with 5% 
CO2.  
The cells were received on dry ice and immediately transferred to 
liquid nitrogen for storage. 12 ml of Preadipocyte Growth Medium in a T75 
flask was put in the incubator for 30 minutes. The preadipocytes were then 
removed from the liquid nitrogen and the vial was gently shaken in a water 
bath at 37oC. When the medium was 90% thawed, the vial was removed to 
the laminar flow hood, sprayed with 70% ethanol and the revived 
preadipocytes were transferred to the pre-incubated T75 flask. The flask 
was placed in the incubator and the medium replaced after 18 hours. 
Thereafter, the medium was changed every 2-3 days. The preadipocytes 
were grown to approximately 70% confluence.  
The preadipocytes were split using trypsin and trypsin neutralising 
solution (TNS, Sciencell, USA) according to the manufacturer 
recommendations to release the cells from the flask. The preadipocyte 
monolayer was washed with filtered PBS, and the trypsin (1 ml) added for 
3-5 minutes until 80-90% of the preadipocytes were rounded and detached 
from the flask. TNS (1 ml) was then added and the liquid was transferred 
to a 15 ml Falcon tube. The flask was washed out with Preadipocyte 
Growth Medium (5 ml) which was also added to the Falcon tube. The cell 
suspension was centrifuged (250 g, 2 minutes), the supernatant discarded 
and the cell pellet resuspended in medium and divided between 4 T75 
flasks. The preadipocytes in these were then grown to approximately 70% 
confluence, before passaging again or seeding plates.  
For various experiments, cell culture treated 6-, 24- and 96-well 
plates were fibronectin (Sigma-Aldrich, UK) coated for 1 hour at 37oC. This 
was done to increase the adherence of the adipocytes to the plates during 
the differentiation phase. The plates were then seeded with preadipocytes 
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at passage no later than 8. At confluence, the medium was changed to 
Promocell Preadipocyte Differentiation Medium for 72 hours. After this, the 
cells were cultured in Promocell Adipocyte Nutrition Medium for 12-14 days 
until differentiation was complete, as assessed by morphological changes. 
Representative images of the differentiated adipocytes are shown in Figure 
2.5. 
 
2.8.1.1 Oil Red O staining of adipocytes 
Oil Red O stain stock was prepared by dissolving 0.7 g of Oil Red O in 200 
PORI,VRSURSDQRO7KHVROXWLRQZDVVWLUUHGRYHUQLJKWWKHQILOWHUHGǋP
filter paper) and stored at 4oC for up to one month. The working solution 
was prepared by mixing 6 parts stock solution with 4 parts distilled water. 
7KHVROXWLRQZDVOHIWIRUPLQXWHVEHIRUHILOWHULQJǋPILOWHUSDSHU 
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Figure 2.5 Differentiated human subcutaneous adipocytes in culture.  
Images are representative of adipocytes unstained (A), stained with Oil 
Red O to show lipid accumulation (B) and at a higher magnification to 
show individual adipocytes with multiple lipid droplets. Images were taken 
14 days after induction of differentiation. 
 
The cultured adipocytes were washed 3 times with distilled water, 
then fixed with 4% paraformaldehyde (PFA, 20 minutes). The PFA was 
removed and the cells were washed once with 60% isopropanol. Sufficient 
isopropanol to cover the cells was then added and left to evaporate. Oil 
Red O stain was added (10 minutes) and the plates were then washed 6 
times with tap water (see Figure 2.5). 
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2.8.2 Effects of endocannabinoids on adipokine secretion  
The acute and chronic effects of anandamide and 2-AG on adipokine 
secretion have not been fully characterised, particularly not in models of 
metabolic dysfunction. These experiments were conducted on human 
subcutaneous adipocytes, cultured as described in section 2.8.1. The cells 
were grown in 24-well plates. In the 2 hour endocannabinoid experiments 
(acute), the Adipocyte Nutrition Medium was changed for medium 
supplemented with insulin (1 µM), glucose (15 mM), or both or neither 
(control). Anandamide, 2-AG or vehicle was added to each well after 22 
hours in increasing concentrations (0.01 to 10 µM). The medium was then 
harvested at 24 hours and immediately stored at -80oC. For the 24 hour 
(chronic) experiments, the Adipocyte Nutrition Medium was supplemented 
with insulin (1 µM), glucose (15 mM), or both or neither (control). At the 
same time, anandamide, 2-AG or vehicle was added to each well. After 24 
hours the medium was harvested and stored (-80oC). The concentrations 
of various adipokines in the media were later determined via ELISAs (see 
section 2.7.3). 
 
2.8.3 Endocannabinoid uptake assay 
7KHVH H[SHULPHQWV ZHUH XQGHUWDNHQ GXULQJ D YLVLW WR 3URIHVVRU )RZOHU¶V
laboratory in Sweden and the assay methods used are those of Rakhshan 
(2000) as modified by Sandberg and Fowler (2005).  
Human white preadipocytes (Promocell) were cultured as previously 
described. 24 well plates were used and half of the wells in the plates were 
left unseeded, but treated with the same media and buffers, to allow 
measurement of background endocannabinoid adsorbance. Glucose (15 
mM) and/or insulin (1 µM), when used, were added to the plates after full 
differentiation of the adipocytes. After treatment, the plates were washed 
at 37oC with 1% BSA Krebs-Ringer-Hepes (KRH) buffer, and then with KRH 
buffer. After aspiration of the buffer, 340 ǋORI.5+EXIIHUFRQWDLQLQJ
fatty acid-free BSA was added to each well plus 10 ǋORIWKH)$$+ inhibitor 
URB597 (1 µM), the MGL inhibitor JZL184 (1 µM), or vehicle, and the 
plates were incubated for 10 minutes at 37oC. 50 ǋORI>3H]-anandamide or 
[3H]-2-AG in 0.1% fatty acid-free BSA KRH buffer was added to each well 
and the plates incubated at 37oC for a further 4 minutes. The reaction was 
stopped by placing the plates on ice and washing the cells three times with 
cold 1% BSA KRH buffer. After removal of the buffer, sodium hydroxide 
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(0.2 M, 500 ǋOSHUZHOOZDVDGGHGDQGWKHSODWHVZHUHLQFXEDWHGDt 75oC 
for 15 minutes. The plates were allowed to reach room temperature before 
aliquots from each well (300 ǋO ZHUH WUDQVIHUUHG WR VFLQWLOODWLRQ YLDOV
Scintillation fluid (4 ml per vial) was added and liquid scintillation 
spectroscopy was used to assess tritium levels. 
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2.9 Chemicals, solutions and buffers  
The following is a table of chemicals, solutions and buffers that were used 
in the assays that have been described in this chapter:  
 
Product or solution Company Components 
[3H]-anandamide 
American 
Radiolabelled 
Chemicals, USA 
 
2-AG Tocris, UK  
2-oleoyl-[3H]-glycerol 
American 
Radiolabelled 
Chemicals, USA 
 
Adipocyte nutrition 
medium 
Promocell, 
Germany 
0.03 ml.ml-1 fetal calf 
serum, 8 ǋJPO-1 d-Biotin, 
0.5 ǋJPO-1 insulin, 400 
ng.ml-1 dexamethasone 
Anandamide Tocris, UK  
Bovine serum albumin 
(essentially fatty acid 
free) 
Sigma-Aldrich, 
UK 
 
Bovine serum albumin 
(for ELISA) 
Sigma-Aldrich, 
UK 
 
Bradford reagent 
Sigma-Aldrich, 
UK 
 
Collagenase (type II) 
Sigma-Aldrich, 
UK 
 
DMSO 
Sigma-Aldrich, 
UK 
 
Ethylenediaminetetraacet
ic acid (EDTA) 
Sigma-Aldrich, 
UK 
 
ELISA wash buffer  0.05% Tween in PBS 
ELISA reagent diluent  1% BSA in PBS 
Ethanol 
Sigma-Aldrich, 
UK 
 
Fibronectin 
Sigma-Aldrich, 
UK 
 
Glucose 
Sigma-Aldrich, 
UK 
 
Insulin  
Sigma-Aldrich, 
UK 
 
JZL184 Tocris, UK  
Krebs-Ringer-Hepes 
buffer (KRH) 
 
120 mM sodium chloride, 
4.7 mM, 2.2 mM calcium 
chloride, 10 mM Hepes, 
0.12 mM monopotassium 
phosphate, 0.12 mM 
magnesium sulphate, pH 
7.4 
Phosphate buffer tablets 
Sigma-Aldrich, 
UK 
 
MAFP Tocris, UK  
Penicillin-Streptomycin Invitrogen, UK  
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Phosphate buffered 
saline (PBS) 
Sigma-Aldrich, 
UK 
10 mM phosphate, 2.7 mM 
potassium chloride and 137 
mM sodium chloride, pH 7.4 
Preadipocyte 
differentiation medium 
Promocell, 
Germany 
8 ǋJPO-1 d-Biotin, 0.5 
ǋJPO-1 insulin, 400 ng.ml-1 
dexamethasone, 44 ǋJPO-1  
IBMX, 9 ng.ml-1 l-thyroxine, 
3 ǋJPO-1 ciglitazone 
Preadipocyte growth 
medium 
Promocell, 
Germany 
0.05 ml.ml-1 fetal calf 
serum, 4 ǋOPO-1 endothelial 
cell growth supplement, 10 
ng.ml-1 epidermal growth 
factor, 1 ǋJPO-1 
hydrocortisone, 90 ǋJPO-1 
heparin 
TE buffer  
50mM Tris, 1mM EDTA, pH 
7.4 
Tris(hydroxymethyl)ami-
nomethane (TRIS) 
Sigma-Aldrich, 
UK 
 
Trypsin EDTA Sciencell, USA 
0.025% trypsin, 0.5 mM 
EDTA, 1 mM sodium 
pyruvate and 10 mM HEPES, 
pH 7.4 
Trypsin neutralising 
solution 
Sciencell, USA 
10% fetal calf serum, 0.5 
mM EDTA, 1 mM sodium 
pyruvate and 10 mM HEPES, 
pH 7.4 
Tween20 
Sigma-Aldrich, 
UK 
 
URB597 
Sigma-Aldrich, 
UK 
 
 
 
2.10 Statistical analysis  
All statistical analysis was performed using GraphPad Prism software 
(GraphPad Software, USA). 
 
2.10.1 Enzyme activity assays 
In all analysis where FAAH and MGL activities were compared between 
three groups, one-way analysis of variance (ANOVA) and Bonferroni¶V post 
hoc test were used. This applies to the three rat strains (lean, obese and 
obese-diabetic), the three adipose tissue depots taken from the rats 
(subcutaneous, abdominal and epididymal) and the three groups of 
surgical patients (healthy, metabolic syndrome and diabetes). A P value 
<0.05 was deemed to be statistically significant. 
 In the surgical patient study, enzyme activities were compared 
between subcutaneous and visceral adipose tissue depots. For this 
analysis, a paired t test was used with P<0.05 as statistically significant.  
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 Various correlation studies were performed in the Zucker rat and 
two human studies, between enzyme activities and anthropometric or 
blood serum values. Normality was tested for in all data sets before further 
analysis. The Pearson correlation coefficient (r) was calculated and  P<0.05 
was taken as statistically significant. 
MGL activity was also measured in cells cultured with insulin and/or 
glucose. These data were analysed using one-ZD\ $129$ DQG 'XQQHWW¶V
multiple comparison test, with all treatments compared against the basal 
activity rate and P<0.05 considered to be statistically significant. 
 
2.10.2 Adipocyte culture adipokine secretion 
The concentrations of various adipokines in harvested culture medium 
were compared using one-way ANO9$DQG'XQQHWW¶VPXOWLSOHFRPSDULVRQ
test. Various concentrations of anandamide and 2-AG were used in these 
experiments, and the adipokine secretion for each of these was compared 
against the secretion measured in vehicle treated cells. P<0.05 was 
deemed to be statistically significant. 
 
2.10.3 Endocannabinoid uptake 
The effects of insulin and glucose on anandamide and 2-AG uptake in 
cultured adipocytes were compared against basal uptake using one-way 
ANOVA and 'XQQHWW¶VPXOWLSOHFRPSDULVRQ test. P<0.05 was deemed to be 
statistically significant. 
 3. A study of the ECS in mature adipocytes from lean, 
obese and diabetic Zucker rats 
3.1 Introduction 
In humans, there is mounting evidence that the peripheral ECS is 
upregulated in obesity. This has been most conclusively demonstrated by 
several reports showing that plasma anandamide and 2-AG levels are 
increased in obese humans compared to lean (Engeli et al., 2005; Blüher 
et al., 2006; Cote et al., 2007). In adipose tissue, there are disagreements 
between studies as to whether various components of the ECS are up- or 
down-regulated in obesity. FAAH and CB1 receptor mRNA levels have been 
most extensively reported (as described in detail in Section 1.5). In 
summary, CB1 receptor mRNA (Engeli et al., 2005; Blüher et al., 2006; 
Sarzani et al., 2009; Bennetzen et al., 2010) and protein (Bennetzen et 
al., 2010) have been shown to be reduced in obese subjects compared to 
lean. Conversely, other research has shown CB1 receptor mRNA to be 
increased in the subcutaneous adipose tissue of obese patients compared 
to lean (Pagano et al., 2007). In contrast to these studies, another found 
no significant differences in CB1 or CB2 receptor mRNA between lean and 
obese groups (Murdolo et al., 2007). In visceral adipose tissue, there are 
similar discrepancies. Some research has shown CB1 receptor mRNA to be 
increased in obese patients compared to lean (Pagano et al., 2007; Sarzani 
et al., 2009; Bennetzen et al., 2010), whilst another study showed that 
CB1 receptor mRNA from lean and obese humans is not correlated with BMI 
(Lofgren et al., 2007). Similarly, levels of FAAH mRNA in human adipose 
tissue have also been measured by multiple laboratories, with conflicting 
results. FAAH mRNA has been reported to be both increased (Murdolo et 
al., 2007; Pagano et al., 2007) and decreased (Engeli et al., 2005; Blüher 
et al., 2006; Kempf et al., 2007; Lofgren et al., 2007) in the subcutaneous 
adipose tissue of obese compared to lean subjects.  
It is important to note that in all of the above mentioned studies, 
the whole adipose tissue sample has been analysed, containing not only 
mature adipocytes, but other cells such as preadipocytes, fibroblasts, 
endothelial cells and macrophages (Trayhurn et al., 2006). As a result, the 
effects of obesity on the ECS in mature adipocytes, the most metabolically 
active component of adipose tissue, remain under-reported. This is 
significant because it has recently been shown that the expression of CB1 
receptors in isolated mature adipocytes is lower than in the stromal-
vascular fraction of adipose tissue (Bennetzen et al., 2010). Additionally, 
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the reporting of mRNA in these studies leaves the question of how the 
activity of the ECS is affected by obesity in adipose tissue unanswered. 
 Several studies have indicated that the peripheral ECS may be 
dysregulated in type 2 diabetes, and that there may be crosstalk between 
insulin, glucose and the ECS. Some of the first evidence for this came from 
a study which showed increased concentrations of anandamide and 2-AG in 
blood plasma from humans with type 2 diabetes compared to matched 
controls of a similar BMI (Matias et al., 2006). More recently, 
endocannabinoid levels have been reported in human subcutaneous 
adipose tissue. It was found that anandamide is increased and 2-AG is 
decreased in obese humans with type 2 diabetes compared to both lean 
humans and obese non-diabetic controls (Annuzzi et al., 2010). FAAH has 
a crucial role in the regulation of anandamide levels and, given that 
peripheral anandamide levels may be increased in diabetes, the role of 
FAAH has been investigated in glycaemic homeostasis and diabetes. In one 
study, the euglycaemic-hyperinsulinaemic clamp technique was used to 
maintain hyperinsulinaemia in obese subjects and matched lean controls. 
This caused an upregulation of FAAH mRNA in the subcutaneous abdominal 
adipose tissue of lean subjects, but no change in the obese group, in which 
FAAH was already chronically upregulated. This suggests that 
hyperinsulinaemia alone may be sufficient to cause FAAH upregulation in 
adipose tissue (Murdolo et al., 2007).  
It is well established that weight loss in obese humans improves 
metabolic function, as measured by markers such as HOMA. A missense 
mutation in the FAAH gene has recently been associated with lack of 
improvements in these metabolic benefits, such that fasting serum insulin 
and glucose concentrations are not reduced after moderate weight loss (de 
Luis et al., 2010a). Similarly, a study using FAAH knockout mice found that 
blood plasma insulin and glucose concentrations were increased compared 
to controls (Tourino et al., 2010). It is not possible from these systemic 
studies to speculate on the role of FAAH specifically in adipocytes, or even 
in adipose tissue.  
 The CB1 receptor has also been investigated in diabetes. In visceral 
adipose tissue, it has been reported that CB1 receptor mRNA levels are not 
different between humans with and without diabetes (Lofgren et al., 
2007). However, CB1 receptor signalling is thought to be important in 
glycaemic regulation, as rimonabant has hypoglycaemic properties and 
improves insulin sensitivity (Scheen et al., 2006) and a CB1 receptor 
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mutation has been associated with similar metabolic benefits (Bordicchia et 
al., 2009). In addition to this, CB1 receptor agonists have been shown to 
increase the rate of basal and insulin stimulated glucose uptake in cultured 
adipocytes (Gasperi et al., 2007; Pagano et al., 2007). 
Taken together, these findings provide evidence for a role of the 
ECS in metabolic regulation and its dysregulation in diabetes, but as yet 
this has not been investigated in isolated mature adipocytes.  
 In this first study, three strains of Zucker rat were used to 
investigate healthy, obese (hyperinsulinaemic) and obese diabetic 
(hyperinsulinaemic and hyperglycaemic) states. The benefits of such 
animal studies are that each strain is well characterised and provides a 
discrete and homogenous population sample of the characteristic of 
interest. This is important given the high number of discrepancies observed 
between results reported on the ECS in adipose tissue in human obesity 
and diabetes, in which the samples represented a greater range of insulin 
sensitivities and percentage body fat. Importantly, the design of this study 
allowed the combined effects of type 2 diabetes and obesity to be 
compared against obesity in the absence of diabetes, as well as against 
lean, healthy rats. 
 Visceral adipose tissue is considerably more metabolically active 
than subcutaneous adipose tissue (for review see Wajchenberg, 2000), but 
as yet there is no conclusive evidence as to whether the activity of the ECS 
differs significantly between these depots. In normal weight subjects, CB1 
receptor expression has been reported to be higher in subcutaneous fat 
than visceral (Sarzani et al., 2009; Bennetzen et al., 2010), unchanged 
(Pagano et al., 2007) or higher in visceral than subcutaneous (Blüher et 
al., 2006). Conversely, in obese patients, CB1 receptor mRNA was found to 
be elevated in the visceral adipose tissue depot compared to paired 
subcutaneous samples (Blüher et al., 2006; Pagano et al., 2007; Sarzani 
et al., 2009) or not different (Bennetzen et al., 2010). The two studies 
which have reported FAAH mRNA in adipose tissue are similarly 
inconsistent. In one study, FAAH mRNA was reported to be increased in 
visceral adipose tissue compared to subcutaneous in obese humans 
(Blüher et al., 2006). However, another study showed no difference in 
FAAH mRNA between visceral and subcutaneous adipose tissue in lean or 
obese subjects (Pagano et al., 2007). In this study, MGL mRNA was also 
measured and it was found that MGL was upregulated in subcutaneous 
adipose tissue compared to visceral adipose tissue in both lean and obese 
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groups (Pagano et al., 2007). This finding is in keeping with another study 
which reported increased levels of 2-AG in visceral adipose tissue 
compared to subcutaneous in obese humans (Matias et al., 2007). 
However, the catalytic activities of FAAH and MGL have not been reported 
or compared between different adipose tissue depots. Furthermore, none 
of these studies have reported on the ECS in isolated mature adipocytes as 
all have used whole adipose tissue. The importance of this has been 
highlighted recently in a study which reported both mRNA and protein 
levels for the CB1 receptor. It was found that, in general, results obtained 
with both methods were similar. However, mRNA analysis showed a 
significant difference between lean and obese patients in visceral adipose 
tissue that was not apparent in CB1 receptor protein levels (Bennetzen et 
al., 2010). 
 
3.2 Aims 
In view of this background literature, the aim of this study was to 
investigate the activity of the ECS in isolated mature adipocytes in the 
Zucker rat models of obesity and diabetes. Initial plans for this study 
included measuring cannabinoid receptor activity, but preliminary 
experiments showed that the level of expression was too low to be 
detected using the methods available. In light of this, the study was 
designed to focus on FAAH and MGL activities. There were two key aims of 
the study, which were designed in order to address inconsistencies in the 
data published to date. The first of these was to compare the three strains 
of Zucker rat to determine whether FAAH or MGL activities in isolated 
mature adipocytes differ between healthy (lean), hyperinsulinaemic 
(obese) and diabetic (obese diabetic) rats. Secondly, the question of 
whether the ECS differs between visceral and subcutaneous adipose tissue 
depots was addressed by comparing enzyme activities in adipocytes from 
subcutaneous and two visceral adipose tissue sites. 
 
3.3 Materials and Methods 
3.3.1 Zucker rats and adipocyte preparation 
Male Zucker rats as described in Section 2.1 were used. Adipose tissue was 
dissected from the subcutaneous abdominal, epididymal and abdominal 
visceral sites immediately after killing, stored at -80OC and processed as 
described in Section 2.2.     
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3.3.2 GTPǄS binding assay 
The GTPǄS binding assay was performed with the membrane fraction of 
mature adipocytes pooled from all adipose tissue depots of several rats, as 
described in Section 2.6.1. The positive control was the membrane fraction 
of homogenised whole rat brain. 
 
3.3.3 FAAH and MGL assays 
The enzyme assays were performed as described in Section 2.5. 
Optimisation of the assays was achieved by using various dilutions of the 
homogenates, until activity was detectable, but produced no more than 
10% substrate turnover. 
 
3.3.4 Protein assay 
The Bradford method was used to determine the protein concentration of 
each homogenate fraction, as described in Section 2.5.3. 
 
3.3.5 Statistical analysis  
GraphPad Prism software was used to analyse all of the results presented 
in this chapter. Comparisons between the three rat strains and three 
adipose tissue depots were made using one-ZD\$129$ DQG %RQIHUURQL¶V
post hoc  test. The correlation studies were performed using linear 
regression and the Pearson correlation coefficient is reported. For all tests, 
P < 0.05 was deemed statistically significant. 
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3.4 Results 
3.4.1 Characteristics of Zucker rats 
In this study 22 Zucker rats were used. These included lean, obese and 
obese diabetic rats, and the mean body weight and blood glucose 
concentration for each group is given in Table 3.1. Blood glucose data are 
missing for two of the obese diabetic rats, and weights were not recorded 
for two of the obese rats. 
 
 Body weight (g) 
Non-fasting blood glucose 
(mmol.L-1) 
Lean 288.5±6.2 6.6±0.3 
Obese 362.7±6.7 10.2±0.6 
Obese diabetic 324.5±6.7 18.3±1.7 
 
Table 3.1 Body weight and blood glucose concentrations of Zucker rats  
 
3.4.2 Cannabinoid receptor assays  
7KH *73Ǆ6 ELQGLQJ DVVD\ GHVFULEHG LQ 6HFWLRQ  PHDVXUHV WKH
amount of [356@*73Ǆ6 ERXQG WR WKH *Į subunit of the G protein, and 
therefore the relative level of G protein activation caused by coupled 
receptor agonists (Harrison and Traynor, 2003). In this study, this assay 
produced a typical dose response curve to WIN-55,212 using a positive 
control sample (rat brain membranes, Figure 3.1A). However, no binding 
was achieved using the rat adipocyte membrane fraction at protein 
FRQFHQWUDWLRQV RI   RU  ǋJPO-1 (n=6, Figure 3.1B), indicating 
that CB1 and CB2 receptor activity was not detectable in the rat mature 
adipocyte membranes. 
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Figure 3.1 *73Ȗ6ELQGLQJ 
*73Ǆ6ELQGLQJLQSRVLWLYHFRQWUROUDWEUDLQ$DQGWKUHHFRQFHQWUDWLRQVRI
rat adipocyte membranes (B). 
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3.4.3 Enzyme activity  
Anandamide hydrolysis in the rat adipocytes was suppressed by the FAAH 
inhibitor URB597 at 1 µM (Figure 3.2A). FAAH activity was present in the 
membrane fraction of the homogenised adipocytes, but was not detected 
in the cytosolic fraction (Figure 3.2B). Similar results for the distribution of 
FAAH have been reported previously (McKinney and Cravatt, 2005). 
 The majority of adipocyte MGL activity was detected in the cytosolic 
fraction, with only a minor amount in the membrane fraction (Figure 
3.2D). MAFP (1 µM), a non-specific MGL inhibitor, completely suppressed 
2-OG hydrolysis (Figure 3.2C). 
  
A B
C D
Le
an
 s
ub
cu
t
Le
an
 a
bd
o
Le
an
 e
pid
Ob
es
e 
su
bc
ut
Ob
es
e 
ab
do
Ob
es
e 
ep
id
Dia
be
tic
 
su
bc
ut
Dia
be
tic
 
ab
do
Dia
be
tic
 
ep
id
0
10
20
30
40
50 Basal
URB597
FA
AH
 a
ct
ivi
ty
(pm
o
le
s/
m
in
/m
g 
pr
ot
ei
n
)
Le
an
 s
ub
cu
t
Le
an
 a
bd
o
Le
an
 e
pid
Ob
es
e 
su
bc
ut
Ob
es
e 
ab
do
Ob
es
e 
ep
id
Dia
be
tic
 
su
bc
ut
Dia
be
tic
 
ab
do
Dia
be
tic
 
ep
id
0
20
40
Membrane
Cytosol
FA
AH
 
a
ct
ivi
ty
(pm
o
le
s/
m
in
/m
g 
pr
ot
e
in
)
Le
an
 
su
bc
ut
Le
an
 
ab
do
Le
an
 
ep
id
Ob
es
e 
su
bc
ut
Ob
es
e 
ab
do
Ob
es
e 
ep
id
Dia
be
tic
 
su
bc
ut
Dia
be
tic
 
ab
do
Dia
be
tic
 
ep
id
0
20
40
M
G
L 
a
ct
ivi
ty
(nm
o
le
s/
m
in
/m
g 
pr
ot
e
in
) Basal
MAFP
Le
an
 s
ub
cu
t
Le
an
 a
bd
o
Le
an
 e
pid
Ob
es
e 
su
bc
ut
Ob
es
e 
ab
do
Ob
es
e 
ep
id
Dia
be
tic
 
su
bc
ut
Dia
be
tic
 
ab
do
Dia
be
tic
 
ep
id
0
20
40
M
G
L 
ac
tiv
ity
(nm
ol
es
/m
in
/m
g 
pr
ot
ei
n
) Membrane
Cytosol
 
 
Figure 3.2 Inhibition of FAAH and MGL 
)$$+ DFWLYLW\ LQ WKH SUHVHQFH RI 85%  ǋ0 RU YHKLFOH LQ WKH
membrane fraction of adipocyte homogenates (A). MGL activity in the 
SUHVHQFH RI 0$)3  ǋ0 RU YHKLFOH LQ WKH F\WRVROLFIUDFWLRQ RI DGLSRF\WH
homogenates (C). FAAH (B) or MGL (D) activity in the membrane and 
cytosolic fractions of adipocyte homogenates. Data are given as means 
with error bars representing S.E.M.  
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3.4.4 Enzyme activity in three rat strains  
The obese rats showed significantly higher FAAH activity than the lean or 
obese diabetic rats in the abdominal (P<0.05, Figure 3.3C) and epididymal 
(P<0.01, Figure 3.3E) adipocytes. In the subcutaneous adipocytes, there 
was no significant difference between the lean, obese and diabetic rats 
(Figure 3.3A).  
The obese and obese diabetic rats had elevated MGL activity 
compared to the lean rats in all adipocytes. In the subcutaneous 
adipocytes, MGL activity was higher in the obese rats than the lean 
(P<0.01, Figure 3.3B) and in the abdominal and epididymal adipocytes this 
relationship reached a higher level of significance (P<0.001, Figure 
3.3D,F). MGL activity in the diabetic rats was higher than in the lean rats in 
subcutaneous (P<0.05, Figure 3.3B), abdominal (P<0.05, Figure 3.3D) or 
epididymal (P<0.001, Figure 3.3F) adipocytes. 
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Figure 3.3 FAAH and MGL in three rat strains 
FAAH and MGL activities in mature adipocytes isolated from subcutaneous 
(A,B), abdominal (C ,D) and epididymal (E,F) adipose depots in lean, obese 
and diabetic Zucker rats. Data presented here are the same as Figure 3.5, 
but displayed to allow comparison between the three rat strains. n = 6 for 
control rats and n = 8 for obese and obese diabetic rats. Data are given as 
means, with error bars representing S.E.M., and were analysed by one-
ZD\$129$DQG%RQIHUURQL¶Vpost hoc  test (* P < 0.05, ** P < 0.01, *** P 
< 0.005). 
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3.4.5 FAAH activity and body mass 
Correlation studies were performed between FAAH activity in the three rat 
strains and total body mass. In the subcutaneous adipocytes, there was no 
relationship between FAAH activity and body mass (Figure 3.4A), but in the 
abdominal and epididymal adipocytes FAAH activity correlated positively 
with body mass (r=0.54, P<0.05; r=0.49, P<0.05, Figure 3.4C,E).  
 
3.4.6 MGL activity and body mass 
A positive relationship was identified between MGL activity and body mass 
in adipocytes from all three adipose tissue depots (subcutaneous r=0.72, 
P<0.001, Figure 3.4B; abdominal r=0.63, P<0.01, Figure 3.4D; epididymal 
r=0.80, P<0.001, Figure 3.4F).  
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Figure 3.4 FAAH and MGL with body mass  
Correlative studies between the total body mass of each rat and enzyme 
activity in mature adipocytes isolated from each adipose tissue depot. Data 
are presented for subcutaneous (A,B), abdominal (C ,D) and epididymal 
(E,F) adipocytes and the Pearson correlation coefficient is reported. Key: 
green, lean rats; red, obese rats; black, obese diabetic rats. 
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3.4.7 Enzyme activity between adipose tissue depots  
In the lean Zucker rats, FAAH activity did not differ between the 
subcutaneous, abdominal and epididymal adipose tissue depots (3.9±0.7, 
8.1±3.7, 6.5±1.3 pmoles.min-1.mg protein-1 respectively, Figure 3.5A). 
However, in the lean rats, MGL activity was significantly lower in the 
subcutaneous adipocytes than in the abdominal and epididymal adipocytes 
(2.2±0.7, 5.9±1.0, 5.9±0.5 nmoles.min-1.mg protein-1 respectively, 
P<0.01, Figure 3.5B). 
In the obese Zucker rats, FAAH activity was not different between 
the three adipose tissue depots (subcutaneous: 26.1±7.4, abdominal: 
32.0±6.7 and epididymal: 18.5±3.2 pmoles.min-1.mg protein-1, Figure 
3.5C). In contrast to the results for the lean rats, MGL activity did not 
differ between the subcutaneous, abdominal and epididymal sites 
(36.2±8.1, 29.5±3.9, 27.8±2.2 nmoles.min-1.mg protein-1 respectively, 
Figure 3.5D). 
In the obese diabetic rats the results were the same as the obese 
rats in that FAAH activity in mature adipocytes did not differ between the 
three adipose tissue depots (19.6±7.4, 10.8±3.4, 6.0±1.6 pmoles.min-
1.mg protein-1, Figure 3.5E) and neither did MGL activity (25.4±3.8, 
20.2±4.0, 20.6±2.4 nmoles.min-1.mg protein-1, Figure 3.5F). 
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Figure 3.5 FAAH and MGL in three adipose tissue depots 
FAAH and MGL activities in mature adipocytes isolated from three adipose 
depots in control (A,B), obese (C ,D) and obese diabetic (E,F) Zucker rats. 
n = 6 for control rats and n = 8 for obese and obese diabetic rats. The 
data are the same as those presented in Figure 3.3, but are arranged in 
this figure to allow comparison between the three adipose tissue depots. 
Data are given as means, with error bars representing S.E.M., and were 
analysed by one-ZD\$129$DQG%RQIHUURQL¶Vpost hoc test (** P < 0.01). 
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3.4.8 Enzyme activity and blood glucose  
Neither FAAH nor MGL (Figure 3.6) activity in adipocytes correlated with 
non-fasting blood glucose concentration in any of the rats or adipose tissue 
depots investigated.  
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Correlative studies between blood glucose concentration and enzyme 
activity in mature adipocytes isolated from each adipose tissue depot. Data 
are presented for subcutaneous (A,B), abdominal (C ,D) and epididymal 
(E,F) adipocytes and the Pearson correlation coefficient is reported. Key: 
green, lean rats; red, obese rats; black, obese diabetic rats. 
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3.5 Discussion 
Over recent years, there has been increasing speculation and evidence that 
the peripheral ECS is upregulated in human and animal obesity, albeit with 
many conflicts in the published data. In view of this, the primary aim of 
this study was to re-examine this topic in a novel manner by determining 
whether the activities (as opposed to mRNA) of the two major catabolic 
enzymes of the ECS, FAAH and MGL, are altered in mature adipocytes (as 
opposed to the whole adipose tissue) in a Zucker rat model of obesity. 
There have also been reports that the ECS may be affected by metabolic 
dysregulation or upregulated in type 2 diabetes. Therefore, the second aim 
of this study was to establish whether enzyme activities are affected by 
hyperinsulinaemia in obese rats, or diabetes in obese diabetic rats, 
compared to the healthy lean controls. Finally, given the discrepancies 
reported for FAAH and MGL mRNA levels in visceral and subcutaneous 
adipose tissue, the activities of these enzymes in isolated adipocytes were 
compared between three different adipose tissue depots in each rat strain.  
The main findings of this study were that FAAH activity correlated 
with total body mass in the visceral adipocytes, and MGL activity correlated 
with total body mass in adipocytes from all three depots. Direct 
comparisons between the three rat strains showed that the obese rats 
tended to have increased FAAH activity compared to the lean and obese 
diabetic rats. Furthermore, both the obese and obese diabetic rats had 
higher MGL activity than the lean rats. Together, this supports the theory 
that the ECS is dysregulated in obesity. In general, FAAH and MGL 
activities in isolated mature adipocytes were not different between the 
three adipose tissue depots analysed.  
 Previous studies have demonstrated that CB1 and CB2 receptor 
proteins are present and functional in human mature adipocytes. This has 
been shown using various methods such as immunostaining, Western 
blotting and measuring cAMP production in the presence of cannabinoid 
receptor agonists and antagonists (Engeli et al., 2005; Roche et al., 2006). 
CB1 receptor mRNA has also been detected in rat adipocytes (Karaliota et 
al., 2009) and in the adipose tissue of obese Zucker rats (Bensaid et al., 
2003). In human studies, CB1 receptor mRNA levels in subcutaneous 
adipose tissue have been reported to be altered in obesity, with some 
studies showing downregulation in obesity (Engeli et al., 2005; Blüher et 
al., 2006; Sarzani et al., 2009; Bennetzen et al., 2010) and others 
showing upregulation or no change (Lofgren et al., 2007; Murdolo et al., 
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2007; Pagano et al., 2007). However, whether the activity of the 
cannabinoid receptors is altered in obesity has not been reported. An aim 
of this study was to measure cannabinoid receptor activity in mature 
DGLSRF\WHV IURP OHDQ DQG REHVH =XFNHU UDWV XVLQJ WKH *73Ǆ6 ELQGLQJ
assay. This assay worked as expected using a positive control (Zucker rat 
whole brain membranes), giving a sigmoidal dose response curve to WIN-
55,212. WIN-55,212 is a non-specific CB1 and CB2 receptor agonist, so 
without the use of specific antagonists, the activity reported here for the 
rat brain control is total cannabinoid receptor activity. In the results 
presented here for rat mature adipocytes, a dose response curve was not 
seen at the three protein concentrations and previous work in this 
laboratory has shown that the assay is not reliable at protein 
concentrations outside of this range. This suggests that in these adipocytes 
there is no appreciable CB1 or CB2 receptor activity and endocannabinoids 
may therefore signal through alternative receptors, such as the TRPs and 
PPARs in Zucker rat adipocytes, potentially increasing rates of lipolysis and 
differentiation. Additionally, the endocannabinoids may act on other cells in 
adipose tissue more than mature adipocytes. In human samples, CB1 
receptor mRNA is markedly lower in whole adipose tissue than in brain 
(Engeli et al., 2005). Additionally, a recent study showed that CB1 receptor 
mRNA levels are higher in the stromal-vascular fraction of human 
subcutaneous adipose tissue than in isolated mature adipocytes 
(Bennetzen et al., 2010). This may explain why cannabinoid receptor 
activity was not detected using WKH*73Ǆ6DVVD\LQWKHPDWXUHDGLSRF\WHV
In the study which showed cannabinoid receptor activity (via cAMP 
reduction), the isolated adipocytes were cultured for 18 hours prior to the 
activity assays (Roche et al., 2006), whereas in the current study, the 
mature adipocytes were stored at -80oC, and to date the effects of cell 
culture on the ECS have not been well characterised. The findings of this 
study, which differ from studies showing that cannabinoid receptor mRNA 
and protein are present, highlight the importance of measuring protein 
activity. However, to do this in isolated mature adipocytes, alternative 
assays may need to be developed.  
 Given these issues with measuring cannabinoid receptor activity in 
mature adipocytes, future studies in this thesis were focussed on the 
activities of FAAH and MGL. The mRNA levels of MGL, and particularly 
FAAH, in adipose tissue have been relatively extensively reported in 
studies investigating the ECS in obesity and diabetes. However, the 
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activities of FAAH and MGL have not been reported in these comparison 
studies and it is therefore unknown whether alterations in mRNA 
expression relate to changes in final activities of the enzymes. Additionally, 
the effects of obesity and diabetes on the ECS enzymes in isolated mature 
adipocytes, rather than whole adipose tissue, have not been reported. 
Enzyme activity assays in mature adipocyte homogenates were used in this 
study to address these issues. These assays, which measure the rate of 
hydrolysis of anandamide and 2-OG, have been described and optimised in 
several published studies (Dinh et al., 2002b; Wilson et al., 2003; Boldrup 
et al., 2004; Ghafouri et al., 2004). As all labelled products are detected, 
enzyme inhibitors are used to indicate the percentage of this total 
hydrolysis that can be attributed to FAAH or MGL. URB597 is a specific 
FAAH inhibitor which inhibits anandamide hydrolysis in rat and human 
tissues with IC50s in the low nanomolar range (reviewed by Piomelli et al., 
2006). In vivo URB597 has been shown to increase the concentrations of 
several fatty acid ethanolamide substrates of FAAH, and does not 
appreciably affect MGL activity (Piomelli et al., 2006). The use of URB597 
in this study indicates that almost 80% of the anandamide hydrolysis 
reported in isolated adipocytes is due to FAAH activity. The inhibitor used 
in the MGL assay, MAFP, is less specific in its binding than URB597. It has 
been shown to inhibit both MGL and FAAH and to bind to the CB1 receptor 
(Martin et al., 2000; Ho and Hillard, 2005). The use of MAFP in the 2-OG 
hydrolysis assay completely suppressed hydrolysis. The first reported MGL 
activity experiments in rat epididymal adipose tissue homogenates showed 
that approximately half of the total MGL activity in whole adipose tissue 
homogenates was in the supernatant fraction, with the remainder  of the 
activity in the fat cake and the membrane pellet (Tornqvist and Belfrage, 
1976). The proportion of 2-OG hydrolytic activity detected in the 
supernatant fraction of the mature adipocyte homogenates used in the 
current study was significantly greater than 50%. Importantly, the study 
showing significant MGL activity in the adipose tissue particulate fraction 
used a longer centrifugation time at greater force (Tornqvist and Belfrage, 
1976), and it is possible that this reduced the concentration of MGL in the 
supernatant fraction. In addition to this, MGL is found in lipid aggregates 
which contain proteins. These may be artefacts from the homogenisation 
process (Tornqvist and Belfrage, 1976) and differences in the 
homogenisation protocols used between studies may also account for some 
of the observed differences in MGL activity distribution. It should also be 
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noted that in our study only mature adipocytes were used rather than 
whole adipose tissue.    
 As previously described in detail, changes in the peripheral ECS in 
obesity have been widely reported in human studies. C irculating 
endocannabinoid levels are generally reported to be elevated, but studies 
in adipose tissue have not been conclusive. FAAH mRNA has been reported 
to be up and downregulated. In order to increase the data available on 
FAAH regulation in the most metabolically active component of adipose 
tissue, this study focussed specifically on FAAH activity in isolated mature 
adipocytes. It was found that in visceral adipocytes, FAAH activity 
correlates with total body mass, and in direct comparisons of the three 
Zucker rat strains, FAAH activity was higher in the obese rats than both 
the lean and obese diabetic rats in adipocytes from the two visceral 
adipose tissue depots. Another study using obese animals showed that 
FAAH protein levels in mice with diet-induced obesity were increased in 
subcutaneous adipose tissue. However, in this study, FAAH protein levels 
were not affected in the visceral adipose tissue (Starowicz et al., 2008). 
This finding is similar to that of a human study which found no difference 
in FAAH mRNA in visceral adipose tissue between lean and obese subjects, 
but an increase in expression in abdominal subcutaneous adipose tissue 
(Pagano et al., 2007). By contrast to our results, another human study 
reported that FAAH mRNA is decreased in both visceral and subcutaneous 
adipose tissue in obesity (Blüher et al., 2006).  
 Whilst FAAH mRNA levels in adipose tissue have been investigated 
in several published studies, MGL has not, and its expression remains 
relatively under-reported. It has been shown in one study that MGL mRNA 
levels in both subcutaneous and visceral adipose tissue are increased in 
obesity (Pagano et al., 2007). The results presented in this chapter show 
that MGL activity correlates with total body weight in adipocytes from all 
three adipose tissue depots and MGL activity is greater in the obese and 
obese diabetic rats than in the healthy lean rats. These findings appear to 
be in agreement with the study that showed MGL mRNA to be increased in 
abdominal subcutaneous and visceral adipose tissue in obese humans 
compared to lean (Pagano et al., 2007). An increase in MGL mRNA in 
visceral adipose tissue has also been reported in mice with diet-induced 
obesity (D'eon et al., 2008). Increased MGL activity in mature adipocytes 
in obesity may explain why the concentration of 2-AG in the subcutaneous 
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adipose tissue of obese Zucker rats was found to be lower than in lean rats 
(Izzo et al., 2009).    
 These results indicate that, in general, the activities of the major 
catabolic enzymes of the ECS, FAAH and MGL, are upregulated in mature 
adipocytes in obesity. This finding in Zucker rats supports the notion that 
regulation of the peripheral ECS is altered  in obesity. 
 There is some evidence that the ECS is dysregulated in diabetes 
and may be under the regulation of insulin (Di Marzo et al., 2009).  
Although there are few published studies in this area of research, one 
study reported that circulating endocannabinoid levels are increased in 
type 2 diabetes (Matias et al., 2006). Levels of anandamide have also been 
found to be increased in the subcutaneous adipose tissue of obese diabetic 
humans compared to obese non-diabetics (Annuzzi et al., 2010). In 
another study, in lean humans, exogenous insulin has been shown to 
increase FAAH mRNA in subcutaneous adipose tissue (Murdolo et al., 
2007). These studies suggest that the ECS in adipose tissue may be 
altered in diabetes, or be under the regulation of insulin. With the studies 
published to date in adipose tissue biopsies, it is not possible to conclude 
whether these changes occur in mature adipocytes. In the study presented 
here, mature adipocytes were isolated from lean, obese and obese diabetic 
rats in order to ascertain whether FAAH activity is affected by 
hyperinsulinaemia (obese rats) or hyperinsulinaemia with hyperglycaemia 
(insulin resistant, diabetic rats). The results show that in subcutaneous 
adipocytes, there is no difference in FAAH activity between lean, obese and 
obese diabetic rats. By contrast, in mature adipocytes from both of the 
visceral adipose tissue depots tested, FAAH activity is higher in the obese 
rats than both the healthy and obese diabetic rats. Furthermore, there is 
no difference in FAAH activity between the lean and obese diabetic rats. In 
some respects, these findings appear to be in agreement with a human 
study which reported FAAH mRNA in subcutaneous adipose tissue to be 
regulated by insulin. In this study, FAAH mRNA was increased in obesity, 
as seen here with activity, and differences in response to intravenous 
insulin infusion were observed between lean and obese subjects. In the 
lean subjects, FAAH mRNA was increased, but in the obese humans FAAH 
mRNA levels did not change in response to insulin (Murdolo et al., 2007). 
These findings show that in an obese, pre-diabetic, moderately insulin 
resistant state, FAAH is chronically upregulated by insulin, but not sensitive 
to acute upregulation by insulin. This may be one explanation as to why in 
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the completely insulin resistant, diabetic rats used in our study, FAAH 
activity was found to be at lean baseline levels despite hyperinsulinaemia. 
Another study, which measured endocannabinoid levels in subcutaneous 
adipose tissue, is also relevant to our findings. It was shown that 
anandamide is higher in obese diabetic humans than in obese non-
diabetics (Annuzzi et al., 2010). Although this was shown in subcutaneous 
adipose tissue, it is otherwise in line with the results reported here in 
visceral adipocytes showing increased FAAH activity in obese but not obese 
diabetic rats. The novel results reported in this chapter support the notion 
that FAAH regulation is altered in obese diabetic compared to obese rats in 
visceral mature adipocytes, possibly by insulin. 
In these studies, positive results have been reported for insulin 
rather than glucose. In agreement with this, the results of the current 
study show no correlations between blood glucose concentrations and 
FAAH or MGL activity in adipocytes from any of the adipose tissue depots 
sampled. A study into MGL activity in rat adipocytes found that activity did 
not differ between fasted and fed rats (Tornqvist et al., 1978), which is in 
keeping with the results presented here showing that the glucose 
concentration at the time of sampling does not correlate with MGL activity. 
Overall, these results do not suggest that acute hyperglycaemia affects 
FAAH or MGL activity in mature adipocytes.  
In addition to increased blood plasma concentrations of 2-AG in 
humans with type 2 diabetes (Matias et al., 2006), a decrease in 2-AG in 
subcutaneous adipose tissue has been reported in obese diabetic humans 
(Annuzzi et al., 2010). Given this evidence for dysregulated 2-AG levels, it 
was considered important to determine whether MGL activity in mature 
adipocytes is altered in the Zucker rat models of obesity and type 2 
diabetes. The results of this study show that MGL activity is increased in 
the obese and obese diabetic rats compared to the lean in mature 
adipocytes from all adipose tissue depots. An interesting difference to the 
FAAH results is that MGL activity is not different between the obese and 
obese diabetic rats. Finally, MGL activity in the adipocytes did not correlate 
with blood glucose concentration. These results are in keeping with the 
human study which showed 2-AG levels to be decreased in subcutaneous 
adipose tissue in type 2 diabetes (Annuzzi et al., 2010). An increase in 
MGL activity in obesity and type 2 diabetes may reduce 2-AG mediated 
VLJQDOOLQJ LQ DGLSRF\WHV DW UHFHSWRUV VXFK DV 33$5Ǆ DQG &%1, potentially 
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further reducing insulin sensitivity (Rockwell et al., 2006; Motaghedi and 
McGraw, 2008).  
 The subcutaneous and visceral adipose tissue depots are often 
considered to be metabolically distinct, with excess visceral adipose tissue 
conferring a greater risk of development of type 2 diabetes and other 
metabolic disorders than excess subcutaneous adipose tissue (Bray et al., 
2008; Taksali et al., 2008). In two human studies, the mRNA levels of 
FAAH have been compared between subcutaneous and visceral adipose 
tissue, but the findings are inconclusive. In the first, FAAH was found to be 
upregulated in visceral adipose tissue, regardless of BMI (Blüher et al., 
2006), whereas the second showed no difference between visceral and 
subcutaneous adipose tissue (Pagano et al., 2007). In a study using obese 
Zucker rats, FAAH activity was found to be higher in the subcutaneous 
than visceral adipose tissue (Batetta et al., 2009), but this has not been 
investigated in isolated mature adipocytes. The results of the current study 
show that in the lean healthy rats there is no difference in FAAH activity 
between the subcutaneous and visceral (abdominal and epididymal) 
adipocytes. This was also found in the obese and obese diabetic rats. 
These findings are in keeping with the human study which showed no 
difference in FAAH mRNA levels between visceral and subcutaneous 
adipose tissue, even in obesity (Pagano et al., 2007). By contrast, the 
relative activities of FAAH reported here do not reflect the differences in 
mRNA between subcutaneous and visceral adipose tissue reported by 
Blüher et al (2007). Importantly, the results presented here are also at 
odds with the study which reported increased FAAH activity in 
subcutaneous versus visceral adipose tissue in obese Zucker rats (Batetta 
et al., 2009). Given the similarities between this latter study and the work 
presented here, one of the most likely explanations for this difference is 
that in the current study isolated mature adipocytes were used rather than 
whole adipose tissue. It has been shown that macrophages have significant 
FAAH expression (Sun et al., 2005), but the FAAH activity of other cells of 
the stromal-vascular fraction of adipose tissue have not been reported. 
Therefore, differences in FAAH activity in the stromal-vascular cells 
between visceral and subcutaneous sites could account for the apparent 
discrepancy. The results given here indicate that the rate of anandamide 
degradation in mature adipocytes is not different between the three 
adipose tissue depots, and that this balance is not affected by obesity or 
diabetes.  
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 MGL is known to have an important role in lipid metabolism, but as 
yet its activity has not been investigated in mature adipocytes from 
visceral and subcutaneous adipose tissue depots. Given the essential role 
of MGL in 2-AG catabolism, and therefore in ECS signalling, its activity 
between depots was investigated in this study. The results show that in the 
lean healthy rats MGL activity is increased in adipocytes from both of the 
visceral adipose tissue depots compared to the subcutaneous adipocytes. 
In the obese and obese diabetic rats this difference is lost, and MGL 
activity is similar in adipocytes from all three depots, as was found with 
FAAH activity. This finding is at odds with the only study which has 
compared MGL mRNA between depots, as this human study showed 
increased MGL expression in subcutaneous compared to visceral adipose 
tissue (Pagano et al., 2007). As explained previously, this may be due to 
the use of isolated mature adipocytes in our study, or the analysis of 
activity rather than mRNA. It is interesting to note the differences 
observed here between the lean healthy rats and the obese rats. In the 
lean rats with normal metabolic physiology, MGL activity is higher in the 
visceral adipocytes than the subcutaneous, as might be expected given 
that visceral adipose tissue is more metabolically active (Wajchenberg, 
2000). However, in both of the obese Zucker rat strains, with disordered 
metabolic homeostasis, the level of MGL activity is higher and not different 
between visceral and subcutaneous adipocytes. This may be an indication 
that in obesity, subcutaneous adipocytes are recruited to assist in lipolysis 
that predominantly occurs in visceral adipocytes in the healthy state. This 
increase in MGL activity in subcutaneous adipocytes in obesity and 
diabetes might reduce 2-AG signalling at both cell surface and intracellular 
receptors. 
 In summary, despite evidence of dysregulation of the ECS in 
adipose tissue in obesity and type 2 diabetes, current data comparing 
mRNA levels of ECS components in adipose tissue are inconclusive. In light 
of this, FAAH and MGL activities were assayed in isolated mature 
adipocytes from lean, obese and obese diabetic Zucker rats. The major 
findings were that FAAH and MGL activities increased with body mass and 
there were differences between lean, obese and diabetic rats. FAAH 
activity was increased in obese rats, and MGL activity was found to be 
increased in obese and obese diabetic rats. Furthermore, in general, the 
enzyme activities did not differ in adipocytes from different adipose tissue 
depots. These changes have the potential to significantly modulate the 
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signalling of anandamide and 2-AG. Having identified these relationships in 
FAAH and MGL activities in Zucker rat models of obesity and diabetes, in 
the next chapter a study to investigate whether these enzymes are also 
altered in adipocytes in human obesity is presented. 
 
 4. Enzyme activities in subcutaneous human mature 
adipocytes  
4.1 Introduction 
One of the major findings of Chapter 3 was that FAAH and MGL activities 
are increased in adipocytes from obese rats. This is consistent with the 
notion that overall ECS tone is increased in human obesity. Some of the 
studies which led to this hypothesis showed that plasma levels of 
anandamide (Engeli et al., 2005) and 2-AG (Blüher et al., 2006; Cote et 
al., 2007) are increased in obesity. Circulating 2-AG levels have also been 
shown to correlate with waist circumference (Engeli et al., 2005) and, 
accordingly, more in depth analysis revealed that the most significant rise 
in plasma 2-AG occurs in those with visceral obesity (Blüher et al., 2006; 
Cote et al., 2007). Additionally, weight loss in obese men has been shown 
to reduce plasma levels of both AEA and 2-AG (Di Marzo et al., 2008). 2-
AG has also been reported to be increased in visceral adipose tissue in 
human obesity (Matias et al., 2006). Despite the reasonably consistent 
findings in circulating endocannabinoid levels between different studies, 
the relative expression levels of other components of the ECS in adipose 
tissue in obese compared to lean humans remain debated. 
As described in Section 1.5.5 and Chapter 3, levels of FAAH mRNA 
in human adipose tissue have been measured by multiple laboratories and 
conflicting findings have been reported. In some studies, FAAH mRNA is 
reported to be higher in the subcutaneous adipose tissue of obese  
compared to lean subjects (Murdolo et al., 2007; Pagano et al., 2007; 
Bennetzen et al., 2011), whereas other studies report FAAH mRNA to be 
decreased (Engeli et al., 2005; Blüher et al., 2006; Lofgren et al., 2007). 
There are no obvious reasons as to why discrepancies have been reported 
with regard to FAAH expression levels in adipose tissue in obesity. The 
techniques used in these studies appear to have been similar, as do the 
subjects sampled, although females are represented more than males in 
the studies showing FAAH to be downregulated in obesity, and males are a 
larger proportion of the results showing FAAH to be upregulated. A further 
connection between FAAH and obesity has been identified via a missense 
mutation in the FAAH gene, which reduces the protein expression and 
activity of FAAH and occurs in 3.6-10.8% of the population (depending on 
ethnicity) (Sipe et al., 2005). This mutation has been associated with 
obesity, as have some variants in the promoter section of the gene 
(Harismendy et al., 2010).  
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The studies described above have compared discrete groups of lean 
and obese subjects, with overweight (BMI 25-30 kg.m-2) humans excluded. 
In addition to this, all of the published studies on FAAH in adipose tissue in 
obesity have reported mRNA levels of FAAH without reference to final 
protein levels or activity. FAAH activity has been reported in human 
adipose tissue, (Spoto et al., 2006) but not in a comparative study, and 
not in isolated mature adipocytes. In order to increase our understanding 
of the role of FAAH in human adipocytes, and whether this alters with BMI, 
it is important to investigate FAAH activity, and thus endocannabinoid 
degradation, in isolated adipocytes. This is also important given that 
previous studies have investigated the ECS in whole adipose tissue rather 
than in mature adipocytes.  
MGL expression in human adipose tissue has not yet been 
extensively investigated with regard to obesity. In one study, MGL mRNA 
in subcutaneous adipose tissue was compared between distinct cohorts of 
lean and obese humans. It was found that obesity had no effect on MGL 
expression in abdominal subcutaneous adipose tissue (Lofgren et al., 
2007). However, in another study MGL mRNA was found to be upregulated 
in the abdominal subcutaneous adipose tissue of obese subjects compared 
to lean (Pagano et al., 2007). In agreement with this study, the results of 
Chapter 3 showed that MGL activity is increased in abdominal 
subcutaneous adipocytes in obese rats compared to lean. As plasma 2-AG 
is increased in obesity (Engeli et al., 2005; Blüher et al., 2006; Cote et al., 
2007), and there is speculation that 2-AG secretion from adipocytes may 
contribute to this, it is important to establish the effects of obesity on MGL 
activity in mature adipocytes in humans.   
Given that the majority of the studies described here have 
compared lean and obese subjects, there are remarkably few data on 
overweight humans (BMI 25-30 kg.m-2) and the ECS in adipose tissue. It 
was decided that overweight humans would be included in the following 
study in order to improve our understanding of the ECS in the pre-obese 
state, and possibly indicate whether ECS dysregulation occurs prior to 
overt obesity. In addition to this, although in the majority of the healthy 
non-athletic population, BMI correlates with overall body fat percentage 
(Deurenberg et al., 1991), the two measurements give different 
information. This has been revealed in some studies into the ECS in 
obesity. In some cases there is a significant relationship between the ECS 
and BMI, but not body fat percentage or other adiposity markers, and 
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sometimes relationships are observed with body fat and its distribution, 
but not BMI (Engeli et al., 2005; Blüher et al., 2006; Cote et al., 2007). As 
BMI alone is not an accurate measure of adiposity and body fat 
distribution, and does not take into account variability between humans of 
the same BMI, anthropometric estimations of adiposity (circumferences 
and skinfold thicknesses) were used in the following study.  
 
 
4.2 Aims  
In light of this background literature, the primary aim of the current study 
was to investigate the activity of FAAH and MGL in subcutaneous mature 
adipocytes from healthy humans representing a continuous range of BMIs. 
Assays were undertaken in mature adipocytes isolated from human 
subcutaneous adipose tissue in order to exclude interference from other 
cells in adipose tissue, such as preadipocytes or immune cells (other 
studies measured enzyme expression in the entire adipose tissue sample 
(Engeli et al., 2005, Blüher et al., 2006, Spoto et al., 2006, Lofgren et al., 
2007, Murdolo et al., 2007, Pagano et al., 2007)). Some studies have 
shown circulating endocannabinoid levels to be dependent on waist 
circumference or visceral adipose tissue to a greater extent than BMI. 
Given this, the second aim of this study was to examine whether there are 
relationships between FAAH and MGL activities in subcutaneous adipocytes 
and waist circumference. Finally, insulin sensitivity was measured to 
investigate whether, within a metabolically healthy sample, glycaemic 
regulation is related to FAAH and MGL activities in adipocytes. 
 
4.3 Materials and Methods 
4.3.1 Subjects 
Ethical approval for this study was granted by the University of Nottingham 
Medical School Ethics Committee. Healthy volunteers from within the 
School of Graduate Entry Medicine and Health were recruited, via posters, 
and health screened as described in Section 2.3.1. After exclusion of 6 
volunteers due to insufficient biopsy size or fasting blood glucose >5.6 
mmol.L-1, the data of 28 participants are reported in this study. 
Volunteers were asked to make two visits. In the first, 
anthropometric measurements and blood pressure were taken. In the 
second, no more than one week later, fasting subcutaneous abdominal 
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adipose tissue and venous blood samples were taken as described in 
Sections 2.3.2, 2.3.3 and 2.3.4.  
 
4.3.2 Homogenisation of adipocytes 
Mature adipocytes were separated from the other adipose tissue cells using 
collagenase and centrifugation within one hour of collection (detailed in 
Section 2.2.1.). The adipocytes were then stored at -80oC until 
homogenisation as described in Section 2.2.2.  
 
4.3.3 FAAH and MGL activity assay 
The enzyme assays were performed as described in Section 2.5. 
 
4.3.4 Protein assays 
The protein concentration of the adipocyte fractions was measured using 
the Bradford method, as described in Section 2.5.3. 
 
4.3.5 Blood serum assays 
Fasting blood serum glucose, insulin, adiponectin, leptin and resistin 
concentrations were assayed for all volunteers, as described in Sections 
2.7.1, 2.7.2, and 2.7.3 respectively. Glucose and insulin assays were 
performed within 6 months of sample collection. Adipokine assays were 
performed within 18 months of sample collection. The homeostatic model 
assessment (HOMA2-%S) figures were calculated using the HOMA2 model 
(www.dtu.ox.ac.uk). 
 
4.3.5 Statistical analysis  
GraphPad Prism Software was used to perform linear regression analyses 
and the Pearson correlation coefficient is reported.  
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4.4 Results 
4.4.1 Subject characteristics  
From an initial sample of 34 volunteers, 28 samples are reported on here. 
Of the excluded subjects, three had a fasting glucose >5.6 mmol.L-1 and 
three adipose samples were of insufficient size to obtain reproducible 
results. The physiological characteristics of this cohort are given in Table 
4.1. The fasting serum glucose and insulin values indicate that these 
subjects were all metabolically healthy (American-Diabetes-Association, 
1997; Alberti et al., 2009), but the HOMA2-%S values indicate a range of 
insulin sensitivities and the BMI range is from lean (<25.0 kg.m -2) to obese 
(>30.0 kg.m-2). As would be expected, in this sample BMI correlated with 
the sum of skinfolds (r=0.62, P<0.001, Figure 4.1A), mean arterial blood 
pressure (r=0.47, P<0.05, Figure 4.1B), waist:hip ratio (r=0.40, P< 0.05, 
Figure 4.1C) and waist circumference (r=0.83, P<0.001, Figure 4.1D), and 
had a non-significant negative trend with HOMA2-%S (r=-0.33, P=0.09, 
Figure 4.1E). 
 
 
 Range Mean±S.D. 
Male:female ratio 1:1  
Age (years) 20-48 31±8.7 
BMI (kg.m-2) 19.1-33.8 24.2±3.4 
Systolic blood pressure (mmHg) 104-135 120.5±8.8 
Diastolic blood pressure (mmHg) 60-91 73.4±7.2 
MAP (mmHg) 77-106 89.1±6.2 
Pulse (beat.min-1) 40-80 63.4±9.5 
Waist circumference (cm) 69-114 82.2±10.7 
Hip circumference (cm) 80-115 96.9±8.0 
Waist:hip ratio 0.69-1.06 0.85±0.08 
Sum of 7-point skinfolds (mm) 63-173 99.9±25.5 
Tricep skinfold (mm) 7-32 15±6 
Bicep skinfold (mm) 4-18 9±4 
Abdominal skinfold (mm) 11-26 20±4 
Suprailiac skinfold (mm) 5-25 17±6 
Subscapular skinfold (mm) 7-36 16±6 
Chest skinfold (mm) 3-18 9±4 
Midaxillary skinfold (mm) 5-26 14±6 
Serum glucose (mmol.L-1) 4.4-5.6 5.1±0.3 
Serum insulin (mU.L-1) 1.8-13.1 5.7±3.2 
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HOMA2-%S 59.4-361.5 165.0±79.2 
Serum adiponectin (ǋg.ml-1) 3.55-21.28 10.93±5.03 
Serum leptin (ng.ml-1) 0.34-36.53 8.5±15.44 
Serum resistin (ng.ml-1) 5.38-32.07 11.49±7.19 
 
 
Table 4.1 Subject characteristics 
Physiological data of metabolically healthy human volunteers. Serum 
samples were taken from fasting subjects (n=28). 
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Figure 4.1 Correlations between BMI and other variables 
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The relationship between BMI and sum of skinfolds (A), mean arterial 
pressure (B), waist:hip ratio (C), waist circumference (D) and HOMA2-%S 
(E) in healthy humans. r and P values were obtained using correlation 
analysis.  
 
4.4.2 Enzyme activity, BMI, body fat and circumferences  
In these metabolically healthy subjects, FAAH activity in subcutaneous 
mature adipocytes correlated positively with BMI (r=0.38, P<0.05, Figure 
4.2A) and with waist circumference (r=0.43, P<0.05, Figure 4.3A). FAAH 
activity did not correlate with calculated body fat percentage (r=0.15, 
P=0.47, Figure 4.2C). In contrast, MGL activity in subcutaneous mature 
adipocytes was not found to correlate with BMI (r=-0.20, P=0.32, Figure 
4.2A) or waist circumference (r=-0.08, P=0.71, Figure 4.3B).  
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Figure 4.2 FAAH and MGL with body fat estimates 
The relationship between FAAH and MGL activities in mature adipocytes 
isolated from abdominal subcutaneous adipose tissue and BMI (A,B) and 
body fat percentage (C ,D). The Pearson correlation coefficient is reported.. 
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Figure 4.3 FAAH and MGL with waist circumference 
The relationship between FAAH (A) or MGL (B) activities in mature 
adipocytes isolated from abdominal subcutaneous adipose tissue and waist 
circumference. The Pearson correlation coefficient is reported.. 
 
 
4.4.4 Enzyme activity and blood pressure  
FAAH and MGL activities in abdominal subcutaneous adipocytes did not 
correlate with mean arterial pressure (r=0.24, P=0.22, Figure 4.4A; 
r=0.17, P=0.39, Figure 4.4B). 
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Figure 4.4 FAAH and MGL with blood pressure 
The relationship between FAAH (A) or MGL (B) activities in mature human 
adipocytes isolated from abdominal subcutaneous adipose tissue and mean 
arterial blood pressure. The Pearson correlation coefficient is reported.. 
 
 
4.4.5 Enzyme activity and insulin sensitivity  
HOMA2-%S did not show a relationship with FAAH or MGL activity in 
mature abdominal subcutaneous adipocytes (r=0.06, P=0.78, Figure 4.5A; 
r=0.12, P=0.56, Figure 4.5B). 
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Figure 4.5 FAAH and MGL with insulin sensitivity 
The relationship between FAAH (A) or MGL (B) activities in mature 
adipocytes isolated from abdominal subcutaneous adipose tissue and 
HOMA. The Pearson correlation coefficient is reported.. 
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4.5 Discussion  
There are several studies showing that the mRNA and protein levels of 
some components of the ECS are upregulated in subcutaneous adipose 
tissue in obesity. In addition to this, the results presented in Chapter 3 
show that FAAH and MGL activities are increased in obese Zucker rats 
compared to lean rats. In light of this information, the principal aim of this 
study was to investigate whether the activities of FAAH and MGL, two key 
catabolic enzymes of the ECS, are altered with increasing BMI in otherwise 
healthy humans. The results show that FAAH activity in subcutaneous 
mature adipocytes increases with BMI and waist circumference. In contrast 
to this and the Zucker rat data, there is no relationship between MGL and 
BMI. Neither FAAH nor MGL activities correlate with insulin sensitivity in 
these healthy volunteers. 
In several published studies, the mRNA levels of FAAH in adipose 
tissue have been compared between lean and obese humans, and major 
discrepancies have been reported over whether FAAH is upregulated 
(Murdolo et al., 2007; Pagano et al., 2007) or downregulated (Engeli et al., 
2005; Blüher et al., 2006; Lofgren et al., 2007) in adipose tissue in 
obesity. In order to investigate this further in the current study FAAH 
activity, rather than mRNA, was measured, as mRNA levels do not always 
accurately reflect final protein levels (Bennetzen et al., 2010) or enzyme 
activity. This is particularly important for FAAH, as post-transcriptional 
regulation of this enzyme has not been reported. This was done in 
subcutaneous mature adipocytes from subjects over a range of BMIs, from 
lean to obese. The results show that in adipocytes from metabolically 
healthy people FAAH activity increases with BMI. This is similar to the 
results seen in Zucker rats showing a correlation between FAAH activity 
and weight. This is in agreement with studies showing increased FAAH 
mRNA in the subcutaneous adipose of obese individuals compared to lean 
(Murdolo et al., 2007; Pagano et al., 2007), and also with a study in mice 
showing that diet-induced obesity led to increased expression of FAAH 
protein in subcutaneous adipose tissue (Starowicz et al., 2008). However, 
other human studies have shown reported decreases in FAAH mRNA in 
obesity (Engeli et al., 2005; Blüher et al., 2006; Lofgren et al., 2007). The 
reasons for conflicting results are currently unclear, but it should be noted 
that two of these studies used entirely female samples (Engeli et al., 2005, 
Lofgren et al., 2007), and the other reported on surgical patients (Blüher 
et al., 2006). A further important distinction to draw is that in this study 
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isolated mature adipocytes were used rather than whole adipose tissue 
homogenates, and it has been shown that macrophages have significant 
FAAH expression (Sun et al., 2005). In addition subjects representing a 
continuous range of BMIs were used in this study, as opposed to the 
discrete cohorts of lean and obese subjects used in many studies. This has 
allowed the inclusion of data from people with a BMI between 25 and 30 
kg.m-2, which is a group that has not been described previously.  
The increase in adipocyte FAAH activity with increasing BMI may 
simply be part of a general upregulation of ECS tone in adipose tissue in 
obesity, as suggested by previous authors (Aurore and Gonthier, 2010; 
Bermudez-Silva et al., 2010). If both the synthesis and degradation of 
anandamide are upregulated in balance, anandamide signalling and the 
functional effects of anandamide within the adipocyte are unlikely to be 
altered. This hypothesis is supported by a recent report that anandamide 
concentrations in subcutaneous adipose tissue do not differ between lean 
and metabolically healthy obese humans (Annuzzi et al., 2010). 
Alternatively, FAAH may be upregulated in isolation. This would potentially 
reduce anandamide signalling both at CB1 and CB2 receptors, and at 
intracellular targets such as TRPV1 and PPARs. As missense mutations in 
the FAAH gene have been associated with an unfavourable metabolic 
profile in obese subjects (de Luis et al., 2010b), the increase of FAAH 
activity with BMI reported here may be metabolically protective. 
In some of the studies of the ECS in humans it has been found that 
adipose tissue distribution (subcutaneous versus visceral) is a better 
determinant of ECS expression than BMI or overall body fat percentage. 
For example, although circulating 2-AG levels have been reported to be 
increased in obesity, this has been shown to be accounted for largely by 
predominantly viscerally obese patients rather than subcutaneously obese 
(Blüher et al., 2006). It is known that in humans of the same BMI, visceral 
adipose tissue accumulation confers greater metabolic and cardiovascular 
risk than excess subcutaneous adipose tissue (Despres et al., 2008), but 
BMI does not distinguish between visceral and subcutaneous adipose 
tissue. For these reasons, in this study skinfold thicknesses and 
circumferences at various anatomical sites were measured to give an 
indication of fat distribution in the subjects. It was found that FAAH activity 
correlates with waist circumference. In general, this result is in keeping 
with studies showing that visceral obesity is a better predictor of circulating 
2-AG levels than non-specific obesity (Engeli et al., 2005; Blüher et al., 
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2006) and may support the notion that central adipose accumulation is 
more significant in relation to the ECS than the amount of subcutaneous 
adipose tissue. 
Humans with type 2 diabetes have increased plasma concentrations 
of anandamide and 2-AG compared to non-diabetic controls (Matias et al., 
2006). It has also been shown that FAAH mRNA is overexpressed in 
subcutaneous adipose tissue in obese humans and that similarly high 
expression was induced in healthy lean humans using the euglycaemic 
hyperinsulinaemic technique (Murdolo et al., 2007). This is evidence that 
hyperinsulinaemia may directly cause FAAH upregulation. Considering this, 
in the present study fasting serum levels of insulin and glucose and 
HOMA2-%S (an estimation of insulin sensitivity) were analysed to establish 
whether there is any relationship with FAAH activity. In this sample of 
metabolically healthy humans, there was no correlation between FAAH 
activity in subcutaneous adipocytes and HOMA2-%S. The subjects in this 
study had fasting serum levels within healthy reference ranges, but a 
range of insulin sensitivities was observed. Despite using only humans with 
normal fasting blood glucose in this study, these findings are consistent 
with the results seen in the Zucker rats, in which FAAH activity did not 
correlate with blood glucose in rats ranging from healthy to fully insulin 
resistant. In order to further investigate whether there are relationships 
between insulin or glucose and FAAH activity in mature adipocytes, some 
patients with poor glycaemic regulation were included in the next study 
(see Chapter 5).  
In mature adipocytes MGL has a primary role in lipid metabolism, 
specifically in the hydrolysis of monoglycerols to release glycerol and fatty 
acids (as described in Section 1.1.3.2). This explains the relatively high 
activity of MGL (~300 fold) compared to FAAH found in this study. The 
effects of MGL activity on 2-AG signalling are substantial, as demonstrated 
recently in mouse models, showing that both MGL gene deletion and 
systemic MGL inhibition lead to increased 2-AG levels in the brain and 
peripheral tissues, and desensitisation of brain CB1 receptors (Chanda et 
al., 2010; Schlosburg et al., 2010). As MGL is not thought to be under 
hormonal control in triglyceride catabolism, it has not been extensively 
investigated in relation to obesity. However, MGL is highly important in 2-
AG signalling in the ECS, and it has been shown that plasma 2-AG 
concentration in humans rises with obesity and in the Zucker rat study 
MGL activity in adipocytes increased with body weight. For these reasons, 
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MGL activity was analysed in this study with relation to BMI and other 
markers of adiposity. In contrast to the results seen with FAAH activity, 
MGL activity in subcutaneous adipocytes had no relationship with BMI, 
adiposityor glycaemic regulation. This is in agreement with at least one 
study in which the level of MGL mRNA in subcutaneous adipose tissue was 
not found to be different between lean and obese humans (Lofgren et al., 
2007) and another showing the same thing in visceral adipose tissue 
(Matias et al., 2006). More generally, our findings are also in agreement 
with the observation that the rate of glycerol release from adipose tissue is 
the same in lean and obese subjects, in both fasting and fed states 
(Bolinder et al., 2000). In contrast, another study has shown an increase 
in MGL mRNA in subcutaneous adipose tissue in obese humans compared 
to lean (Pagano et al., 2007). It is also interesting that the results 
observed in humans in this study are different to the finding in the Zucker 
rats, in which MGL activity in subcutaneous adipocytes increased with body 
weight. Our findings in humans suggest that, with regard to adipocyte 
contribution to systemic 2-AG catabolism, the increase in circulating 2-AG 
observed in obese humans may be due to enhanced production rather than 
decreased degradation. 
In summary, the results of this study show that FAAH activity in 
human subcutaneous mature adipocytes from healthy volunteers increases 
with BMI and waist circumference, but not with other markers of adiposity 
or metabolism. Conversely, MGL activity does not correlate with BMI or 
any other markers measured in this study. In the relatively metabolically 
healthy humans used in this study, neither FAAH nor MGL activities 
correlated with serum glycaemic markers, so in the following study obese 
patients with a range of metabolic dysfunction were investigated. 
 
 
 5. FAAH and MGL in mature adipocytes from obese 
patients  
5.1 Introduction 
Dysregulation of the peripheral ECS has been described in obesity, 
diabetes and other metabolic disorders in several published studies and in 
the work presented in this thesis. To summarise the results given so far, 
Chapter 3 showed that FAAH activity in adipocytes was increased in 
obesity, but not increased in the obese diabetic rats. This indicates that 
FAAH regulation in diabetes may differ from that in the obese but relatively 
insulin sensitive state. By contrast, MGL activity was increased in both 
obesity and in the obese diabetic rats compared to the lean rats. In 
Chapter 4 evidence was given that in healthy human subcutaneous 
adipocytes, FAAH activity increases with BMI, whereas MGL activity does 
not. However, the potential effects of metabolic disorder and diabetes were 
not investigated in this human sample as all subjects had normal fasting 
blood glucose concentrations.  
The published studies that are relevant to this work have been 
described in detail in previous chapters. Very briefly, acute 
hyperinsulinaemia in lean humans has been found to increase FAAH mRNA 
expression in subcutaneous adipose tissue, but this acute response does 
not occur in obese humans with chronic hyperinsulinaemia and chronically 
elevated FAAH expression (Murdolo et al., 2007). Furthermore, in humans 
with type 2 diabetes, plasma endocannabinoid levels are increased (Matias 
et al., 2006), and endocannabinoid levels in subcutaneous adipose tissue 
are altered (Annuzzi et al., 2010). These studies, along with the results of 
Chapter 3, suggest that insulin and/or diabetes affect FAAH, but to date, 
the effects of diabetes or metabolic syndrome of the activities of FAAH and 
MGL in human mature adipocytes have not been investigated.  
The function and signalling of adipose tissue are affected by both 
total body mass and the site of adipose tissue deposition. This has been 
clearly demonstrated for hormones such as leptin and adiponectin (Sethi 
and Vidal-Puig, 2007), but in the case of the ECS the findings are not as 
well established. In normal weight humans CB1 receptor mRNA has been 
reported to be higher in subcutaneous fat than visceral (Sarzani et al., 
2009; Bennetzen et al., 2010), unchanged (Pagano et al., 2007) or 
elevated in visceral compared to subcutaneous (Blüher et al., 2006). 
However, in obese patients, CB1 receptor expression may be higher in 
visceral fat than subcutaneous (Blüher et al., 2006; Pagano et al., 2007; 
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Sarzani et al., 2009) or not different (Blüher et al., 2006). As a further 
complicating factor, this may depend on whether the majority of excess 
adipose tissue is visceral or subcutaneous (Blüher et al., 2006). FAAH 
mRNA has also been reported in visceral and subcutaneous adipose tissue 
in humans. One study has shown that FAAH mRNA levels do not differ 
between visceral and subcutaneous adipose tissue, even in obesity 
(Pagano et al., 2007), but another found that FAAH mRNA is upregulated 
in visceral compared to subcutaneous depots (Blüher et al., 2006). MGL 
mRNA was found to be elevated in subcutaneous compared to visceral 
adipose tissue, regardless of BMI (Pagano et al., 2007). In the published 
literature to date, there are few studies in which FAAH and MGL mRNA 
have been measured in different adipose tissue depots, and none in which 
the activities of the enzymes have been measured in mature adipocytes.  
 
5.2 Aims 
This study was based on the findings of Chapters 3 and 4, which showed 
that FAAH and MGL activities differed between the lean, obese and obese 
diabetic rats, and that FAAH activity in human subcutaneous adipocytes is 
increased with BMI. This study was also designed to address the 
contradictions in published studies which show various effects of diabetes 
or insulin on the ECS in adipose tissue. Therefore, clinically obese patients 
with varying degrees of metabolic dysfunction were recruited. The first aim 
of the study was to investigate whether FAAH or MGL activities in isolated 
mature adipocytes correlate with BMI, waist circumference or long-term 
glycaemia. Another closely associated aim, using the same data set, was to 
determine whether FAAH or MGL activities are different between relatively 
healthy obese patients, and those with metabolic syndrome or diagnosed 
type 2 diabetes. Finally, as Chapter 3 showed no difference in enzyme 
activities in adipocytes from different adipose tissue depots, the activities 
of FAAH and MGL between paired subcutaneous and visceral mature 
adipocytes were compared. 
 
5.3 Materials and Methods 
5.3.1 Patient recruitment 
The study was approved by Derbyshire Regional Ethics Committee and 
Royal Derby Hospital Trust, and written informed consent was obtained 
from all patients. Patients were recruited to this study prior to surgery as 
described in Section 2.4.1. Anthropometric measurements were taken as in 
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Section 2.4.2. Briefly, the sample comprised patients undergoing 
laparoscopic bariatric surgery for weight loss, and a few patients 
undergoing laparoscopic cholecystectomies. This latter group of patients 
was recruited in order to include data on people with BMI <40 kg.m -2. 
Patients were selected to represent three subgroups of the obese 
population, which have been extensively characterised in previous studies. 
These are obese patients who are metabolically healthy; obese patients 
with metabolic syndrome; and obese patients with type 2 diabetes.  
 
5.3.2 Healthy, metabolic syndrome and diabetic grouping 
The patients in this study were assigned to one of three groups after 
recruitment and sample collection: metabolically healthy, metabolic 
syndrome and diabetic. Patients were included in the type 2 diabetes group 
according to clinical diagnosis prior to surgery. The remaining patients 
were then assigned to the metabolic syndrome group or healthy group 
according to criteria published jointly by several major associations and 
groups (Alberti et al., 2009). Metabolic syndrome is diagnosed if any 3 of 
the 5 major factors associated with increased metabol ic and cardiovascular 
ULVNDUHSUHVHQW7KHVHIDFWRUVDUHZDLVWFLUFXPIHUHQFHFPPDOHRU
 FP IHPDOH EORRG VHUXP WULJO\FHULGH  mmol.L-1; blood serum 
HDL-cholesterol <1 mmol.L-1 (male) or <1.3 mmol.L-1 (female); systolic 
EORRGSUHVVXUHPP+JDQGRUGLDVWROLFEORRGSUHVVXUHPP+J
and fasting EORRGVHUXPJOXFRVHPPRO/-1. The prescription of drugs 
to control dyslipidaemia (fibrates or nicotinic acid), blood pressure or 
hyperglycaemia negates the requirement for the relevant factor to be 
outside these ranges. All patients in this study had a waist circumference 
>100 cm, but patients with only one other marker of metabolic syndrome 
were assigned to the obese but metabolically healthy group. It should be 
noted that these patients cannot be considered a healthy sample of the 
general population, but they do represent a relatively healthy sample of 
the obese population. 
 
5.3.3 Medications 
At the time of surgery 14 of the patients were taking prescription drugs to 
treat dyslipidaemia, hypertension and/or diabetes (see Table 5.1). In the 
relatively healthy group, one patient was taking a statin, one patient an 
angiotensin converting enzyme (ACE) inhibitor, and two patients were 
taking both ACE inhibitors and thiazide diuretics. In the metabolic 
Chapter 5: Surgical patients 
 
   116 
 
syndrome group one patient was taking a statin, one patient an ACE 
inhibitor, one patient an ACE inhibitor plus a ȕ1 adrenoceptor antagonist 
and one patient an ACE inhibitor plus a thiazide diuretic. In the diabetic 
group five patients were prescribed metformin. Of these, one was also 
taking an ACE inhibitor, one was taking a statin and one was taking an ACE 
inhibitor plus a statin. One patient in the diabetic group was prescribed a 
thiazide diuretic only. 
 
5.3.4 Adipose tissue sample collection 
Subcutaneous and omental adipose tissue biopsies were obtained from 
patients during surgery as described in Section 2.4.3. 
 
5.3.5 Adipocyte isolation and enzyme assays  
The adipose tissue samples were collected and stored as described in 
Section 2.4.3. The samples were thawed at a later date and the mature 
adipocytes isolated and homogenised as in Sections 2.2.1 and 2.2.2. FAAH 
and MGL assay were performed on the adipocyte homogenate fractions as 
described in Section 2.5. 
 
5.4 Results 
5.4.1 Patient characteristics  
Subcutaneous adipose tissue samples were obtained from 27 patients, and 
visceral adipose tissue samples were also obtained from 14 of these 
patients. The physiological characteristics of these patients are given in 
Table 5.1, which shows the sample divided into three groups. These groups 
are: patients with clinically diagnosed type 2 diabetes (n=10), patients 
without diabetes but with at least three markers of metabolic syndrome 
(Alberti et al., 2009) (n=11), and patients without diabetes and with only 
one or two markers of metabolic syndrome (n=6). Between these groups, 
age, BMI, fasting serum insulin concentration, HOMA and mean arter ial 
pressure did not differ. The mean fasting serum glucose concentration and 
HbA1c were higher in the diabetic group than both the healthy and 
metabolic syndrome groups (P<0.05). Patients in all groups were 
prescribed similar medications for dyslipidaemia and hypertension, but 5 
patients in the diabetic group were taking hypoglycaemic medication 
compared to none in the healthy and metabolic syndrome groups (see 
Table 5.1). 
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Metabolically 
healthy (n = 6) 
Metabolic 
syndrome  
(n = 11) 
Diagnosed 
diabetes 
(n = 10) 
Age (years) 44.0±4.7 44.5±3.3 45.5±2.7 
BMI (kg.m-2) 44.0±4.7 46.3±1.7 44.8±1.5 
Insulin 
(mU.L-1) 12.2±3.1 14.0±2.3 15.9±1.9 
Glucose 
(mmol.L-1) 5.0±0.2
~ 5.1±0.2* 8.7±1.4~* 
HbA1c (%) 5.8±0.1 5.8±0.3# 7.9±0.7 
HOMA2-%S 85.8±26.2 71.4±14.2 50.4±6.8 
MAP (mmHg) 96.1±4.8 96.3±4.3 104.8±3.6 
Dyslipidaemia 
medication 
1 
(statin) 
1 
(statin) 
2 
(statin) 
Hyperglycaemia 
medication 0 0 
5 
(metformin) 
Hypertension 
medication 
3 
(1: ACE inhibitor; 2: 
ACE inhibitor + 
thiazide diuretic) 
3 
(1: ACE inhibitor; 1: 
ACE inhibitor + ȕ1 
antagonist; 1: ACE 
inhibitor + thiazide 
diuretic) 
3 
(2: ACE inhibitor; 1: 
thiazide diuretic ) 
 
 
Table 5.1 Characteristics of patients  
Physiological characteristics of the subjects included in this study. Values 
given as mean±S.E.M. Values marked with the same characters are 
significantly different from each other. Data analysed using ANOVA and 
%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVWP<0.05 for all significant values. 
 
5.4.2 Enzyme activities, BMI and waist circumference 
In this sample of obese patients, neither FAAH activity (Figure 5.1A) nor 
MGL activity (Figure 5.1B) in subcutaneous adipocytes correlated with BMI. 
Similarly waist circumference did not correlate with FAAH (Figure 5.1C) or 
MGL (Figure 5.1D) activity.  
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Figure 5.1 FAAH and MGL with BMI and waist circumference 
The relationship between FAAH or MGL activities in subcutaneous 
adipocytes from obese humans and BMI (A,B) and waist circumference 
(C ,D). The Pearson correlation coefficient is reported. 
 
5.4.3 Enzyme activities and HbA1c 
There were no correlations between FAAH or MGL activities and HbA1c 
(Figure 5.2).  
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Figure 5.2 FAAH and MGL with HbA1c  
The relationship between FAAH (A) or MGL (B) activities in subcutaneous 
adipocytes from obese humans and HbA1c. The Pearson correlation 
coefficient is reported. 
 
5.4.4 Enzyme activities in different metabolic groups 
The patients in this study were divided into healthy, metabolic syndrome 
and diabetic groups. FAAH activity in subcutaneous adipocytes did not 
differ between the three groups (Figure 5.3A). Similarly, MGL activity was 
not different between the groups (Figure 5.3B). 
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Figure 5.3 FAAH and MGL in three metabolic groups 
FAAH (A) and MGL (B) activities in subcutaneous adipocytes from obese 
humans. Subjects were assigned to one of three groups based on the 
following criteria: healthy <2 components of metabolic syndrome (n=6); 
PHWDEROLF V\QGURPH  FRPSRQHQWV RI PHWDEROLF V\QGURPH n=11); 
diagnosed type 2 diabetes with or without metabolic syndrome (n=10). 
Data are presented as means, with error bars representing S.E.M., and 
ZHUHDQDO\VHGXVLQJRQHZD\$129$DQG%RQIHUURQL¶s multiple comparison 
test.   
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5.4.5 Enzymes in subcutaneous and visceral adipocytes  
In this human study, FAAH activity did not differ between subcutaneous 
and visceral adipocytes (69.3±14.5 vs 70.3±25.1 pmoles.min-1.mg protein-
1, n=14, Figure 5.4A). The results were the same for MGL, with no 
difference between subcutaneous and visceral adipocytes (9.0±2.3 vs 
12.7±1.9 nmoles min-1.mg protein-1, Figure 5.4B). Correlation studies 
showed that there was no relationship between FAAH activity in 
subcutaneous adipocytes and FAAH activity in visceral adipocytes (Figure 
5.4C). Similarly, there was no correlation between MGL activities in 
adipocytes from these two adipose tissue depots (Figure 5.4D). 
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Figure 5.4 FAAH and MGL in subcutaneous and visceral adipocytes 
FAAH (A) and MGL (B) activities in paired samples of subcutaneous and 
visceral mature adipocytes from obese humans (n=14). Data are 
presented as means, with error bars representing S.E.M., and were 
DQDO\VHGXVLQJ6WXGHQW¶VSDLUHGt test. Relationships between FAAH activity 
in subcutaneous and visceral adipocytes (C) and MGL activity in 
subcutaneous and visceral adipocytes (D). The Pearson correlation 
coefficient is reported. 
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5.5 Discussion 
The results of the previous chapters indicate that FAAH and MGL activities 
in isolated mature adipocytes are altered in obesity and diabetes in Zucker 
rats, and FAAH is upregulated in subcutaneous adipocytes in obese but 
otherwise healthy humans. In light of these findings, the primary aim of 
the study presented here was to determine whether FAAH or MGL activities 
in subcutaneous adipocytes are altered in diabetes or other metabolic 
dysfunction in clinically obese humans. Given that FAAH activity correlated 
with BMI and waist circumference in healthy humans, relationships 
between the enzyme activities and these anthropometric measurements 
were also investigated. In the obese Zucker rats, FAAH and MGL activities 
were not different between subcutaneous and visceral adipocytes, despite 
the differing metabolic roles of these adipose tissue depots. Therefore, the 
second aim of this study was to determine whether these enzyme activities 
differed between sites in obese humans. The main finding of this study was 
that FAAH and MGL activities were not altered in patients with metabolic 
syndrome or diabetes compared to obese but relatively healthy patients. 
Finally, FAAH and MGL activities did not differ between paired 
subcutaneous and visceral (omental) adipocytes. 
The results presented in Chapter 4 showed that FAAH activity 
increased not only with BMI, but with waist circumference. In another 
study, obese humans with predominantly subcutaneous adipose tissue 
were shown to have higher FAAH mRNA in adipose tissue than viscerally 
obese patients of the same BMI (Blüher et al., 2006). For these reasons, 
BMI and adipose tissue distribution were included in the analysis in the 
obese patients used in this study. The results show that FAAH activity in 
subcutaneous adipocytes from obese humans does not correlate with BMI  
or waist circumference. The patients used in this study were all clinically 
obese, but had a range of BMIs between 36.6 and 58.2 kg.m -2. Given that 
in Chapter 4 it was found that FAAH activity in mature adipocytes from 
subcutaneous adipose tissue correlates with BMI, it might be expected that 
this relationship would be seen in obese patients, and it is interesting to 
note that this is not the case. In a study in which FAAH mRNA was found to 
be downregulated in subcutaneous adipose tissue in obese patients 
compared to lean, a 5% reduction in total body weight following calorie 
restriction did not affect the mRNA levels of FAAH (Engeli et al., 2005). A 
similar finding was reported for anandamide concentration and FAAH 
mRNA in subcutaneous adipose tissue, as weight loss in obese humans did 
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not alter their expression levels (Bennetzen et al., 2011). Overall, this 
indicates that in the obese population, weight loss must be larger before 
alterations in the ECS are seen and there may not be significant 
differences in the expression of the ECS between obese patients. A 
possible conclusion from these findings is that in human obesity FAAH 
activity in adipocytes is dysregulated in a way that is not proportional to 
the level or distribution of adiposity. It would have been interesting to 
include the results from Chapter 4 in the correlation studies to investigate 
this further, but this was not appropriate as the samples were obtained 
very differently between the two studies. 
Blood plasma 2-AG levels are increased in obesity, but to date MGL 
activity in human adipocytes from obese humans has not been reported. 
More specifically it has been shown that circulating 2-AG levels are higher 
in viscerally obese humans than in subcutaneously obese subjects (Blüher 
et al., 2006). Therefore in this study MGL activity in adipocytes was 
analysed in relation to BMI and waist circumference. The results for MGL in 
this study are the same as for FAAH, in that MGL activity in the 
subcutaneous mature adipocytes does not correlate with BMI or waist 
circumference. These findings are in agreement with the results seen in the 
Zucker rats, as there was no difference in MGL activity between the two 
strains of obese Zucker rat, which between them covered a continuous 
range of obese body mass. In another study, MGL mRNA in subcutaneous 
adipose tissue did not differ after weight loss in obese humans (Bennetzen 
et al., 2011). Together with the results of Chapter 4, these findings 
indicate that MGL in human adipocytes does not vary with BMI or adipose 
tissue distribution. Furthermore, these results raise the possibility that 
differences in circulating and adipose tissue levels of 2-AG in obese 
humans (and subsets of subcutaneously and viscerally obese humans) may 
be due to alterations in the synthesis of 2-AG rather than degradation. This 
is speculative however, as the contribution that MGL activity in mature 
adipocytes makes to the reduction of circulating 2-AG has not been 
reported. 
In Chapter 3 a wide range of blood glucose concentrations were 
seen, but glucose did not correlate with FAAH activity. Likewise, in Chapter 
4 insulin sensitivity did not have a relationship with FAAH activity. Several 
authors have suggested that insulin has a role in peripheral 
endocannabinoid regulation (Murdolo et al., 2007; Di Marzo et al., 2009), 
but this has not yet been investigated with regard to FAAH activity. To 
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address this issue, in the current study obese patients with a range of 
fasting glucose and insulin concentrations were recruited. The results show 
that FAAH activity in mature adipocytes does not correlate with HbA1c. 
This finding is in keeping with the results of the Zucker rats and healthy 
humans, showing no relationship between glucose or insulin and FAAH 
activity. In the current study, HbA1c was measured, which is a marker of 
long-term (approximately 3 month) glycaemic regulation, whereas the 
random blood glucose concentration reported in the Zucker rat study is a 
better indicator of short term glucose handling. The HOMA values in this 
sample of patients indicate that, although all of the patients were clinically 
obese, they ranged from insulin sensitive to insulin resistant. In another 
study, FAAH mRNA levels in subcutaneous adipose tissue from lean and 
obese humans with a range of insulin sensitivities were measured. FAAH 
mRNA was found to correlate negatively with fasting plasma glucose, 
fasting insulin and glucose infusion rate during a euglycaemic-
hyperinsulinaemic clamp in men but not in females (Blüher et al., 2006). 
This may be an important finding given that the majority of the sample 
used in the current study was female.   
There are several reports that the ECS is dysregulated in type 2 
diabetes. For example, anandamide levels are increased in both blood 
(Matias et al., 2006) and subcutaneous adipose tissue (Annuzzi et al., 
2010) in obese diabetic humans compared to obese metabolically healthy 
humans. This relationship was investigated in the Zucker rats and it was 
found that FAAH activity in the subcutaneous adipocytes did not differ 
between the obese and obese diabetic rats. This was not explored further 
in Chapter 4 as all of the humans used were metabolically healthy. The 
patients in this present study were assigned to healthy, metabolic 
syndrome and type 2 diabetic groups according to clinical diagnosis of type 
2 diabetes and recent criteria for metabolic syndrome (Alberti et al., 
2009). The results presented here show that there is no difference in FAAH 
activity in the subcutaneous mature adipocytes between the healthy, 
metabolic syndrome and type 2 diabetic patients in this sample. This 
finding is the same as that observed in the Zucker rats, in which FAAH 
activity in the subcutaneous adipocytes did not differ between the obese 
and obese diabetic rats. These results suggest that the reported increases 
in anandamide levels in adipose tissue in diabetes (Annuzzi et al., 2010) 
are not due to a decreased rate of anandamide degradation. It should be 
noted that in practice there is not clear separation between the three 
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metabolic groups defined in the results presented here. Many of the 
diabetic patients also fulfil the criteria for metabolic syndrome (Després et 
al., 2008; Alberti et al., 2009) and the results from this sample of patients 
are complicated by the range of diseases and medications included. Also, 
the diabetic patients, due to tight adherence to medical advice and 
medication, achieved better glycaemic control in the period preceding 
surgery than some patients who do not have overt diabetes or receive 
glycaemic therapy. In addition, due to pharmacological interventions a 
very low number of patients in this study had a high fasting insulin 
concentration. By contrast, in the study showing adipose tissue 
anandamide to be upregulated in obese diabetic humans, the patients were 
not taking any glycaemic or hypolipidaemic drugs (Annuzzi et al., 2010). 
These findings suggest that any influence of diabetes or insulin sensitivity 
may only be observed in uncontrolled diabetes. In itself, this is interesting 
and may support the evidence for a relationship between the ECS and 
insulin sensitivity which has been described previously. 
As has been reported for anandamide, circulating 2-AG 
concentrations have been found to be increased in obese diabetic humans 
compared to obese healthy humans (Matias et al., 2006). However, in 
subcutaneous adipose tissue 2-AG concentrations have been reported to 
be decreased in diabetes (Annuzzi et al., 2010). In the Zucker rats, MGL 
activity in mature subcutaneous adipocytes did not differ between the 
obese and obese diabetic rats, but in light of the studies showing altered 2-
AG concentrations in human diabetes, MGL activity was measured in the 
current study. The results presented in this chapter are in agreement with 
the Zucker rat study, in that MGL activity in subcutaneous adipocytes does 
not differ between the relatively metabolically healthy, metabolic syndrome 
and diabetic patients. As with FAAH, these novel results suggest that 
altered 2-AG concentrations in adipose tissue in diabetes (Annuzzi et al., 
2010) are not due to increased 2-AG degradation by mature adipocytes.  
In terms of lipid metabolism and cardiovascular risk, subcutaneous 
and visceral adipose tissue are often considered to be different, with 
visceral adipose tissue generally having greater metabolic activity and a 
greater impact on cardiovascular health (Wajchenberg, 2000). Differences 
in adipose tissue between different depots have also been reported in 
various components of the ECS. For example, in obese humans CB1 
receptor mRNA has been reported to be higher in visceral adipose tissue 
than subcutaneous (Pagano et al., 2007; Sarzani et al., 2009). No studies 
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have been published on the activities of FAAH or MGL in adipocytes from 
different adipose tissue depots, so this was included in the current study. 
The results of this chapter show that in paired subcutaneous and visceral 
adipocytes, neither FAAH nor MGL activity is affected by adipose tissue 
depot in obese humans. Additionally, there is no correlation between the 
enzyme activities in subcutaneous and visceral adipocytes. These results 
match those observed in the obese and obese diabetic Zucker rats (see 
Chapter 3). With regard to human studies, similar results have been 
reported in that FAAH mRNA levels were not found to be different in 
subcutaneous and visceral adipose tissue in obese humans (Pagano et al., 
2007). However, another study has shown that FAAH mRNA levels are 
higher in visceral than subcutaneous adipose tissue (Blüher et al., 2006). 
Only one published study has reported MGL mRNA expression, and the 
result of this was that MGL is downregulated in visceral adipose tissue 
(Pagano et al., 2007). The results of this chapter indicate that the rate of 
endocannabinoid degradation does not differ between visceral and 
subcutaneous mature adipocytes. It may be that differences in the 
stromal-vascular fraction between depots may account for the overall 
changes in mRNA observed in other studies, as in the current only mature 
adipocytes were used. It is interesting that in this study neither FAAH nor 
MGL activity correlated between adipocytes from the two adipose tissue 
depots tested. In another study, FAAH mRNA in adipose tissue was found 
to correlate with a high level of significance between visceral and 
subcutaneous depots. However, in that study lean and obese patients were 
included and whole adipose tissue was used (Blüher et al., 2006). The 
results presented here indicate that in obese humans the rate of 
endocannabinoid degradation in adipocytes does not tend to be higher in 
visceral adipocytes than subcutaneous adipocytes.  
In summary, several previous studies have shown that in obese 
humans circulating endocannabinoid levels and components of the ECS in 
adipose tissue are altered by insulin or diabetes. However, there are 
contradictions in the literature to date, and the effects of metabolic 
function on FAAH and MGL activities in mature adipocytes have not been 
reported. The results presented in this chapter show that FAAH and MGL 
activities in subcutaneous adipocytes from clinically obese humans are not 
altered in relation to BMI, adipose tissue distribution or insulin sensitivity. 
It has also been shown that these enzymes are not directly affected by 
metabolic syndrome or diabetes. Furthermore, no differences in activity 
Chapter 5: Surgical patients 
 
   127 
 
were identified between subcutaneous and visceral adipocytes. These 
results indicate that any alterations in endocannabinoid signalling in 
metabolic disorders, including type 2 diabetes, are not regulated by FAAH 
or MGL in mature adipocytes. 
 
 6. The effects of endocannabinoids on adipokine 
secretion in cultured human adipocytes 
6.1 Introduction 
The culture of human adipocytes has been improved considerably in 
recent years (Matsumoto et al., 2008). Human adipocytes in culture are 
morphologically distinct from those taken from biopsies, but according to 
one study their function is comparable (Nobusue et al., 2008). Cultured 
preadipocytes which are induced to differentiate become rounded and filled 
with many small lipid droplets. By contrast, mature adipocytes are 
spherical and almost completely filled with one large lipid droplet (Jiang et 
al., 2007). If mature adipocytes are cultured, the volume of intracellular 
lipid decreases and after 12 days in culture their morphology closely 
resembles that of cell culture differentiated preadipocytes (Van et al., 
1976). In many studies, the 3T3-L1 murine fibroblast cell line is used. The 
advantages of these cells are that they proliferate at a significantly faster 
rate than human adipocytes and differentiation into mature adipocytes 
takes approximately a week less (Fowler et al., 2009). However, few data 
are available on the comparability of this cell line to human adipocytes, 
particularly with regard to ECS expression and regulation. 
 To date relatively few papers regarding the effects of the ECS in 
cultured human adipocytes have been published, although it is clear that 
there are interactions between insulin stimulation and endocannabinoid 
turnover. There is some evidence that cannabinoid receptor activation in 
adipocytes increases insulin-induced glucose uptake. This has been 
demonstrated in differentiated murine 3T3-L1 cells in culture with both 
anandamide (Gasperi et al., 2007) and THC  (Gallant et al., 2009). This has 
also been reported in human adipocytes in culture, using WIN-55,212 
(Pagano et al., 2007). 7KH VWUHQJWK RI DFWLYDWLRQ ZLWK 7+& ǋJPO LV
such that glucose uptake occurs even in insulin resistant cells (Gallant et 
al., 2009). The use of rimonabant has shown that insulin±stimulated 
glucose uptake is not directly CB1 mediated (Pagano et al., 2007). 
It has also been demonstrated that insulin affects the ECS in 
adipocytes. In differentiated 3T3-L1 cells, an 8-hour exposure to high 
concentrations of insulin was found to increase FAAH expression, but MGL 
H[SUHVVLRQ ZDV VLJQLILFDQWO\ HOHYDWHG RQO\ DIWHU  KRXUV¶ treatment. As 
might be expected, in insulin resistant cells, insulin failed to raise FAAH 
mRNA. By contrast, MGL expression remained chronically raised once 
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insulin resistance had been induced and it was not further increased by 
acute insulin treatment. A 24-hour treatment with insulin reduced 
intracellular concentrations of anandamide and 2-AG by around a third 
(D'eon et al., 2008). These results were supported by similar findings using 
DIO mice (D'eon et al., 2008). 
Interactions between adipokines and the ECS in adipocytes have 
also been reported. The consequences of these interactions could be 
important, given that two of the adipokines in particular, adiponectin and 
leptin, are known to have significant roles in whole body metabolic 
homeostasis. In one study using 3T3-L1 cells, production of anandamide 
and 2-AG was suppressed by both acute and chronic treatment with leptin 
(Matias et al., 2006). Another study involving leptin showed that human 
subcutaneous adipocytes in culture produce PEA in concentrations at least 
10-fold higher than anandamide or 2-AG. Leptin treatment of the cells for 
1 hour was found to decrease this expression by 27%. In contrast, PEA 
treatment of the adipocytes did not significantly affect leptin or adiponectin 
concentrations (Gonthier et al., 2007). Similarly, in cultured human 
adipocytes neither the cannabinoid receptor agonist WIN-55,212 nor 
rimonabant were found to affect leptin or adiponectin mRNA expression, 
but adipokine secretion was not measured (Pagano et al., 2007). In 
contrast, CB1 receptor stimulation using HU-210 was shown to reduce 
adiponectin mRNA expression in differentiated 3T3-L1 cells, and 
rimonabant markedly increased adiponectin mRNA in these cells (Matias et 
al., 2006).  
It has been reported that adipose tissue explants in culture secrete 
resistin (Fain et al., 2003), but the mechanism of resistin secretion from 
adipose tissue remains debated. Mature adipocytes have been reported to 
secrete resistin in culture up to 48 hours after biopsy (McTernan et al., 
2003), but this has not been demonstrated in other studies or in 
adipocytes cultured for longer time periods. Some studies have also 
reported resistin mRNA in preadipocytes (Kim et al., 2001; Janke et al., 
2002), but secretion of the protein has not been reported. Other studies 
have concluded that the majority of secreted resistin is produced by non-
adipocyte cells (Fain et al., 2003; Kaser et al., 2003). Interactions between 
the ECS and resistin secretion have not been reported, and as yet no 
studies have investigated whether anandamide and 2-AG, known to be 
increased in obesity, alter adiponectin or leptin secretion. 
  
Chapter 6: Cell culture ± adipokines 
 
   130 
 
6.2 Aims 
The aim of this study was to investigate whether endocannabinoids 
(anandamide and 2-AG) affect the secretion of adipokines from human 
adipocytes in culture under normal physiological conditions and under high 
glucose and/or insulin conditions. These conditions were chosen to model 
hyperglycaemia and/or hyperinsulinaemia. The adipokines tested were 
adiponectin and leptin, as these are known to have roles in metabolism 
and their dysregulation in obesity has been characterised. Resistin was 
also included, as this protein may have a role in inflammatory processes 
and possibly in metabolic signalling, but its secretion from human 
adipocytes and preadipocytes remains debated.  
 
6.3 Materials and Methods 
6.3.1 Adipocyte culture 
Human abdominal subcutaneous preadipocytes pooled from women 
undergoing cosmetic liposuction were purchased at passage 2 (Promocell, 
UK). These were cultured and differentiated in Promocell adipocyte media 
as described in Section 2.8.1. Briefly, the preadipocytes were grown in 
fibronectin coated 24-well plates until confluent, then induced to 
differentiate for 3 days. The adipocytes were left to differentiate for 12-14 
days, with media changes every 2-3 days, before the treatments were 
initiated. For the resistin experiments, preadipocytes were also used. In 
this case the preadipocytes were treated as soon as the plates were 
confluent. 
 
6.3.2 Insulin and glucose  
The differentiated adipocytes (see Figure 2.5) were cultured in normal 
Adipocyte Nutrition Medium (Promocell, UK) or Adipocyte Nutrition Medium 
supplemented with glucose (15 mM) and/or insulin (1 ǋ0 for 24 hours. 
This glucose concentration is similar to the serum glucose concentration 
that may be seen in uncontrolled human diabetes. The insulin 
concentration used in this study was considerably greater than 
physiological concentrations, but this was required to mimic 
hyperinsulinaemia, as the adipocytes were continuously cultured with a 
physiologically high concentration of insulin in order to maximise cell 
growth and differentiation. 
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6.3.3 Anandamide and 2-AG  
In the acute (2 hour) experiments varying concentrations of anandamide 
or 2-AG (final concentrations 10 nM to 10 ǋ0 were added to the plates at 
the same time as the medium was changed. In the chronic experiments 
(24 hours), anandamide or 2-AG was added 2 hours before the media were 
harvested (see Picture 6.1). In each plate, three wells were used for each 
concentration of endocannabinoid, with a further three wells for the vehicle 
control. The harvested media were immediately frozen and stored at -80oC 
for later analysis. 
 
6.3.4 Adipokine assays 
Commercially available sandwich ELISA sets (R&D) were used to measure 
the concentrations of adiponectin, leptin and resistin in the cell culture 
media (see Section 2.7.3). 
 
6.3.5 Statistical analysis  
All data were analysed using GraphPad Prism software. The adipokine 
concentrations from different culture conditions were compared using one-
ZD\$129$DQG'XQQHWW¶Vmultiple comparison test. 
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Picture 6.1 Timelines of cell culture experiments 
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6.4 Results 
6.4.1 Effects of glucose and insulin 
Adiponectin concentration was not affected by glucose, insulin or glucose 
and insulin combined at either 2 or 24 hours. Similarly, leptin secretion 
was not affected by glucose or insulin. 
  
6.4.2 Acute endocannabinoid treatment and adiponectin 
Treatment of differentiated adipocytes with anandamide for 2 hours did not 
affect adiponectin secretion compared to the vehicle control at any of the 
FRQFHQWUDWLRQV WHVWHG  Q0 WR  ǋ0 7KLV ZDV WUXH LQ DGLSRF\WHV
cultured in normal, high glucose (15 mM), high insulin  ǋ0 RU KLJK
glucose and insulin media for 24 hours (Figure 6.1). Exposure to varying 
concentrations of 2-$*  Q0 WR  ǋ0 IRU  KRXUV DOVR GLG QRW DIIHFW
adiponectin secretion under normal, high glucose, high insulin or high 
glucose and insulin concentrations (Figure 6.2). 
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Figure 6.1 Effects of acute anandamide on adiponectin secretion  
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The effects of anandamide (2 hour treatment) on adiponectin secretion, in 
normal (A), high glucose (B), high insulin (C) and high glucose and insulin 
(D) media. n=12 (based on 4 experiments). Data are given as means, with 
error bars representing S.E.M., and were analysed using one-way ANOVA 
DQG 'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
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Figure 6.2 Effects of acute 2-AG on adiponectin secretion 
The effects of 2-AG (2 hour treatment) on adiponectin secretion, in normal 
(A), high glucose (B), high insulin (C) and high glucose and insulin (D) 
media. n=12 (based on 4 experiments). Data are given as means, with 
error bars representing S.E.M., and were analysed using one-way ANOVA 
DQG 'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
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6.4.3 Acute endocannabinoid treatment and leptin 
Anandamide treatment for 2 hours, at increasing concentrations, did not 
affect the concentration of leptin in the adipocyte culture media. Glucose, 
insulin and combined glucose and insulin did not alter the leptin 
concentration, nor cause anandamide to have an effect on leptin secretion 
(Figure 6.3). Similarly, the acute 2-AG treatments did not affect the 
concentration of leptin in the media under any of the conditions tested 
(Figure 6.4). 
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Figure 6.3 Effects of acute anandamide on leptin secretion  
The effects of anandamide (2 hour treatment) on leptin secretion, in 
normal (A), high glucose (B), high insulin (C) and high glucose and insulin 
(D) media. n=12 (based on 4 experiments). Data are given as means, with 
error bars representing S.E.M., and were analysed using one-way ANOVA 
DQG 'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
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Figure 6.4 Effects of acute 2-AG on leptin secretion 
The effects of 2-AG (2 hour treatment) on leptin secretion, in normal (A), 
high glucose (B), high insulin (C) and high glucose and insulin (D) media.  
n=12 (based on 4 experiments). Data are given as means, with error bars 
representing S.E.M., and were analysed using one-way ANOVA and 
DuQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
 
 
6.4.4 Chronic endocannabinoid treatment and adiponectin 
Adiponectin secretion by the cultured adipocytes was not affected by 
exposure to anandamide for 24 hours, or by glucose, insulin or glucose and 
insulin (Figure 6.5). Likewise, chronic 2-AG did not alter adiponectin 
secretion at any of the concentrations tested, even in the presence of high 
concentrations of glucose and/or insulin (Figure 6.6). 
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Figure 6.5 Effects of chronic anandamide on adiponectin secretion  
The effects of anandamide (24 hour treatment) on adiponectin secretion, in 
normal (A), high glucose (B), high insulin (C) and high glucose and insulin 
(D) media. n=12 (based on 4 experiments). Data are given as means, with 
error bars representing S.E.M., and were analysed using one-way ANOVA 
DQG 'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
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Figure 6.6 Effects of chronic 2-AG on adiponectin secretion 
The effects of 2-AG (24 hour treatment) on adiponectin secretion, in 
normal (A), high glucose (B), high insulin (C) and high glucose and insulin 
(D) media. n=12 (based on 4 experiments). Data are given as means, with 
error bars representing S.E.M., and were analysed using one-way ANOVA 
DQG 'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
 
 
6.4.5 Chronic endocannabinoid treatment and leptin 
Treatment of the cultured adipocytes for 24 hours with anandamide did not 
affect leptin secretion. Exposure to glucose, insulin and glucose and insulin 
in combination did not cause anandamide to have an effect on leptin 
(Figure 6.7). Similarly, the leptin concentration of the cell culture media 
was not altered in response to chronic 2-AG under basal, high glucose, 
high insulin or high glucose and insulin culture conditions (Figure 6.8). 
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Figure 6.7 Effects of chronic anandamide on leptin secretion  
The effects of anandamide (24 hour treatment) on leptin secretion, in 
normal (A), high glucose (B), high insulin (C) and high glucose and insulin 
(D) media. n=12 (based on 4 experiments). Data are given as means, with 
error bars representing S.E.M., and were analysed using one-way ANOVA 
DQG 'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
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Figure 6.8 Effects of chronic 2-AG on leptin secretion 
The effects of 2-AG (24 hour treatment) on leptin secretion, in normal (A), 
high glucose (B), high insulin (C) and high glucose and insulin (D) media.  
n=12 (based on 4 experiments). Data are given as means, with error bars 
representing S.E.M., and were analysed using one-way ANOVA and 
'XQQHWW¶V multiple comparison test to compare different anandamide 
concentrations against vehicle. 
 
 
6.4.6 Resistin in cultured adipocytes 
Resistin was not detectable in the media harvested from mature adipocytes 
cultured under any of the conditions described in this chapter. Similarly, 
the media harvested from preadipocyte cultures did not have detectable 
resistin concentrations. Treatment of the preadipocytes and differentiated 
adipocytes with anandamide and 2-AG did not induce resistin secretion. 
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6.5 Discussion 
The results of Chapters 3-5 indicated that FAAH and MGL activities in 
mature adipocytes are not directly related to metabolic markers in rats or 
humans. However, there is other evidence that insulin and glucose affect 
the ECS in adipocytes. There is also a small amount of contradictory 
evidence that the ECS can affect adipokines and vice-versa, but this has 
not been extensively investigated in cultured human adipocytes. Therefore, 
the aim of this study was to investigate whether acute or chronic exposure 
to anandamide or 2-AG affects the secretion of adipokines from 
differentiated human adipocytes in culture under high insulin and/or 
glucose conditions. The results of this study showed that neither acute nor 
chronic anandamide or 2-AG treatments affect adipokine secretion in 
differentiated human adipocytes in culture. This was observed regardless 
of the glucose or insulin concentration of the treatment media. 
 There is some evidence that adipokines may regulate 
endocannabinoid levels. The most established theory is that leptin 
suppresses endocannabinoid levels at the central level, particularly in the 
hypothalamus (Di Marzo et al., 2001). The effects of adipokines on 
endocannabinoids in adipocytes are not as clear. In human adipocytes in 
culture, leptin has been shown to decrease anandamide and 2-AG (Matias 
et al., 2006). However, leptin and adiponectin have also been shown to 
have no effect on anandamide or 2-AG concentrations in cultured human 
adipocytes (Gonthier et al., 2007). It has also been shown that ECS 
activation may affect adipokine expression, however adipokine secretion in 
response to anandamide and 2-AG has not yet been reported. In the 
results presented here, it is shown that anandamide and 2-AG do not affect 
the concentration of adiponectin or leptin in the adipocyte culture media 
after either 2 or 24 hours treatment. This was also found in the presence 
of excess glucose and insulin. It should be noted that the results from the 
two different timepoints cannot be directly compared, as different batches 
of cells were used for each. In the literature to date, there are no reports 
of the effects of anandamide or 2-AG on adipokine secretion in isolated 
adipocytes. Previously, PEA was reported to have no effect on adiponectin 
or leptin secretion from isolated human adipocytes, even at high 
FRQFHQWUDWLRQVǋ0(Gonthier et al., 2007). In humans, in the context 
of whole adipose tissue, it has been reported that CB1 receptor mRNA is 
not correlated with adiponectin secretion, or its concentrations in adipose 
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tissue or blood (Lofgren et al., 2007), which is in keeping with the cell 
culture results given in this chapter. 
 In this study, neither high glucose nor insulin affected the adipokine 
concentrations of the cell culture media. In recent years it has been widely 
reported that insulin increases the secretion of leptin from adipocytes, 
particularly rat adipocytes (reviewed by Lee and Fried, 2009). However, in 
earlier studies there were also reports of insulin having no effect on leptin 
in adipocytes (Considine et al., 1997; Reul et al., 1997). The reasons for 
these differences are not clearly apparent. To date the results reported for 
adiponectin are not conclusive. Insulin has been reported to increase 
adiponectin secretion or have no effect, and some of the differences have 
been attributed to the adipocytes used (3T3-L1, rat, human, omental or 
subcutaneous) (Motoshima et al., 2002; Cong et al., 2007). In the study 
presented here, the adipocytes were cultured for at least 5 weeks in 
commercial media containing higher than physiological concentrations of 
insulin. This was as recommended by the supplier of the adipocytes 
(Promocell) and has been reported elsewhere to increase the growth and 
differentiation rates of the adipocytes. Under the experimental conditions, 
the insulin concentration was increased further still, but it is possible that 
the adipocytes were partially insulin-resistant, which may account for the 
lack of adiponectin and leptin response to insulin. In support of this, it has 
been reported previously that primary culture of healthy rat adipocytes 
rapidly causes changes in gene expression patterns that are similar to the 
expression patterns seen in fresh adipocytes from obese Zucker rats 
(Xiang et al., 2007). 
 Resistin secretion has been detected from adipose tissue explants 
(Fain et al., 2003), and in isolated adipocytes and preadipocytes resistin 
mRNA and protein have also been reported (Kim et al., 2001; Janke et al., 
2002; Degawa-Yamauchi et al., 2003). However, several other studies 
have failed to detect resistin mRNA or protein in adipocytes (Nagaev and 
Smith, 2001; Savage et al., 2001; Janke et al., 2002; Fain et al., 2003). 
The effects of insulin and glucose on resistin secretion in cultured human 
adipocytes have not been reported. Furthermore, to date, the effect of 
endocannabinoids on resistin have not been investigated. In this study it 
was found that resistin was not present in the cell culture media of 
adipocytes or preadipocytes under normal cell culture conditions. High 
concentrations of glucose and/or insulin did not stimulate resistin secretion 
after 24 hours, and short treatments (2 hour) with anandamide or 2-AG 
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did not induce resistin production. These findings are in keeping with 
several studies which have not detected resistin in cultured or  fresh 
adipocytes (Nagaev and Smith, 2001; Savage et al., 2001; Janke et al., 
2002; Fain et al., 2003). In two studies in which resistin was detected in 
human adipocytes, either fresh adipocytes (Degawa-Yamauchi et al., 
2003) or primary adipocytes cultured for short time periods (48 hours) 
(McTernan et al., 2003) were used. In 3T3-L1 cells resistin mRNA levels 
have been shown to be increased by glucose and decreased by insulin 
(Haugen et al., 2001; Shojima et al., 2002; Liu et al., 2008), but this has 
not been replicated in human adipocytes. The results presented here show 
that glucose does not induce resistin production in human adipocytes. In 
addition, in this study the endocannabinoids anandamide and 2-AG did not 
cause resistin secretion. This suggests that there is not a direct 
relationship between the ECS and resistin in human preadipocytes or  
differentiated adipocytes. A recent review concluded that circulating 
resistin is predominantly from non-adipocytes (Schwartz and Lazar, 2011) 
and this is supported by the results of this chapter.  
 In summary, the effects of anandamide and 2-AG on adiponectin, 
leptin and resistin secretion by adipocytes have not been previously 
reported. In the novel study presented here it has been shown that these 
two endocannabinoids do not affect adiponectin, leptin or resistin secretion 
after 2 or 24 hours. Furthermore, glucose and insulin were not found to 
affect the action of anandamide or 2-AG on adipokine secretion. These 
results suggest that modulation of adipokines is unlikely to be an effect of 
endocannabinoids under normal conditions, or those associated with 
obesity and diabetes.  
 
 7. Endocannabinoid uptake in cultured human 
adipocytes 
7.1 Introduction  
The termination of endocannabinoid signalling is characterised by two key 
stages: cellular uptake of the endocannabinoids and subsequent enzymatic 
inactivation (Yates and Barker, 2009a). The mechanism(s) of 
endocannabinoid uptake have yet to be elucidated. There is evidence that 
anandamide uptake occurs by simple diffusion, which is plausible due to 
the lipophilic structure of the molecule (Glaser et al., 2003). Alternatively, 
other data suggest that facilitated diffusion, possibly via the putative 
anandamide membrane transport (AMT) protein, or endocytosis is 
responsible (Di Marzo et al., 2004; Yates and Barker, 2009b; Ligresti et 
al., 2010). In support of this hypothesis it has been shown that 
anandamide uptake is time and temperature dependent, saturable and 
subject to inhibition by structural analogues of anandamide (Beltramo et 
al., 1997; Hillard et al., 1997). It may be that anandamide uptake occurs 
via both simple and facilitated diffusion, perhaps to differing degrees in 
different cell types or under different conditions. Whatever the mechanism, 
the uptake of anandamide in many cell types is at least partially regulated 
by the level of intracellular FAAH activity, as inhibition or deletion of FAAH 
has been shown to reduce anandamide uptake in several studies (Ortega-
Gutierrez et al., 2004; Kaczocha et al., 2006). This indicates that in some 
systems anandamide uptake is dependent on maintenance of a 
concentration gradient. 
Anandamide trafficking is still a relatively novel area of research, 
and as such has only been studied in a few cell  types and systems. It is 
likely that binding proteins are required, as anandamide is a structurally 
simple molecule and is too lipophilic to exist unbound in the cytosol (for 
review see Maccarrone et al., 2010). Several putative binding proteins 
have been proposed, including heat shock protein 70 (HSP70; Oddi et al., 
2009), albumin (Oddi et al., 2009) and fatty acid binding proteins 5 and 7 
(FABP5 and 7; Kaczocha et al., 2009). The relevance of these proteins in 
anandamide trafficking in adipocytes is not yet known. Albumin is 
expressed by 3T3-L1 adipocytes (Yoo et al., 2010) and HSP 70 is 
expressed in cultured rat adipocytes (Jiang et al., 2007), but these 
proteins have not yet been described in human adipocytes. The FABPs are 
known to transport hydrophobic long chain fatty acids in the aqueous 
environment of the cytosol. It may be that FABP4 (the FABP expressed in 
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adipocytes) binds anandamide as FABP5 and 7 do (Kaczocha et al., 2009), 
but this awaits confirmation. 
Adiposomes are lipid droplets surrounded by protein which are 
found in most cells, but they are particularly pronounced in differentiating 
and mature adipocytes. It has been demonstrated in vitro that the rate of 
anandamide uptake increases with adiposome size and that anandamide 
readily accumulates at adiposomes (Oddi et al., 2008). Biotin and tritium 
labelled anandamide have been used to study the intracellular distribution 
of anandamide and it has been found that the majority of anandamide is 
incorporated into intracellular membranes within minutes of uptake (Oddi 
et al., 2008; Oddi et al., 2009). The implications of this for anandamide 
uptake and trafficking in adipocytes have yet to be investigated. Given the 
role and physiological nature of adipocytes and the lipophilic properties of 
anandamide, it may be that different trafficking systems are involved in 
mature adipocytes compared to other cells.  
Anandamide uptake has been reported in 3T3-L1 adipocytes 
(Gasperi et al., 2007), but no published work to date has described 
anandamide uptake in human adipocytes. In 3T3-L1 cells, anandamide 
uptake was reported to be AMT mediated, as uptake was saturable, 
significantly increased at 37oC compared to 4oC and reduced by OMDM1 (a 
putative selective AMT inhibitor). Anandamide uptake, reported as AMT 
activity, was approximately double at 9 days after induction of 
differentiation compared with day 0. These data are in keeping with many 
of the studies described in Section 1.4 showing that the ECS becomes 
activated during adipocyte differentiation. 
The cellular uptake of 2-AG has been investigated less than that of 
anandamide. In common with anandamide uptake, the mechanisms of 2-
AG uptake remain under debate, although it has been suggested that 
anandamide and 2-AG uptake may rely on the same transport system (for 
review see Hermann et al., 2006). In one study in which 2-AG uptake has 
been reported, the non-specific enzyme inhibitor MAFP did not reduce 2-AG 
uptake in several of the cell types assayed (Fowler and Ghafouri, 2008). 
This is in contrast to anandamide uptake which is generally more 
susceptible to reduction via FAAH inhibition. The authors of this work 
suggest that 2-AG may undergo transformation by other enzymes, such as 
acyltransferases or kinases, which have not yet been investigated with 
regard to 2-AG uptake (Fowler and Ghafouri, 2008). 
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One of the major findings of all the studies into endocannabinoid 
uptake is that it varies widely between different cell types. Not only does 
the rate of uptake vary between cells, but inhibition of enzymes which 
catalyse endocannabinoid degradation causes reductions in 
endocannabinoid uptake in some cells but not others (Thors et al., 2007; 
Fowler and Ghafouri, 2008). To date there are no data available on the 
contribution of FAAH and MGL to anandamide and 2-AG uptake in human 
adipocytes. In Chapters 3 and 5 evidence from the current literature was 
discussed which suggested possible relationships between insulin, glucose 
and FAAH and MGL expression. The effects of insulin and glucose on FAAH 
and MGL activities have not been reported in cultured human adipocytes. 
In the current chapter, the enzyme activities were measured under the 
same conditions as the endocannabinoid uptake studies in order to 
determine whether insulin and glucose affect these two stages of 
endocannabinoid inactivation.  
There is mounting evidence that the endocannabinoids anandamide 
and 2-AG affect various aspects of metabolism in adipocytes, including 
glucose uptake, lipolysis and lipogenesis (see Section 1.5). By contrast, 
there are very few data on the effects of insulin and glucose on the ECS in 
adipocytes. Investigating whether insulin or glucose affect anandamide or 
2AG uptake will contribute to the understanding of the role of the ECS in 
adipocytes. 
 
7.2 Aims 
The uptake of endocannabinoids is an essential step of their inactivation by 
FAAH and MGL, but as yet this has not been described in human 
adipocytes. This study was based on the current literature showing that 
the ECS in adipocytes in health is not fully characterised, and that 
alterations in the ECS in adipose tissue have been reported in metabolic 
disorders. Therefore, the primary aim of this study was to investigate 
whether the uptake of anandamide or 2-AG in human adipocytes is 
affected by chronic or acute treatment with high concentrations of glucose 
or insulin. In this study, specific FAAH and MGL inhibitors had no effect on 
endocannabinoid uptake, so the second aim was to assess the effect of 
insulin and glucose treatments on FAAH and MGL activities. This also 
allowed the effects of insulin and glucose on FAAH and MGL to be 
investigated in a controlled, uniform study to complement the work of 
Chapters 3-5. 
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7.3 Materials and Methods 
7.3.1 Endocannabinoid uptake experiments  
This work was carried out at Lund University, Sweden, under the 
supervision of Professor Christopher Fowler (Fowler et al., 2004; Fowler, 
2006; Fowler and Ghafouri, 2008). Cultured human adipocytes (see 
Section 2.8.1) and the anandamide and 2-AG uptake assays (see Section 
2.8.4) were used in these experiments. The endocannabinoid uptake 
DVVD\V DUH ZHOO HVWDEOLVKHG WHFKQLTXHV ZLWKLQ 3URIHVVRU )RZOHU¶V WHDP
Glucose (15 mM) and insuOLQǋ0ZKHQXVHGZHUHDGGHGWRWKHSODWHV
for 2 or 24 hours. $IWHUWKHILUVWZDVKLQJVWDJH ǋORIYHKLFOH'062 
URB597 (final concentration 1 ǋM) or JZL184 (final concentration 1 ǋM) 
were added to the plates.   
 
7.3.2 FAAH and MGL activity experiments 
The FAAH and MGL activity assays were performed as described in Section 
2.5. The adipocytes for these experiments were cultured in 6-well plates, 
as described in Section 2.8.1, and treated with glucose (15 mM) and/or 
insulin (1 ǋM) for 2 or 24 hours. Following the treatment period, the cell 
culture medium was removed and 1 ml of TE buffer was added to each 
well. The plates were frozen at -80oC and subsequently thawed and re-
frozen twice in order to lyse the adipocytes. After the third freeze-thaw 
cycle, the cells from each well were collected in the TE buffer using a cell 
scraper, transferred to tubes and stored at -80oC until enzyme activity 
analysis and protein assay. The cell lysates were used in the FAAH and 
MGL assays without further dilution. Each sample was run in duplicate.  
 
7.3.3 Statistical analysis  
All data were analysed using GraphPad Prism software. The enzyme 
activities from different culture conditions were compared using one-way 
$129$DQG'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVW 
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7.4 Results 
7.4.1 Anandamide uptake  
,Q GLIIHUHQWLDWHG KXPDQ DGLSRF\WHV DFXWH H[SRVXUH WR LQVXOLQ  ǋ0
glucose (15 mM) or both for 2 hours did not affect anandamide uptake 
(Figure 7.1A). In the chronic experiments, exposure to insulin for 24 hours 
led to a significant increase in total anandamide uptake (1.2±0.2 vs 
1.8±0.2 pmoles). Statistically, this effect was ameliorated by the presence 
of glucose (Figure 7.1B). There were no differences in anandamide uptake 
between cells cultured with glucose or insulin and glucose for 2 hours 
compared to those exposed to the conditions for 24 hours (Figure 7.1A,B). 
 
7.4.2 FAAH inhibition and anandamide uptake  
Preincubation with URB597, a FAAH inhibitor, did not affect basal 
anandamide uptake over the 4 minute period studied here (Figure 7.1C,D). 
Additionally, FAAH inhibition did not alter the amount of anandamide 
uptake in the acute or chronic experiments with insulin and glucose. 
Furthermore, insulin-stimulated anandamide uptake was not reduced by 
FAAH inhibition (1.1±0.2 vs 1.9±0.2 pmol; Figure 7.1D).  
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Figure 7.1 Anandamide uptake 
Anandamide uptake in human adipocytes cultured in the absence and 
presence of glucose (15 mM) and insulin ǋ0IRURUKRXUV5HVXOWV
shown for vehicle after acute (A) and chronic (B) exposure, and using the  
FAAH inhibitor URB597 after acute (C) and chronic (D) exposure. Data 
were analysed by one-ZD\$129$DQG'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVW  
(* P<0.05). n=4 (in triplicate). 
 
7.4.3 2-AG uptake  
The basal level of 2-AG uptake in differentiated human adipocytes was not 
affected by insulin, glucose or both in combination at either the 2 or 24 
hour time point (Fig.7.2A,B).  
 
7.4.4 MGL inhibition and 2-AG uptake 
Inhibition of MGL, using the specific irreversible MGL inhibitor JZL184, did 
not alter 2-AG uptake by adipocytes in any of the conditions investigated 
(Figure 7.2C,D).  
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Figure 7.2 2-AG uptake 
2-AG uptake in human adipocytes cultured in the absence and presence of 
JOXFRVH  P0 DQG LQVXOLQ  ǋ0 IRU  RU  KRXUV5HVXOWV VKRZQ IRU
vehicle after acute (A) and chronic (B) exposure, and using the FAAH 
inhibitor URB597 after acute (C) and chronic (D) exposure. Data were 
analysed by one-ZD\ $129$ DQG 'XQQHWW¶V PXOWLSOH FRPSDULVRQ WHVW 
P<0.05). n=4 (in triplicate). 
 
7.4.5 Enzyme activity  
The finding that URB597 did not affect anandamide uptake was supported 
by the finding that FAAH activity is negligible in human adipocytes cultured 
under the conditions described here. FAAH activity was not increased to 
detectable levels in adipocytes cultured with either insulin or glucose. By 
contrast, MGL activity was detectable in cultured adipocytes at a basal 
level of 7.8±0.4 nmoles.min-1.mg protein-1  (Figure 7.3).  
Exposure to glucose for 2 hours did not affect MGL activity (6.4±0.2 
nmoles.min-1.mg protein-1), but after 24 hours glucose decreased MGL 
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activity (5.9±0.1 nmoles.min-1.mg protein-1, P<0.01). Insulin decreased 
MGL activity at 2 and 24 hours (5.8±0.7 and 5.0±0.4 nmoles.min-1.mg 
protein-1 respectively, P<0.01 and P<0.001), and glucose and insulin in 
combination also reduced MGL activity at 2 and 24 hours (5.1±0.4 and 
3.1±0.3 nmoles.min-1.mg protein-1 respectively, P<0.001). 
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Figure 7.3 MGL activity 
MGL activity in human adipocytes cultured in the absence and presence of 
JOXFRVHP0DQGLQVXOLQǋ0IRURUKRXUV'DWDZHUHDQDO\VHd 
by one-ZD\ $129$ DQG 'XQQHWW¶V PXOWLSOH FRPSDULVRQ WHVW WR FRPSDUH
basal activity against all treatments (** P<0.01, *** P <0.001). n=4 (in 
triplicate). 
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7.5 Discussion 
The principal aim of this study was to determine whether the uptake of 
anandamide or 2-AG by differentiated human adipocytes is affected by 
acute or chronic exposure to high concentrations of insulin or glucose. The 
results presented here show that anandamide uptake is increased in 
adipocytes which have been exposed to insulin for 24 hours, but not under 
any of the other conditions tested. 2-AG uptake is not affected by insulin or 
glucose. Furthermore, anandamide and 2-AG uptake by adipocytes 
cultured under the conditions described in this study are not FAAH or MGL 
dependent. As anandamide and 2-AG uptake were not affected by enzyme 
inhibition, the secondary aim of the study was to measure FAAH and MGL 
activities in these cells to determine whether they are affected by glucose 
or insulin. FAAH activity was not detectable in the human adipocytes used 
here, but MGL activity was suppressed by high concentrations of insulin 
and glucose.  
The concentration of anandamide in subcutaneous adipose tissue 
has been reported to be increased in obese diabetic humans, compared to 
lean and obese non-diabetic subjects (Annuzzi et al., 2010). Furthermore, 
in 3T3-L1 cells 24 hour exposure to insulin decreases the intracellular 
concentration of anandamide by approximately a third (D'eon et al., 2008). 
These findings suggest that glucose or insulin may affect the regulation of 
anandamide levels in adipocytes, but the mechanisms behind this have not 
been extensively investigated to date. In particular, the effects of insulin 
and glucose on anandamide uptake have not been reported. The results 
presented in the current study show, for the first time, that 24 hour 
exposure to a higK LQVXOLQ FRQFHQWUDWLRQ  ǋ0 LQFUHDVHV WKH UDWH RI
anandamide uptake in human adipocytes. The two potential effects of this 
would be to reduce extracellular signalling, such as at the cannabinoid 
receptors, and to increase intracellular signalling at targets such as the 
PPARs and TRPs. One possible reason for increased anandamide uptake is 
VXJJHVWHG E\ WKH ILQGLQJV WKDW DQDQGDPLGH LQFUHDVHV WKH UDWH RI 33$5Ǆ
mediated differentiation of 3T3-L1 cells (Bouaboula et al., 2005) and rat 
adipocytes (Karaliota et al., 2009). In a state of chronic hyperinsulinaemia, 
increased anandamide uptake may be one of the mechanisms for 
increasing the number of mature adipocytes, and therefore the glucose 
and lipid storage capacity of adipose tissue.   
It is interesting to note that in 3T3-L1 cells anandamide has been 
shown to increase the rate of insulin-stimulated glucose uptake after 24 
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hours, but not at 4 hours (Gasperi et al., 2007). Taken with the results 
presented here, this finding suggests interactions between anandamide 
and glucose uptake in response to insulin only after prolonged exposure. 
This may indicate that anandamide concentration and signalling is 
reflective of metabolic balance in the medium and long-term rather than 
acute.  
In many cell types, it has been shown that anandamide uptake is at 
least partially driven by FAAH and the maintenance of an anandamide 
concentration gradient between the cytosol and extracellular space (Thors 
et al., 2007). There are also reports of cells in which anandamide uptake is 
not dependent on the rate of anandamide hydrolysis (Di Marzo et al., 
1998), but no data have been published on the contribution of FAAH to 
anandamide uptake in adipocytes. Having showed that anandamide uptake 
was not URB597 (FAAH) dependent, the presence and activity of FAAH was 
investigated in these cells. The results presented in the current study show 
that FAAH activity is not detectable in cultured human adipocytes. By 
contrast, in a study using cultured 3T3-L1 cells FAAH activity was reported, 
and found to be higher in differentiated adipocytes than the fibroblasts 
(Gasperi et al., 2007). It may be that 3T3-L1s genuinely have higher FAAH 
expression than human adipocytes in culture, or that differences in the 
culture medium affected FAAH expression. For example, the 3T3-L1s were 
cultured without insulin for 3-5 days before FAAH activity was measured, 
whereas the differentiated adipocytes used in the study described here 
were cultured with insulin constantly, as this is a component of the 
adipocyte medium. The absence of appreciable FAAH activity in this study 
explains why the specific FAAH inhibitor URB597 did not affect anandamide 
uptake. Given that FAAH activity was not detected, it is not possible to 
comment on whether anandamide uptake has a FAAH dependent 
component in vivo in human adipocytes, as in the mature adipocytes 
isolated from human biopsies (Chapters 4 and 5) FAAH activity was 
detected. Several differences between freshly isolated and cultured 
adipocytes have been reported. One obvious difference is that cultured 
human adipocytes which are differentiated in vitro are morphologically 
very different from freshly isolated mature adipocytes. The environment of 
cell culture is clearly very different from the in vivo environment, and it 
may be that the ECS is not highly expressed in cultured adipocytes 
compared to fresh adipocytes. In future studies it might prove informative 
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to measure anandamide uptake in mature adipocytes isolated from adipose 
tissue biopsies. 
2-AG uptake has not been investigated in adipocytes, but other 
fatty acids have been reported on. Several studies have shown that fatty 
acid uptake by adipocytes can be stimulated by insulin (Stump et al., 
2001; Stahl et al., 2002; Varlamov et al., 2010). In the current study, 
neither glucose nor insulin was found to affect 2-AG uptake in cultured 
human adipocytes. This indicates that insulin and glucose do not affect the 
ECS through alterations in the extracellular signalling of 2-AG. Fatty acid 
uptake by adipocytes has been suggested to occur through two distinct 
mechanisms: a non-saturable passive process and a saturable active 
transport system (Stump et al., 2001). It is the active transport of fatty 
acids that is thought to be regulated by insulin (Varlamov et al., 2010). 
The results of this study suggest that insulin does not signif icantly affect 
any proteins which may be involved in 2-AG transport. 
In previous Chapters (3-5) of this thesis it has been shown that 
there is no direct correlation between MGL activity in adipocytes and blood 
plasma glucose and insulin concentrations. However, insulin has been 
shown to decrease intracellular 2-AG concentration and increase MGL 
mRNA levels in differentiated 3T3-L1 adipocytes (D'eon et al., 2008). 
Additionally, the concentration of 2-AG in subcutaneous adipose tissue has 
been shown to be decreased in obese diabetic humans compared to lean 
and obese non-diabetic subjects (Annuzzi et al., 2010). The data from the 
current study show that MGL activity in cultured human adipocytes is 
reduced by both acute and chronic treatment with insulin, with or without 
glucose. Furthermore, glucose alone decreases MGL activity after 24 hours. 
These data are at odds with the study which shows MGL mRNA in 3T3-L1 
cells to be increased in response to insulin (D'eon et al., 2008). This may 
reflect a difference between human adipocytes and the murine fibroblast 
cell line, or between mRNA and final protein activity. Other studies have 
shown adipose tissue 2-AG concentrations to be decreased in obese 
diabetic humans (Annuzzi et al., 2010) and rats (Starowicz et al., 2008), 
which is in keeping with the results observed in this chapter. One of the 
effects of insulin in adipocytes is to increase the rate of lipogenesis. From a 
metabolic perspective, it is reasonable that insulin and glucose should 
decrease MGL activity in adipocytes, as MGL is generally involved in 
lipolysis. However, this finding does contradict the widely held view that 
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MGL is present in abundance and does not fluctuate under the influence of 
hormones (Mead et al., 2002).  
In this study insulin and glucose did not affect 2-AG uptake, despite 
altering MGL activity. This provides further evidence, in addition to the lack 
of effect of the MGL inhibitor JZL184, that 2-AG uptake in human 
adipocytes is MGL independent. This has also been reported in several 
other cell types (Fowler and Ghafouri, 2008).  
This study has provided evidence that anandamide uptake in human 
adipocytes increases in response to chronic insulin exposure, but is not 
affected by acute treatment or glucose. By contrast, 2-AG uptake was not 
affected by acute or chronic insulin or glucose, but MGL activity was 
suppressed by both insulin and glucose. In contrast to some other cel l 
types, anandamide and 2-AG uptake in this study were not FAAH or MGL 
dependent, suggesting that concentration gradients may not be important 
for endocannabinoid uptake in human adipocytes. FAAH activity was not 
detected in these cultured adipocytes, indicating that ECS signalling is 
markedly affected by culturing adipocytes for extended time periods. MGL 
activity was detected in these adipocytes, presumably reflecting its role in 
lipid metabolism. The differences observed in the uptake profiles of 
anandamide and 2-AG suggest that there is at least some proportion of 
their uptake that is dependent on specific transport proteins, which, in the 
case of anandamide, may be sensitive to insulin. 
 
 
 8. General discussion 
In recent years, a large number of studies have identified the ECS as a 
potentially important regulatory system in metabolic homeostasis, both in 
the CNS and peripheral organs associated with metabolism. In adipose 
tissue, many of the results published to date have been contradictory and 
raised questions about the expression, role and regulation of the ECS in 
adipose tissue, particularly in obesity and diabetes. Furthermore, although 
there are several studies in which ECS proteins have been investigated in 
whole adipose tissue samples, there are very few reports on the ECS in 
isolated mature adipocytes. Therefore, the overall aim of this thesis was to 
further understand the role of the ECS in adipocytes, and how this might 
be affected by obesity or metabolic dysfunction.  
 In the first phase of this project, three strains of Zucker rat were 
used as models of lean, obese and obese diabetic states, as some aspects 
of the ECS have been found to be similar between these rat models and 
human studies (for recent reviews see Andre and Gonthier, 2010; Silvestri 
et al., 2011). The major novel findings of this study were that both FAAH 
and MGL activities in mature adipocytes were correlated with body weight. 
$ UHYLHZ RI )$$+UHOHYDQW WR WKLV VWXG\ SURSRVHG WKDW ³HQGRFDQQabinoid 
VLJQDOLQJLVXQGHUWKHWRQLFFRQWURORI)$$+LQYLYR´(McKinney and Cravatt, 
2005). If this is true in adipocytes, it suggests that the upregulation of 
FAAH activity seen in the obese rats may significantly alter the overall 
expression and signalling of the ECS in adipocytes.  
Previous studies have shown differences in FAAH and MGL mRNA 
expression between subcutaneous and visceral adipose tissue in humans 
(Blüher et al., 2006; Pagano et al., 2007), so adipocytes from two visceral 
and one subcutaneous adipose tissue depot were investigated in the 
Zucker rats. It was found that FAAH and MGL activities were generally not 
different between visceral and subcutaneous adipocytes. This shows that, 
even in obesity and diabetes, endocannabinoid degradation does not differ 
significantly between visceral and subcutaneous adipocytes.  
 In light of the data obtained in the Zucker rats, similar studies were 
conducted in humans. The first of which was based on metabolically 
healthy volunteers representing a range of BMIs (Chapter 4), and with 
normal glucose and insulin blood concentrations. This design allowed the 
effects of obesity (fat accumulation) on FAAH and MGL to be assessed, 
with no interference from co-morbidities such as diabetes. In this study 
FAAH activity in adipocytes was found to correlate with BMI, which is in 
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keeping with the results seen in the Zucker rats. FAAH activity also 
correlated with waist circumference, but not with other anthropometric 
measurements. Together, this suggests a strong relationship between 
visceral adiposity and endocannabinoid degradation in adipocytes. 
However, in this human study, MGL activity did not correlate with any of 
the variables measured, indicating that 2-AG degradation in adipocytes is 
not affected by obesity. This is in contrast to the correlation with weight 
seen in the Zucker rats, and may be evidence of differing roles or 
regulation of MGL between species, as discussed later.  
 The ECS may be dysregulated in diabetes, as blood concentrations 
of the endocannabinoids are increased (Matias et al., 2006), and 
endocannabinoids levels are altered in adipose tissue (Annuzzi et al., 
2010). In the present research, in Zucker rats, differences in FAAH and 
MGL activities were observed between the three metabolic groups 
(healthy, obese and obese diabetic). This was not further investigated in 
the healthy humans (Chapter 4), as the study was specifically designed to 
exclude metabolic disorders. Therefore, the effect of metabolic disease on 
FAAH and MGL in adipocytes was addressed in Chapter 5, using obese 
patients with a spectrum of metabolic dysfunction. In this obese sample, 
FAAH and MGL activities in adipocytes were not altered in relation to 
anthropometric estimates of adiposity, or blood serum markers of 
metabolic homeostasis. Taken with the results of Chapter 4, showing a 
correlation between FAAH activity and BMI, this suggests that obesity 
affects anandamide degradation in adipocytes, but that none of the 
individual factors often associated with obesity appears to be driving this 
FAAH upregulation. A noticeable similarity between the Zucker rat and 
obese patient studies is that FAAH and MGL activities were similar between 
adipose tissue depots (visceral or subcutaneous). This is in contrast to 
studies which have shown FAAH mRNA to be increased (Blüher et al., 
2006) and MGL mRNA to be decreased (Pagano et al., 2007) in visceral 
adipose tissue compared to subcutaneous adipose tissue. Given that in the 
studies presented here there is no difference between depots in rats or 
humans, the differences seen in the mRNA studies may highlight the value 
of measuring enzyme activity rather than gene transcripts. This may be 
particularly important as studies on post-transcriptional modifications of 
FAAH and MGL have not been published to date.  
 In the Zucker rats, FAAH activity was higher in the obese rats than 
in the obese diabetic rats, but this was not observed in the obese patients. 
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This difference may have arisen from the use of discrete rat strains, 
compared to the relatively continuous human data, or because the obese 
rats had a higher mean weight than the obese diabetic rats (which was not 
seen in the humans). It is also important to note that many of the patients 
were using diet and/or medication to try to control their blood glucose 
FRQFHQWUDWLRQ ZKHUHDV WKH UDWV¶ GLDEHWHV ZDV XQFRQWUROOHG $QRWKHU
difference between the Zucker rats and humans that may be important is 
that the maximum FAAH activities seen in the human adipocytes were 
much higher than the maximum activities measured in the rat adipocytes. 
Conversely, for MGL this relationship was reversed. In regards to MGL, 
similar results have been reported previously in experiments using cultured 
adipose tissue explants. It was found that the rate of stimulated lipolysis 
(involving MGL) was higher in animal samples than in human (reviewed by 
Arner, 1988). This suggests that there are differences in the roles of FAAH 
and MGL between rats and humans, and if so, data on the ECS 
(particularly endocannabinoid catabolism) collected from rat studies should 
be interpreted with some caution when extrapolations and comparisons to 
human data are made.  
 Various studies have demonstrated that there may be relationships 
between metabolic function and the ECS in adipocytes, but many of the 
specific aspects of these relationships remain unexplored. In particular, the 
effects of anandamide and 2-AG on adipokine secretion have not been 
reported in the literature. In Chapter 6, this concept was investigated 
under normal conditions, and high glucose and/or insulin conditions. This 
study found that the endocannabinoids did not affect adiponectin or leptin 
secretion, under any of the conditions tested. This study therefore strongly 
suggests that the endocannabinoids do not affect metabolic function via 
direct regulation of adipokine secretion. 
 In order to affect metabolic pathways via intracellular targets, the 
endocannabinoids first have to get into adipocytes. Endocannabinoid 
uptake, and the factors which may drive it, have been investigated in 
several cells types, but not in human adipocytes. In the context of the 
present research, it was considered important to establish whether insulin 
or glucose may affect endocannabinoid uptake. The human adipocyte cell 
culture model used in Chapters 6 and 7 also represented a convenient way 
to measure the effect of high insulin and/or glucose on FAAH and MGL 
activities to support our animal and human data. It was found that chronic 
exposure to insulin increased anandamide uptake. Taken with the results  
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of Chapter 4, showing increased FAAH activity in obesity, this suggests 
that in obese humans (who tend to have higher serum insulin 
concentrations than lean people), both anandamide uptake and 
degradation may be increased. In another human study, it was found that 
lean and obese humans have similar concentrations of anandamide in their 
subcutaneous adipose tissue (Annuzzi et al., 2010). If both uptake (driven 
by insulin) and degradation of anandamide are increased in this obese 
state, this suggests that production of anandamide may also be increased 
in adipose tissue in obesity. This supports the concept of a general 
upregulation of the ECS in obesity. Interestingly, in obese, diabetic 
humans anandamide levels were reported to be increased in adipose tissue 
(Annuzzi et al., 2010). According to the model suggested above, this could 
be mediated by a lack of insulin-stimulated anandamide uptake by insulin 
resistant adipocytes.    
 In Chapter 7, 2-AG uptake was not affected by insulin or glucose. 
Additionally, the results of Chapters 4, 5 and 6 show that MGL activity does 
not appear to have relationships with obesity, metabolic dysfunction or 
adipokine secretion. Together, these suggest that 2-AG signalling is not a 
key regulator of adipocytes. Considering the high concentration of 
intracellular 2-AG and high activity of MGL in adipocytes, and their roles in 
lipid metabolism, it might be surprising if 2-AG and MGL were also tasked 
with specific regulatory roles. Insulin has been shown to downregulate the 
rate of lipolysis (Duncan et al., 2007), and a similar relationship was seen 
in the cell culture study (Chapter 7), in which insulin decreased MGL 
activity. Intriguingly, this finding does question the widely held tenet that 
MGL is not a rate-limiting step in lipolysis and is not under hormonal 
regulation. It may be that other enzymes in the lipolytic pathway are 
downregulated to a greater extent than MGL, and that therefore MGL 
activity remains relatively high, but further experiments would be required 
to investigate this. The focus of this thesis however is the ECS in 
adipocytes, and the conclusion from Chapter 7 is that the rate of 2-AG 
catabolism is increased by insulin, and by chronic glucose. It is important 
to consider this finding in light of the results of Chapters 3-5. In the 
hyperinsulinaemic Zucker rats, MGL activity was increased, and in the 
humans MGL activity did not show any relationship with insulin or 
metabolic status. These findings suggest that there are other factors in 
vivo which have a greater influence on MGL activity than insulin. It might 
also be that insulin resistance in the obese rats and humans had some 
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effect in altering the signalling between insulin and MGL. The use of insulin 
resistant adipocytes in culture could provide further insight in this 
complicated area. 
 
8.1 Limitations and future work 
One of the key aspects of this project was to investigate the ECS in 
isolated mature adipocytes rather than whole adipose tissue. Whilst this 
approach has given novel data about the ECS in adipocytes and increased 
knowledge in this area, in hindsight, it would have been informative to 
include the same FAAH and MGL activity investigations in the stromal -
vascular fraction of adipose tissue. This would have allowed the activities 
of FAAH and MGL in mature adipocytes to be directly compared to the level 
of activity in adipose tissue as a whole. This is an important consideration 
for future studies, as it has been shown that CB1 mRNA levels are higher in 
stromal-vascular cells of adipose tissue than mature adipocytes (Bennetzen 
et al., 2010), but this has not been investigated for FAAH or MGL. Detailed 
information on the distribution of ECS activity in different cells in adipose 
tissue may also be of use when comparing samples from lean and obese 
subjects, as the composition of adipose tissue varies between these groups 
(Weisberg et al., 2003; Arner et al., 2010). 
The results of Chapter 4 showed that FAAH activity in subcutaneous 
mature adipocytes increased with BMI. It might therefore be expected that 
the FAAH activities in subcutaneous adipocytes from the obese patients 
used in Chapter 5 would be higher than the activities seen in Chapter 4. 
However, the results from the two chapters cannot be directly compared, 
as the adipose tissue samples were obtained differently. The samples from 
healthy volunteers were taken with a needle under local anaesthetic, 
whereas the samples from surgical patients were dissected out with a 
scalpel under general anaesthetic towards the end of surgery. It has been 
shown that propofol, a common drug used in general anaesthesia, inhibits 
FAAH activity (Patel et al., 2003), so the samples cannot be directly 
compared. In light of this, a future study could be designed to recruit 
volunteers both with and without metabolic disorders and take needle 
biopsies, such as in Chapter 4. One of the other benefits of this would be 
the potential recruitment of diabetic patients without tight glycaemic 
regulation, as the surgical patients were under extensive primary care 
prior to surgery.  
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 It is important to note the limitations of experiments performed 
using cell cultures. Whilst the studies reported in Chapters 6 and 7 of this 
thesis have value in trying to elucidate simple mechanisms involved in 
endocannabinoid signalling, the cell culture environment cannot be 
considered to be comparable to the in vivo environment of adipose tissue. 
The results of Chapter 6 showed that adipokine secretion is not stimulated 
by endocannabinoids, but it is possible that in vivo other factors may 
promote the endocannabinoids to have effects that are not seen in vitro. 
This may be an important consideratiRQ DV WKH ³HQWRXUDJH´ HIIHFW LQ
which the signalling of ligands is affected by other structurally related 
molecules, has been reported repeatedly in endocannabinoid pharmacology 
(for examples see Smart et al., 2002; Ho et al., 2008; Garcia Mdel et al., 
2009).  
In Chapter 7, FAAH activity was not found in the cultured 
differentiated adipocytes. This is very important finding, considering the 
high levels of FAAH activity seen in adipocytes isolated from healthy, obese 
and diabetic rats and humans (Chapters 3, 4 and 5). This strongly 
indicates that at least some components of the ECS are regulated by 
factors that are not present in the cell culture media, or that available 
adipocyte cell cultures do not have normal expression of all the 
components of the ECS, and emphasises the need to interpret cell culture 
results with caution. A key area that could be addressed in future studies 
would be to identify physiological factors which induce FAAH activity in 
cultured adipocytes. This would both provide data on the potential in vivo 
regulation of the ECS, and provide a better cell culture model for 
investigating the ECS.   
The activities of the catabolic enzymes reported in this thesis give 
an accurate estimate of the rate of endocannabinoid degradation between 
samples, but in future studies more could be done to investigate the other 
mechanisms by which endocannabinoid levels are regulated. In particular, 
measuring the activities of NAPE-PLD and DAGL, the major enzymes 
required for anandamide and 2-AG synthesis. In conjunction with 
endocannabinoid concentrations in the samples, this would give a more 
detailed picture of endocannabinoid regulation and the effects of obesity 
and diabetes.  
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8.2 Conclusion 
The overarching aim of this thesis was to investigate the role of the ECS in 
adipocytes in health, obesity and metabolic dysfunction. It has been 
demonstrated, for the first time, that the rate of anandamide degradation 
is increased in obesity, whereas 2-AG catabolism by MGL is unaltered in 
obesity and metabolic dysfunction in humans. Insulin and glucose appear 
not to affect endocannabinoid degradation rates in vivo, but in vitro insulin 
increases anandamide uptake, and insulin and glucose suppress MGL 
activity. Adipocyte culture work showed that the endocannabinoids do not 
appear to affect adipokine secretion, and are therefore unlikely to affect 
adiposity through this mechanism. This study supports the notion of 
dysregulation of the endocannabinoid system in obesity, and overall the 
results indicate that this is driven by total or visceral adiposity rather than 
any of the specific co-morbidity markers associated with obesity.  
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